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 PART 1: BACKGROUND 
   
1.1 1 INTRODUCTION 
A common theme can be identified in the introductory passages of most scholarly articles concerning 
biobanks. This theme can be perhaps best be described as one of recent, yet speedy, development.1-3 
This is in large part linked to the concurrent boom in genomic research and medicine, as information 
about the human genome begins to be used to “uncover the genes that play a significant role in the 
hereditary contribution to common disease.” 4 The WHO report on genomics and world health of 
2003 already predicted that “unprecedented advances in the science of genomics […] has important 
implications for health improvement,”5 and this prediction has proven true in the subsequent  
d e c a d e . Genomic studies require large pools of samples as DNA sources;6 other forms of medical 
research too are coming to depend on the convenient, large-scale, international sample provision 
which biobanks can offer.7 
Biobanks – a study in diversity 
 
There is no universally employed, or accepted, definition of the term “biobank” (this matter is 
addressed in detail in Chapter 3.2, below). Recognized as distinct entities for a little over a decade 
(the term itself dates from this time),3 a biobank is some form of collection of biological material, 
frequently but not necessarily stored together with data concerning this material.8 Although 
collections of biological material have existed for decades,9 kept in the back cupboards of surgeons 
and pathologists, the recognition that such collections are valuable for research, and can be made 
available to external groups, marks the transition to “biobanking.” Biobanks can comprise animal, 
insect and plant samples;10 in this project, only collections of human material and data are 
addressed. The kinds of samples stored in a human biobank include blood, saliva, sperm, urine, 
tumour sections, organ sections, whole organs and skin cells11. Some biobanks may have a variety of 
such samples for a single individual, collected simultaneously or over a period of time.12 In the 
majority of cases, biosamples will be accompanied by patient or donor data, which can range from 
basic demographic information to specific case history, at varying levels of anonymity.13 
Numerous types of biobank can be identified, although the distinctions between them are not always 
clear-cut. Some banks are started prospectively, perhaps with the goal of gathering a set number of 
samples; they may or may not have a planned research goal for those samples14. Some banks may 
come into being retrospectively, as samples which were stored informally in a hospital are 
categorized and classified.15 The term can apply equally to collections of human gametes, stored 
exclusively for future use by the donors, who have paid for the service, as to freezers storing saliva 
samples from a representative sample of an entire population, purely for research purposes. This 
variety reflects the many potential applications of banked samples. Different diseases, research  
goals, and study groups will all envisage different uses for their collections, and the storage is 
accordingly diverse.16 
When it comes to size, biobanks again vary widely,17 ranging from small refrigerators containing a 
few dozen samples collected in the course of routine clinical work, to planned, population-wide 
resources such as the UK Biobank, which has recruited 500,000 individuals who will provide 
numerous biosamples over many years.18   The value of a collection is to some degree a product of its 
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size, relative to the prevalence of the condition in the population; greater size enables the statistical 
validation which renders research powerful.19 Biobanks focusing on rare diseases may have relatively 
few samples, but are still valuable resources if they are able to amass high quality material from a 
significant number of affected individuals. While conducting research with human subjects on a  
large scale is an enormous undertaking, the progress of biobanking has meant that amassing 
statistically significant numbers of biosamples is now more feasible for researchers20. 
Finally, stored samples can be used for research that was unforeseeable even a few years ago, not to 
mention thirty or forty21. Biosamples taken at that time can still be perfectly preserved (though the 
individuals they were taken from may have no idea that they exist, and may indeed have moved far 
away from the initial site of collection, or passed away.22) Likewise, samples may be taken today by 
researchers without any specific research goal in mind (though this may be limited by local ethics 
committees, an issue discussed at various points below).23 
Beyond storage units 
 
The potential benefits of biobanks for biomedical research have received much attention in the last 
decade. In the popular press, Time Magazine, in 2009, named biobanks as an “idea changing the 
world right now”,24 emphasizing the enormous value of population-wide repositories, and the 
potential to build gene profiles associated with specific diseases. Biobanks have rapidly and widely 
become lauded as indispensable tools for biomedical research. Cambon-Thomsen (2004) concisely 
sums up three explanations for this: “[…] the growth of biomedical research has increased the 
number of people who might benefit from biobanks; the growing size of the collections increases 
their scientific value; and the range of applications of databanks has grown, especially in genomics 
and in population genomics.”25 Biobanks have potential benefits for a large number of individuals 
because they make possible investigation into the effects of myriad lifestyle and environmental 
factors on health and disease,26,27 factors which to some degree affect us all. Furthermore, as 
repositories of genetic information, they are also at the forefront of the move towards personalized 
medicine,28 the tailoring of health treatment based on individual responses to drugs and therapies. 
Biobanks with a particular research focus (for example, liver tumours) aim to provide new insight and 
treatment options which could benefit future, if not current, sufferers.29 
A secondary aspect of biobank research is its much lower invasiveness vis-à-vis research “subjects”.30 
Investigations can be carried out on samples without the need for a human subject to be present 
over days and weeks, subjected to numerous tests and return visits to a hospital31. The taking of the 
sample itself is also frequently far less unpleasant than protracted interventions; in many cases, a 
sample can be taken within a few seconds, painlessly, or is obtained during the course of routine 
diagnostic or therapeutic processes. However, it must also be borne in mind that sample provision is 
not completely effortless; in many cases (for example in longitudinal studies), donors must continue 
to give samples at regular intervals, and fill out questionnaires or undergo additional tests.32 The 
potential benefit for the donor must also not be overemphasized; as Andersson (2010) notes, 
“…Usefulness for research is in general increasing with increasing storage time, whereas the opposite 
is true for usefulness for the patient ’s own clinical diagnosis…”33 
Additionally, caution must be taken with regards to the claims that biosample research implies fewer 
risks for sample donors than traditional human subject research does for participants. This is true, in 
so far as there will be no side-effects, unexpected adverse reactions, or painful symptoms which will 
affect a sample donor when his or her sample is used.34 There is however a significant risk element in 
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biosample research posed by the potential to identify sample donors.35 Depending on the degree to 
which the sample has been anonymised, and the amount of accompanying clinical data, there is a 
real possibility that a sample could be matched to its donor. This in turn can have several negative 
consequences for the donor. He or she may be at risk of stigmatization for having a particular health 
condition, may face difficulties with health insurance companies, and may be in the unpleasant 
position of knowing less about his or her own health status than a group of unknown researchers.36 
Identifying a supposedly anonymous sample donor is a serious violation of that individual’s privacy, 
and there is consequently important emphasis placed on the measures to reduce this risk. This is 
discussed in detail in Chapter 2.2 below. 
 
While the above goes some way towards demonstrating why biobanks are such potentially powerful 
research tools, it is crucial to bear in mind that the value of biobanks does not lie with the banks 
themselves, or with their sample collections.37 The value of a collection is the research it enables.38,39 
In other words, the only valuable biobank is one which is frequently used. Researchers must 
therefore be able to identify, contact, and receive samples from biobanks;40 the banks themselves 
must be able to obtain, store, and ship samples. As Kaye (2011) notes, “Research is increasingly of a 
global nature with data and samples exchanged, accumulated and created through a number of 
dynamic research networks and collaborations that involve multi-disciplinary teams located in 
different countries.” 41 This transnational aspect of biobanking is what enables large sample sizes,  
and consequently statistically powerful research. Providing good quality samples for research is at 
least one, if not the most, important feature of biobanks42. This fact is the foundation of what follows 
in this thesis. 
 
Important distinction 
 
Before continuing, it is important to clarify one of the key terms in the title of this thesis, and how it   
is used, and not used, throughout. The biosample provision process may be referred to as 
transferring, making accessible, exchanging, or supplying; our initial idea was to employ the term 
“sharing”. Sharing implies a give and take relationship, and this back and forth aspect is generally a 
feature of the biosample provision system. Biobanks may trade samples back and forth, or send them 
to researchers on the understanding that they will receive some kind of recognition, or perhaps 
collaborate in some way in the research. Furthermore, numerous research groups may be able to 
make use of the same set of samples, so a biobank can be said to “share” the samples amongst them. 
However, after time spent researching the situation in Switzerland, and discussions with those in the 
field, there are reasons to argue that sharing may not always be the most appropriate description of 
what is done with biosamples for research. First, some biobanks have a cost recovery system to  
offset any financial burden of shipping samples (indeed, some commercial biobanks also sell human 
tissue at a profit), a process which is far more accurately characterized as “service provision” than 
sharing; they may also offer advice and diagnostic services in this transaction. In addition, the fact 
that in Switzerland, samples tend to move between research groups more frequently than from 
third-party biobanks to researchers, means that the term “sharing” misses the spirit of collaboration 
and mutually beneficial cooperation which characterizes these exchanges.1 Overall, it seems that the 
 
 
1 It is also important to bear in mind that the expression „data sharing“ is also widely used in the literature on 
genetic and genomic research, yet has quite a different meaning. Individuals working with the data derived 
from such research are typically required to make it available so that others may test, or avoid duplicating, 
their results. This data has been defined as “the full range of research results, techniques, and materials useful 
in future investigations” (Campbell, 2002). It is not the data often accompanying samples, which I deal with in 
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multiple kinds of biobank also entail multiple forms of sample provision process. Therefore, no single 
term is used throughout this thesis; in some cases, sharing may be the best description of the 
process, while in others, exchange or provision is more accurate. 
 
Untapped potential 
 
The importance of access to biosamples is highlighted in the literature.44 As noted in the opening 
sentence of this thesis, these articles are frequently reactions to the rapid rise in importance of 
biobanks. 
 
However, coupled with this are numerous calls for more fully exploiting the potential of these 
banks.45,46 As Clark (2010) puts it: “We are currently in an ‘‘age of the biobank […] Despite this, 
significant challenges remain and jeopardize the ability of research using human biospecimens to 
make the impact it should.” 9 Vaught, Kelly, and Hewitt (2009) echo this: “[…] specimens are 
collected and stored for lengthy periods before being used, delaying their productive use by 
researchers, and possibly delaying new discoveries and treatments for patients. It is therefore 
reasonable to hypothesise that these extremely promising research tools are not yet being used to 
their fullest potential. The question then is, why not?” 47 
Despite, indeed perhaps because of, its rapid evolution, the biobanking world is not yet operating 
smoothly. Obstacles and inefficiencies exist. Specifically, numerous commentators now pinpoint the 
problem as a lack of sharing.48-51 Among authors who address this issue, there are some particularly 
elegant summings-up of the problem. In an article synthesizing the European efforts to promote 
closer biobank collaboration, Ballantyne (2008) explains that “…the mission of pooling resources, 
sharing samples and exchanging data represents a difficult task…” 52 Hagen and Duke (2004) reiterate 
that it is the accessibility of sample collections, not the collections themselves, which must be the 
focus of improvements: “…in spite of their seemingly overwhelming size, greater networking  
between these national initiatives could only further benefit our understanding of the most common 
causes of morbidity and mortality.” 53 Enabling sample sharing and exchange is urgently required in 
order that biobanking can move forward: “Only when we all share our toys, and put as much 
information and resources into the precompetitive space, will we really make a dent in the 
challenges. This means we must find ways to build shared infrastructure systems, essentially über- 
registries and biobanks…”(Horn, 2010) 9 This is a major roadblock which, in light of the explosive 
growth of genomic research, affects even established organisations: “[…] even the major academic 
hospitals are not capable of swiftly setting up the needed large data and sample collections on their 
own or performing all the necessary research; therefore, the research pipeline needs to be able to 
take part in multicenter medical research in cooperation with other institutes and industry on a 
national and, if needed, international level. On a national and international level, research 
infrastructures would be needed to support such a form of cooperation.” (Riegman, 2011)54 The raw 
material to enable advances in research exists: the challenge now is to connect this material with 
those who need it. As Horn and Riegman, above, suggest, Dillner and Andersson (2011) also stress the 
lack of infrastructure that contributes to the problem: “Although it is commonly perceived that       
lack of sufficiently high numbers of samples is the major bottleneck of the research in molecular 
 
 
 
this thesis. The data discussed here is exchanged as a part of the initial research, and not made available so 
that this research can later be validated. Campbell, E.G. et al. Data withholding in academic genetics - 
Evidence from a national survey. Jama-Journal of the American Medical Association 287, 473-480 (2002). 
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medicine today, very large amounts of samples do indeed exist and bottlenecks are more related to 
the fact that the clinical biobanks have not been designed to work as a scientific infrastructure.” 55 
Based on these findings, there are three potential explanations for why commentators feel that 
biobanks could be more widely, frequently or thoroughly used. First, they may be wrong. However, 
since the great majority of authors addressing the subject work in, or closely with, biobanks, and their 
analyses have at least partly contributed to the substantial sums of money devoted to            
improving the field, this suggestion is unpersuasive. Second, it may be that researchers have no  
desire to carry out the projects that these banks enable, they may prefer to gather and work with 
their own sample collections, rather than accessing others. This explanation is unsatisfying too; first, 
many biobanks are created or managed by individuals who are also actively engaged in research, and 
second, calls by researchers for better sample accessibility are also documented. Third, it may be that 
biobanks should indeed be used more, that researchers are indeed eager, but that obstacles are 
currently preventing this from occurring. It therefore becomes reasonable to consider the hypothesis 
that obstacles to researchers accessing biosamples may be one of the factors which explains the 
current under-use of biobanks. 
 
Contents of the thesis 
 
Above, the foundations have been laid which introduce a currently pressing roadblock to the further 
development of biobanking. The goal of this thesis is to examine the causes of the insufficient sample 
sharing. In order to do this, several steps must be taken. First, the material in the literature which 
discusses barriers to sample sharing in biobanking will be presented. One significant difficulty which  
is currently receiving attention at the highest level of biomedical research regulation will then be 
addressed in more detail. In 2008, research using biosamples was for the first time specifically 
addressed by the Declaration of Helsinki. The relevant paragraph, which influenced numerous other 
national regulatory documents, is a first step towards tackling one obstacle to sample sharing: the 
appropriate form of consent which must accompany the biosamples. The revision and the difficulties 
in regulating this field are discussed. Since the completion of the article, the Declaration has once 
more been revised, and comments on this are included in the summary. 
This is followed by the results of a past empirical study with Swiss ethics committee members, who 
were questioned about their approaches to informed consent for research using samples from 
biobanks. These findings corroborate the statements of our interviewees on consent (see Chapter 
3.5), and suggest that the topic of informed consent is one which requires further attention in order 
to facilitate biobank sharing. 
Following this introduction, we move on to the empirical part of the current study. This comprises the 
results of the main body of research, and is supplemented by findings from a second empirical 
investigation. The findings from 36 interviews with biobank stakeholders on the subject of barriers to 
sharing in biobanking are presented. The results of the literature review are first compared to the 
variety of barriers cited by interviewees, in order to develop a clearer picture of the current situation 
in Switzerland, and to explore whether the predominance of certain issues in the literature matches 
the real-world experiences of a sample group of professionals. With this comparison, a picture of the 
significant obstacles to biosample sharing evolves 
The barriers which were described with unprecedented detail by the interviewees are then examined 
in greater detail. First, the fact that there is no current globally-accepted definition of the term 
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biobank is discussed, and this has a number of potentially negative implications for biosamples 
researchers. 
The next focused topic is that of authorship on publications arising from biosample research. As 
sample exchange typically involves some form of collaboration between independent research 
groups, assigning appropriate, mutually satisfactory authorship credit becomes a significant concern. 
This section illustrates how current practices reported by our interviewees may be negatively 
impacting on sample sharing, as inappropriately assigning authorship damages the very practice that 
is so important to researchers. 
The fairness of current sample sharing practices, and stakeholders’ perceptions of what this term 
means, is discussed in Chapter 3.4. Mutual satisfaction is an essential element in encouraging 
successful collaboration, and we obtained valuable data about researchers’ interests and priorities in 
a subject sparsely addressed in the literature to date. 
The final subject addressed is that of informed consent for biobank research, discussed in the 
theoretical section. I present the responses of our interviewees regarding this issue, and in particular 
their views on the role ethics committees play in obtaining consent. 
This dissertation concerns the current situation in Switzerland, insofar as all interviews were carried 
out with individuals who were employed by Swiss institutions at the time of interviewing. While the 
findings cannot simply be generalized to make claims about the global field of biobanking based   
upon these results, it is emphasized that a third of our respondents were not themselves Swiss, and 
that the majority has spent at least some significant period of time working for institutions in other 
nations. This, combined with the necessarily international aspects of biosample research, allows for 
cautious optimism that some of the results can be extrapolated the global situation. However, given 
the discrepancies between the findings from the literature review and those from the interviews, and 
particular the comments from some interviewees that certain ways of working are “Swiss ways”, the 
generalizability of these results must not be taken for granted; this is addressed in more detail in 
Chapter 3.1 below. The aim was to develop insight into the current obstacles to sharing biosamples   
in Switzerland: the nature of our responses leads us to feel confident that our interviewees 
understood this aim, and provided us with the information to develop our research goals. 
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1.2 RESEARCH OBJECTIVES 
 
This project was undertaken with the following aims. 
 
1) Establish whether there are currently obstacles affecting the sharing and/or exchange of 
biological samples and/or data amongst biobanks and researchers. Document these 
obstacles. 
2) Establish the degree to which obstacles are experienced by biobank stakeholders currently 
working in Switzerland. Document their experiences. 
3) Analyze findings, comparing data from the literature and the empirical investigation. 
4) Identify areas of particular importance in the field, describe them, and suggest possible 
solutions. 
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1.3 METHODOLOGY 
 
Our methodology is described in detail in the Methods section of each article presented below. 
Therefore, it is unnecessary to repeat these details here. The full interview guide used, as well as the 
timetable which structured the research, can be found in Chapter 4.5, Appendices. 
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1.4 COLLABORATIVE TEAM 
Although this work is the doctoral project of Flora Colledge, several individuals were involved in the 
development of the articles that appear below, and the design of the research. This was particularly 
important for two reasons; first, it is the nature of qualitative research that numerous individuals 
must perform the same data coding process in order to verify the findings; and second, the 
unexpected depth with which a number of themes were addressed necessitated the contribution of 
new team member who could properly develop themes for publication. 
Bernice Elger, professor and head of the Institute for Biomedical Ethics, developed the initial concept 
and research question, and elaborated the study hypotheses and methodological approach. Upon 
completion of the data collection, she performed content analysis on all transcripts and compared 
these findings with Flora Colledge and Heidi Howard. She contributed to the development of each 
manuscript based on these codes. Furthermore, she developed the article on the Declaration of 
Helsinki together with Flora Colledge, and provided the data and input on the article on ethics 
committees. 
Heidi Howard, former senior research at the Institute, worked on the initial research question and 
hypotheses, and took the lead in formulating the interview guide. She was instrumental in 
developing, selecting articles, and writing and editing the literature review. She searched for 
interviewees carried out a number of interviews. She analysed, coded and compared all transcripts 
with Flora Colledge and Bernice Elger. In the middle of the project, she accepted an offer to work in a 
different institution, and consequently did not contribute to the manuscripts developed from the 
empirical data. 
David Shaw, a senior researcher at the Institute for Biomedical Ethics, analysed all transcripts and 
codes specifically addressing the issues of definitions, authorship and consent. He contributed 
substantially, in one case as first author, to the manuscripts on these topics, and was instrumental in 
their successful publication. 
Kirsten Persson, a doctoral student at the Institute, analysed all transcripts and specifically addressed 
the issues of ethics committees and informed consent. She elaborated these codes and compared 
them with David Shaw, Bernice Elger, and Flora Colledge. She played a key role in developing the 
article on this issue, as joint first author with Flora Colledge. 
Jakob Passweg, senior physician at the Hematology Laboratory at the University Hospital of Basel, 
contributed to the development of the overall results analysis. His experience in the field enabled key 
issues to be properly identified and described, and his comments were also essential in formulating a 
clear research question and ordering of the thesis. 
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 PART 2: THEORETICAL EXAMINATION 
   
2.1 1 A REVIEW OF THE BARRIERS TO SHARING IN BIOBANKING 
 
Flora Colledge, Bernice Elger, Heidi Howard 
 
Biopreservation and Biobanking. December 2013, 11(6): 339-346. doi:10.1089/bio.2013.0039. 
 
(Impact Factor 1.500) 
Abstract 
Although biobanks are gaining importance as tools in the field of biomedical research, enabling 
investigators to access large numbers of catalogued samples and/or data, most have not reached 
their full potential. Numerous obstacles may prohibit the efficient sharing of, and access to their 
sample and data collections. In order to minimize or overcome these obstacles while meeting ethical 
criteria, the first step is to identify the challenges to sharing between biobanks and between 
biobanks and researchers, thus enabling targeted solutions to be implemented. To date, no article 
has specifically addressed the full scope of currently-identified barriers to sample sharing, yet such a 
list is essential if these matters are to be dealt with swiftly. We have reviewed the literature on 
biobanks in order to identify the issues mentioned as barriers to sharing samples with or without 
data. Our literature search identified 15 barriers, including among others, logistical, ethical and legal 
issues. We provide a description of all barriers, discuss key themes, and conclude that empirical 
research is required to determine the full extent of the problems addressed in the literature. 
 
Introduction 
 
Biobanks are “organized collections of biological samples and associated data”.1 Although often used 
in the context of materials and data from humans, the term is also employed to describe collections 
of plant and animal matter;2 this review addresses only collections of human material. Biobanks vary 
greatly based on, among other characteristics, the size, degree of accessibility, the reason(s) for the 
collection (clinical studies, academic research, judiciary or forensic reasons), and the types of 
institutions in charge of the collection and/or management of the biobank (public or private, for 
profit or not). The prevalence of biobanks of human material for medical and academic research has 
been increasing over the last decade, as has the recognition that the large size of collections 
increases their scientific value.3 The growing importance of biobanks for research, diagnosis and 
medical advancement has been emphasized by many academic authors.4-7 Furthermore, in 2009, 
Time Magazine named biobanking as one of the ideas that is “changing the world now”.8 
The general tone of recent literature is that biobanking for biomedical research is now an established 
practice, and it should be exploited to its full potential.9-11 In 2008 the European Science Foundation 
appealed to the European biobank community to combine the wealth of biobank data and materials: 
“There is an urgent need for the coordination and harmonization of biobanking and biomolecular 
resource infrastructure”.10 As a concrete sign of this desire to unite European efforts in biobanking, 
the European Union reserved 5 million Euros for the Biobanking and Biomolecular Resources 
Research Infrastructure (BBMRI) project. Harmonisation of operating practices, networking and 
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increased funding are among the methods suggested for advancing the field, and are intended to 
allow biobanks to build up statistically significant sample collections, and bring them into closer 
contact with the researchers who use them. 9,10,12-15 While these positive steps forward are crucial, it 
is also necessary to examine the current specific roadblocks to sample distribution, which must be 
managed and/or removed before the full research potential of biobanks can be achieved. One of the 
primary goals of human biobanks is to make resources available to the researchers who need them. 
Barriers to the accessing or sharing of resources can therefore reduce the usefulness of biobanks, at 
the regional, national and international levels. To date, no article has specifically addressed the full 
scope of currently-identified barriers to sample sharing, yet such a list is essential if these matters are 
to be dealt with efficiently. 
 
We define a barrier to sharing as any factor which constitutes an obstacle in the sharing process, be   
it logistical, ethical, or theoretical. The term “barrier” is not used here in an absolute pejorative sense, 
or to suggest that every obstacle to sharing is completely undesirable; we recognize that some 
processes which can, in some ways, limit sample and data sharing, such as ethical review, are 
necessary and desirable. We consider sharing as the process of biobanks (or scientists with registries 
or laboratory collections) supplying samples with or without data to those requesting it. We do not 
address herein the particular problems of initial sample collection by the biobank, unless these 
specifically impact on the subsequent sharing of samples with others once the samples and data have 
already been collected. In order to provide a structured list of the obstacles to sharing samples with 
or without data, we have conducted a review of the literature. In identifying and discussing these 
issues, we aim to provide a unique and focussed resource which will allow stakeholders to recognise 
and understand potential obstacles to sharing, and in doing so allow for a more concrete approach to 
devising solutions to optimize ethical sharing above and beyond the general calls for harmonization 
and standardization. 
 
Methods 
 
We conducted a literature search concerning the obstacles to sharing samples with or without data   
in biobanking. We searched three databases: PubMed, Web of Knowledge and JStor. Key terms used 
in pairs and sequentially included: (biobank OR biobanks OR biorepository OR data bank) AND 
(sharing OR barriers OR challenges OR obstacles OR problems OR nomenclature OR terminology OR 
practical OR ethical OR consent OR governance OR legal OR data collection OR territoriality OR justice 
OR fair OR fairness). The articles retrieved included all those published until June 26th 2012 
(inclusive). The term biobank is relatively recent, appearing in PubMed for the first time in 1996, and 
used more frequently from 2000 onwards, therefore, no lower date limit was set on the search. After 
eliminating all double entries, we read and evaluated the abstracts (or introductions, for articles 
without abstracts) of all remaining articles to assess their relevance to our study and papers were 
included if they explicitly addressed barriers to sharing samples with or without data in biobanking. 
Articles addressing only the sharing of data were excluded. We then used a “snowball” approach to 
obtain additional relevant articles from the reference list of initially selected articles. The full text of 
articles was then scrutinised to identify the obstacles to sharing samples with or without data in 
biobanking. Since the goal of this article is to identify in as much detail as possible the barriers to 
sharing as discussed in the academic literature, we counted only those issues which were addressed 
in the context of stopping, deterring, complicating or hindering sharing. Themes or areas that were 
addressed in general as benefiting from improvement in biobanking*, of which the literature has 
many examples, were not interpreted as being barriers to sharing. Our aim in using this more 
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restrictive interpretation was to avoid the reification of barriers by confusing a call for optimisation 
with the existence of an obstacle. 
Any issue which was cited specifically in the context of hindering sharing was selected, and the full 
sentences (or sentences) were then extracted from the articles and placed in a table. The procedure 
was performed by FC and HCH independently, and results were then compared. Any discrepancy was 
discussed until both authors agreed on the full list of barriers extracted from the articles. Once each 
mention of a barrier had been agreed upon, they were further defined and organized into groups 
based on commonalities. The category labels given to each group of barriers were initially developed 
by FC based on the list of barriers identified in the articles and not on pre-existing categories. These 
categories were then discussed for coherence by FC and HCH and the final categories were agreed 
upon by all authors. These three categories are an attempt to further reveal where some of these 
barriers may principally originate from but we underline that they are indeed non-exclusive, and do 
overlap with each other, such that some barriers may have some characteristics from all categories. 
 
Findings 
 
Twenty-seven articles published between 2003 and June 2012 and authored by 23 distinct first 
authors were retrieved using the search strategy described above. The nature of the articles ranges 
from empirical studies, to reviews, to commentaries and discussion articles, with the latter two being 
the most numerous. We report on 15 barriers to sharing samples with or without data found through 
this search.The identified barriers were organized into three macro-categories (Table 1): internal 
issues, external issues and ethical issues. These macro-categories are designed to focus the review 
and group similar topics. They are not mutually exclusive or exhaustive, but are meant as a way to 
organise this article, and reflect the way in which we have chosen to approach these issues. 
 
Table 1: Definitions and examples of the 15 barriers to sharing in biobanking identified in 27 articles 
 
Barrier 
Categories 
 
Definition 
 
Barriers 
Number of 
times 
mentioned* 
 
Examples 
Internal issues Barriers which 
exist within the 
workings of the 
biobank itself, 
and over which 
the biobank 
exerts the most 
control. 
SOPs 
Availability 
Awareness 
Fees 
Networks 
Governance 
8 
3 
1 
2 
4 
4 
Damage to samples in 
transit, lack of publication 
of a biobank’s resources 
leading to low demand 
for samples. 
 
20 
 
 
External issues Barriers imposed 
on biobanks by 
external factors, 
which the 
biobank itself has 
less control over. 
Commercialisation 
Legal issues 
IP and patents 
Nomenclature 
Publication credit 
2 
10 
6 
2 
2 
National laws prohibiting 
human tissue export. 
Ethical issues Barriers which 
involve bio- 
ethical 
considerations, 
such as fairness, 
and patient 
autonomy. 
Consent 
Territoriality 
Prioritisation 
Safe Transfer/ 
Confidentiality 
4 
3 
1 
1 
Consent forms which 
limit the scope of 
research in order to 
protect patients, but 
which prohibit 
collaboration. 
* This refers to the number of times the barrier was mentioned explicitly as a barrier to sharing 
samples with or without data in the articles studied. We recognize that some of these barriers have 
been mentioned in articles as a general problem in biobank operations but these were not included 
here. 
Internal issues: standard operating procedures, availability, awareness of existence, fees, 
networks, governance 
Internal issues are those over which the biobank exerts most control, either because it established 
the systems (which cause problems), and/or because it has the wherewithal to change them. They 
are issues which arise from the way the bank currently runs, and over which, crucially, professionals 
involved with that bank exert influence. 
As defined by Asslaber and Zatloukal (2007), standard operating procedures (SOPs) “should define 
the whole process of sample acquisition, sample processing and preservation as well as storage and 
retrieval”.12 Given the large range of activities included in this category, it is not surprising that 
barriers in SOPs are mentioned frequently in the literature, with only legal issues being more 
frequently cited. The differences in procedures between banks are described as a challenge, and in 
some cases, the bank’s current practices may be sub-optimal, and therefore a barrier, regardless of 
the differences with other banks. 
 
Many of the problems with respect to SOPs are related to the quality of the stored samples and this 
is identified by Myles et al (2011) as the primary challenge in biospecimen exchange.17 Biobanks may 
be unable to assure the quality of their samples,17,18, or correctly link the patient’s treatment history 
to a particular sample or, there may be a lack of clinical data .17 The variety of methods by which 
biobanks store and process the samples was mentioned, as researchers obtaining samples from 
numerous sources may have difficulty working uniformly with them.13,19-21 Samples are thus not 
exploited to their fullest potential.11 Along the same line, and specifically with respect to 
international interoperability Kiehntopf and Krawczak (2011) address in more detail the following 
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aspects: pre-analytical sample-handling, the standard pre-analytical code, sample quality 
management, technological issues (with respect to storage, retrieval, sample identification and 
automated technical processes), sample-related IT and data-management and shipping.20 From an 
empirical study of European biobanks, Zika et al. (2011) also identified the complications related to 
shipping with dry ice as being a barrier.21 Budimir et al (2011) sum up the issue by stating that 
biobanks with “different designs and different settings” can hinder sharing, and that international 
harmonisation is therefore needed.22 
Sample availability, by which we mean the existence of a useable number of samples in a bank, is 
mentioned on three occasions as a hindrance to sharing. We address it because it is indeed 
mentioned in the specific context of sharing, despite the contradictory issue that if samples are 
unavailable in the first place, sharing is a moot point. Availability is brought up as a barrier to 
biobanks which are engaged in sharing, but could do more if more samples were obtainable. The lack 
of “local” biobanks which would facilitate sample collection by potentially being easily accessible to 
both researchers and donors is mentioned, in an interesting contrast to the general 
recommendations for more centralised banking.23 An example at the micro-level is the sharing of 
prostate cancer samples, which is limited by the fact that such samples are in high demand, yet little 
tissue is, in fact, collected.24 The general scarcity of certain kinds of sample is also mentioned by 
Myles et al (2011).17 
Related to the topic of availability, but not strictly the same notion, Zika et al (2011) mention the lack 
of knowledge or awareness of existing sample collections as a barrier to sharing.21 
The financing of biobank infrastructure and personnel is a big challenge to the existence of 
biobanks.11,25 That being said, the specific issue of cost or fees with respect to sharing samples 
specifically was not mentioned often. Fees charged by biobanks (cost recovery rather than profit- 
generating) are mentioned as obstacles on two occasions. Somewhat surprisingly, prohibitive costs 
shutting out certain users are not brought up, nor are for-profit banks mentioned. Rather, the issue is 
confusion about costs. Biobank fee structures, which will have been elaborated internally, are said to 
become confusing as they differ from one another in a networking context.17 At a more basic level, 
however, the very practice of assigning a financial value to samples is problematic. To do so 
responsibly, the variety of man-hours, the potential usefulness of the sample, and the finances of 
those who might wish to access it must all be considered, yet there are no concrete guidelines to  
help calculate how these factors can and should be quantified.26 
Also an internal issue, to a certain extent, is the matter of networks of biobanks. The lack of efficient 
networks in biobanking is mentioned three four times as a barrier. Having to elaborate and decide on 
the details of biobank management, ownership, and confidentiality, issues which are in and of 
themselves sometimes problems in biobank sharing, limits the effectiveness of creating and or 
sustaining collaborative networks. 20,21 Asslaber and Zatloukal (2007) emphasize that the fragmented 
nature of biobank networks, especially in Europe, is a key factor preventing biobanks from pooling 
their samples, and hence prohibiting researchers from accessing large sample and data sets.12   As a 
potential aid to create functioning biobank networks, the lack of which stands in the way of 
proliferating “well organised and accessible” collections, Yuille et al. (2008) describe the BBMRI as a 
network with a “distributed hub structure” that has as an aim to “enable access by researchers to 
different sample types (with associated data) collected under different study designs”.11 
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Biobank governance, widely discussed in biobanking literature, is touched on four times specifically  
in the context of problems in sharing. Governance in biobanking refers to the systems, procedures 
and documents which regulate the banks’ activity, and to the people who oversee this sphere; 
without innovation in this realm, the flow of research material will be limited.27 Biobanks in certain 
institutions may sometimes place restrictions on access to their data in order to protect their 
mandate,12   an issue which can also be considered in the context of territoriality. On the other end of 
the scale, attempts by those who govern biobanks to broaden their sharing policies can be met with 
resistance from researchers, who are either confused by the changes or seek to limit access to their 
findings samples for the territorial reasons identified below.28 While we have included governance in 
our list of internal issues, certain aspects of the problem, such as legislative and guideline  
documents, may be imposed from outside the bank itself. Governance may therefore also be a partly 
external issue and/or an ethical matter, and as such may share some characteristics with the legal 
and ethical issues mentioned below. With respect to guidelines, Elger and Caplan summarize the 
problem regarding international collaboration by saying that many national and biobank-specific 
“guidelines contain clearly divergent recommendations in important areas, which interfere with 
international collaboration. Not only do different systems exist for the collection of data, and the 
processing of samples but also the guidelines reflect fundamentally different ethical frameworks”. 16 
External issues: commercialisation, legal issues, intellectual property and patents, nomenclature, 
publication credit 
The constraints imposed on biobanks from sources external to biobanks themselves constitute some 
important barriers to sample and data sharing, and in contrast to internal issues, are less controlled 
by the biobank operators. Typically the obstacles take the form of requirements, imposed by non- 
biobank organisations, designed to improve some aspect of biobanking, but which also have an 
unwanted secondary effect of causing difficulties in sharing. 
The potential to commercialise biobank samples represents a further barrier to sharing. While Hewitt 
et al (2011b) merely mention that this is so, suggesting that the broader issue is the effect of 
commercialisation on public trust,18 elsewhere it is noted that the biotechnological policies which 
influence sharing are dominated by the market interests of industry.29 In other words, biobanks may 
be prevented from making their samples available, at least to certain groups, or researchers may 
likewise be prohibited from storing their samples in banks with an open sharing policy, due to the 
conditions of funding they receive from private biotechnological companies. 
 
Legal issues were the most frequently listed barriers to sharing in biobanking from our pool of 
articles. Legal issues here refer to national or international laws, and exclude non-legally binding 
agreements and guidelines created between biobanks and other parties. The latter agreements are 
not mentioned in the literature as being problematic because of their legal status, and are therefore 
included in the internal issues section, in sub-categories such as governance. Despite the frequency 
with which legal barriers are mentioned, there is little variation in the main problems mentioned. 
Broadly, the divergence of regulations on the uses, storage, transfer and nature of tissues and data is 
repeatedly mentioned as an obstacle to international collaboration. 11,12,21,30-33Laws and guidelines 
contain “clearly divergent” instructions, which can be either prohibitive or confusing.20 Furthermore, 
tissue export or import is limited or banned by certain countries.34 Even within the European Union, a 
disruptive amount of variance exists.11,32 Based on the their survey of 126 biobanks, Zika and co- 
authors state that most of the problems in sharing samples were related to legislative barriers.21 The 
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effort and biobank-specific organisation required to understand and comply with these regulations is 
a secondary barrier.27 
Intellectual property (IP) rights and patenting are also primarily legal issues; we feel they merit 
separate attention here as the barrier they pose is described distinctly from broader legal questions. 
IP and patents are mentioned six times as challenges in sharing in biobanking. When a patent or claim 
of intellectual property is anticipated on some work deriving from banked samples, access to those 
samples may be restricted, at least for a set time period.35 This fact may further erode public          
trust in biobanking, as the public are not keen to see beneficial research restricted for ostensibly 
financial reasons.30 Such restrictions, where they exist, may stop the optimum use of such samples by 
cutting out other research groups, and limits the knowledge-mining uses of the samples or data. 17,18 1 
However, as Cambon-Thomsen et al (2007) point out, confusion about the very nature of IP and 
patents, even when no restrictions are yet in place, may be a hindrance to some researchers.28 
Nomenclature concerns the terms used in the medical or scientific field, and not just those terms 
which are specific to biobanking. The profusion of terms relating to sample and data types, research 
methods, and databases is, in part, a natural result of changing language habits over the years, but is 
of course highlighted when samples taken ten years ago are compared with those obtained more 
recently. The problem is exacerbated on the international level, where even if all collaborations take 
place in English, the various translations and culturally different uses of words are still not likely to 
make for easy collaboration. Nomenclature may, therefore, be an important barrier to international 
sharing.33 Pearson (2004) also points out that medical histories which accompany samples are useless 
if those from different institutions use different words.13 
Publication credit and proper recognition of time and effort devoted to creating a useful tool (like 
bioresources) can be a difficult issue in all spheres of academic research, not just biobanking. Shickle 
et al (2010) point out that access to samples might be conditional on publication credit, and not 
simply “altruistically” available. This is distinct from researchers not wanting to make samples 
available at all (addressed below, as territoriality); in this case, the obstacle is meeting conditions, 
rather than confronting sheer unwillingness to share. 36 According to Cambon-Thomsen (2003), 
biobanks which are not properly credited or recognised for their work in establishing and maintaining 
their samples will not receive the professional recognition that they need to keep attracting 
researchers, and will risk becoming storage warehouses with no “clients”,37 or potentially losing 
funding: hence, their samples will not be shared with a wider pool of researchers. 
 
Ethical issues: consent, territoriality, prioritisation, recognition, safe transfer/confidentiality 
 
Ethical issues appear as a distinct category, although they can in some cases be both internal, that is, 
under the control of the biobank, and external, as they are to some extent imposed by socio-cultural 
context and/or national standards. However, in all cases they are examples of decisions which 
require some degree of moral reasoning to resolve and we therefore judge that they merit separate 
attention here. 
The question of informed consent for biobank research is ubiquitously mentioned in the literature. 
16,38-41This is not surprising considering the huge role the topic plays in the ethical sphere of 
biomedical sciences. Indeed, not obtaining the proper consent can prevent samples and associated 
information from ever being used at all in biobank research.42 However, informed consent explicitly 
mentioned as a hurdle to sample sharing is relatively rare in the articles retrieved through our search. 
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Consent, when mentioned strictly as an obstacle to sharing, appears in different contexts. Consent 
forms differ between biobanks, or between the institutes which initially collect the samples and then 
send them to banks. 13,20,39 Therefore researchers may be unable to use the samples or data for 
certain projects. This is linked to the difficulty of obtaining consent for prospective research, as it is 
difficult to inform donors of as-yet unplanned projects.39   It is stated that the current formulation and 
interpretation of most biosample consent forms hinders data sharing, as they were not conceived 
with transnational projects in mind.43 Kiehntopf and Krawczack specify that regarding the 
interoperability of consent to use samples and data, the prime issues of interest are the right to 
transfer to third parties and the scope of research allowed.20 
The barrier that we have called “territoriality” describes the phenomenon of unwillingness to share 
data or samples; this can also be described as wanting to keep samples and data exclusively for one’s 
own research. In the literature, territoriality is generally attributed to individual researchers, rather 
than to biobank managers or operators.17 The axiom “publish or perish” appears, in light of the fact 
that researchers may well be keen to foster an environment of trust and altruism in their field, but 
are equally aware that the samples, especially rare ones, can be an entry into prestigious research 
teams.36 More broadly, “elitism and competition”17 among researchers is a threat to sharing, and 
access to data is therefore “vulnerable to researchers’ incentives”.29 
Prioritisation refers to the weight the biobank assigns to competing research projects (i.e. those 
which seek to use the same samples simultaneously). It is mentioned only once in the literature. 
Fortin et al (2011) indicate that banks which seek to prioritise the work of local researchers, even 
with the laudable goals of supporting their community and keeping donors close to the work, will be 
hindering others, at the national and international level, from accessing their samples.26 This is not a 
barrier to all forms of sharing, as the samples are still in use, but rather an obstacle to wider sharing. 
 
Recognition is also cited as a potential hurdle to sharing. This barrier is indirect in a way that most 
others mentioned here are not; in other words, it does not currently hamper sharing, but the net 
effect, if left unchecked, would be to damage the biobank, and hence its potential to operate 
successfully. According to Cambon-Thomsen (2003), biobanks which are not properly credited or 
recognised for their work in establishing and maintaining their samples will not receive the public 
recognition that they need to keep attracting researchers, and will risk becoming storage warehouses 
with no “clients”,43 or potentially losing funding. 
The ability to transfer useful data or information relating to samples while maintaining the 
confidentiality of the donors’ information is held to be a difficulty particularly in international 
collaboration.33 Although data is usually transferred with samples, the reverse is not always true and 
data-sharing has become a topic in and of itself. In this respect, data-sharing may include the sharing 
of both clinical information as well as results of analysis using samples and clinical data. Since we 
focus this review on the sharing of samples with or without data, we have not included articles 
dealing only with data sharing. 
 
Discussion 
 
Based on the articles included in this review, we identified 15 obstacles to sharing samples with or 
without data in biobanking. This is the first review which specifically identifies and discusses the 
obstacles to sharing addressed in the academic literature. Our findings show that a broad variety of 
barriers have been discussed. The majority of issues receive one or two mentions; however, a small 
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number are cited by numerous authors. Two identified barriers (legal issues and SOPs) are 
mentioned frequently, and IP and patents also emerged often. 
Although the attention which the barriers receive appears to vary significantly, the conclusions to be 
drawn from this require caution. It cannot be presumed that the frequency directly corresponds to 
the actual severity or extent of these barriers in practice. Certain frequently-cited factors may seem 
overemphasised or relatively unproblematic to some readers and stakeholders. For instance, certain 
banks may experience no problems at all with storing or shipping samples, while others will feel that 
a shortage of samples is unlikely to hinder sharing.9 While we do not suggest that any of the issues 
mentioned in the literature were invented or were purposefully ignored by the authors, it is 
important to note the following: i) the large majority of articles retrieved through our search do not 
aim to address barriers to sharing per se. Many articles simply mention barriers in the introduction 
and/or discussion and hence do not elaborate on these issues; ii) some aspects may have been 
repeated due to their perceived importance, whether or not this reflects the current state of affairs 
in biobanking; iii) less than a third only about a third of the articles under study actually addressed 
empirical data on barriers to sharing. In the absence of such data, it is impossible to assess how 
accurately the issues in the literature reflect current experiences. Our findings are a valuable initial 
approach, but require comparison with further empirical research. 
 
Our results do, however, provide indications of what authors feel are important hurdles to sharing; 
therefore, we suggest that legal issues, SOPs, and to a lesser extent IP and patent considerations, are 
particularly problematic issues facing the biobanking world. An interesting aspect of this result is that 
each of these issues affects biosample sharing in a different way. National laws are an obstacle to 
sharing because they conflict with one another, but the effects of this are magnified because the 
laws, as they stand, are non-negotiable, and the very networking solutions designed to overcome this 
obstacle can be hampered by it.12 Goebel et al point out that biobanks can circumvent some gaps in 
the transnational legal setting by drafting their own contracts to regulate cross-border sharing;44 
however, as some authors emphasise, uniform regulation must be developed, and biobank 
stakeholders alone cannot achieve this.31,45 
SOPs, on the other hand, can, to some degree, be influenced from within the biobanking sphere. Our 
findings suggest that the problem in this case is not only one of divergence, but also one of quality.  
As Shaw and Patterson note, the rise in translational and genomic research has meant a greatly 
increased demand for samples which are not only well preserved, but are accompanied by 
comprehensive clinical data. This places an extra burden on surgeons and pathologists, who are often 
not the end-users of those samples, or even directly involved with the biobank itself.46 Numerous 
suggestions for enhancing the sample extraction and preservation process already exist;47,48 a  
number of the articles which identified this barrier did so in the context of discussion on biobank 
networks.11,13 It may be the case that barriers which are in the process of being overcome are more 
frequently cited, by way of “introduction” to the proposed solutions. 
 
Intellectual property rights and patenting, while cited fairly often as barriers, differ from general legal 
issues and SOPS in that these are, to a degree, self-imposed desirable limitations to widespread 
sharing. In this sense, they may be considered less as obstacles than as tools to support innovation, 
with some restriction on sharing as a secondary side-effect. While they therefore, in some cases, curb 
sharing, the benefits accruing to researchers and the public may offset this.35,49 
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In contrast to those barriers which are frequently mentioned, it is interesting to note that ethical 
issues receive relatively little attention in terms of barriers to sharing; even the issue of informed 
consent is mentioned infrequently. This is in marked contrast to the plethora of articles on the ethical 
aspects of biobanking, particularly the ongoing debates on the optimal measures for obtaining 
consent.50-52 This may mean that ethical issues are fairly unproblematic in terms of sample sharing, 
but have a greater impact on sample acquisition (or that the focus, anyhow, has been on the latter); 
and/or that as with IP and patenting, ethical issues are a desirable measure to limit the risks harms (to 
participant privacy and autonomy) associated with widespread sharing. While both of these 
explanations may be at play, we feel that, particularly in the case of informed consent, the necessity 
of some restriction on sharing is well recognized. Consideration regarding the justifiability of the 
barriers discussed in this review, and the extent to which they should be “kept” in place will also be  
an important step in optimizing ethical and responsible sample sharing. 
 
Limitations 
 
Our review of the literature has certain limitations. First, it must be emphasised that our decision to 
exclude papers which imply barriers may mean that certain issues were not addressed, but as 
mentioned above, our goal was to avoid accidentally, either through our own perception bias or the 
ambiguity of the writing, including issues which were not in fact intended to be seen as barriers. 
Second, it must be noted that some of the papers referred to here are out of date by as much as eight 
or nine years.13,33 Hence, while we do not feel there are any completely obsolete issues        
mentioned here, some problems may be less pressing in light of recent developments in networking 
or sample processing. Third, the articles captured in our search range from surveys, to reviews, to 
commentaries. Therefore, as mentioned above, some problems are mentioned in a more 
hypothetical way than others. While it could be useful to analyse the rates at which problems are 
mentioned as concretely occurring versus merely being suspected to occur, the lack of empirical 
studies and relatively small literature pool on this topic means that such an exercise would be  
unlikely to produce valid results. Finally, our inclusion criteria and our desire to use explicit 
statements mean that we excluded articles that did not mention sharing in the abstract or 
introduction, which we understand means that we may have missed articles that discuss this subject 
later on in the article. Furthermore, our decision to exclude articles that deal solely with data sharing 
mean that we have not included such important articles as that by Kaye et al (2009) or Knoppers et al 
(2011).53,54 which provide important insight into aspects on data sharing. However, since data sharing, 
especially within the realm of genomics has created an entire field of study of its own, we                
feel it would be best to address this issue separately. 
 
Conclusion 
 
Biobanks are important tools for researchers and clinicians. Regardless of their size and scope, they 
exist to enable some extent of access to biological samples and/or data. Facilitating this access is an 
essential step to maximise the research potential of biobanks; to date, no single article has sought to 
unify the numerous obstacles to sharing mentioned in the literature. As a first step towards tackling 
these obstacles, we have compiled and discussed the above list of barriers to sharing samples with or 
without data, as a basic overview of some of the challenges biobanks and their stakeholders face. 
What is required now is empirical research to determine whether biobank operators and 
stakeholders are in fact experiencing the issues identified, and whether other obstacles exist that 
have not been mentioned in the literature. Biobanks have not yet fulfilled their potential, and 
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overcoming obstacles to their efficient operation is essential.55,56 The consolidation of this list of 
issues is the first step needed to studying existing problems, and ultimately to find solutions. 
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Abstract 
 
The 2008 revision of the Declaration of Helsinki includes a new paragraph dealing specifically with 
the standards of informed consent required for research involving identifiable human tissue samples 
and/or data. In cases where obtaining consent would be impossible or unduly burdensome, 
researchers may now proceed without it, following approval of the project by an ethics committee. 
This is a significant development in the Declaration, yet so far it has received little attention. We 
examine the implications of paragraph 25, and assess its role in the debates on proper sample 
handling. In particular, we question whether the use of the term “identifiable” weakens the 
paragraph, as its meaning depends on national context. Relying on this term to designate samples 
which could be traced to the donor, and therefore carries risk for that donor, is impossible if its 
meaning is not universally accepted. The Declaration of Helsinki is now entering a new revision 
phase. In order to protect sample donors, paragraph 25 should be enhanced, and the remit of the 
Declaration strengthened, by a more precise description of which samples and data count as 
identifiable. 
 
Introduction 
 
The Declaration of Helsinki, developed in 1964 by the World Medical Association (WMA), is the core 
set of ethical principles governing biomedical research. It provides concise guidance to medical 
practitioners and researchers on all aspects of research involving humans, identifiable human 
biological material and/or data. At the heart of the document is the requirement to inform potential 
subjects about proposed research, and obtain their consent before it is carried out. This reflects the 
roots of the Declaration in the ten principles of the Nuremberg Code, a reaction to the horrific 
human experiments carried out during the Second World War.1,2 Since its creation the document has 
been revised six times: the WMA states explicitly that the current version is the only valid and 
applicable one. Furthermore, in the 2000 revision, the document declared its own primacy over  
other national and international guidelines and laws, stating that these must not directly contradict 
the Declaration’s broad provisions.3 While the Declaration of Helsinki is not legally binding, its Article 
14 states that researchers should make clear in their study protocols how they adhere to its 
principles.  The document is also a cornerstone of ethical guidance for physicians globally, which 
many national medical associations and ethics committees turn to when developing their own 
guidelines and laws. 4,5 
 
32 
 
A defining feature of the Declaration is its brevity.6 Designed to be readable within fifteen minutes, 
each paragraph is as concise as possible, with no word used unnecessarily. It is therefore especially 
noteworthy that in the revision of 2008, an entire new paragraph was dedicated to the issue of 
obtaining consent for research involving human samples and data. However, despite the 
Declaration’s central role in the field of bioethics, this revision has received comparatively little 
mention in the literature. Fewer than 25 articles discuss the 2008 changes in detail, and of these, few 
go further than mentioning that a new paragraph is in place, while none offer any detailed analysis of 
the change itself, or the reasons for it. Indeed, in his account of the revision process leading to the 
2008 version, Kuroyanagi only mentions that the new paragraph “ratifies our reality”, as human  
tissue research is becoming increasingly common.7 This is particularly striking as the changes 
regarding placebo-controlled trials, implemented in the 2000 revision, have received extensive 
attention and commentary. 8,9 
It is essential not only to draw attention to the significance of paragraph 25, but also to foster 
dialogue on the reasons for its creation, and on potential revisions to its wording. We aim to fill the 
gap in the literature regarding revisions to the Declaration. Our paper situates the paragraph in the 
debates surrounding human sample use, and explores the wording and its implications for sample 
research. We conclude that improvements could be made to the paragraph in order to strengthen its 
protection of human research subjects, and to solidify the Declaration’s role as the international 
standard in bioethics. 
 
A new paragraph 
 
All previous versions of the Declaration included human samples and data in the general provisions 
governing research on human beings. This is made explicit in paragraph 1: 
“The World Medical Association (WMA) has developed the Declaration of Helsinki as a statement of 
ethical principles for medical research involving human subjects, including research on identifiable 
human material and data.” 
Up until 2000, all human subject research had to satisfy the requirement of paragraph 22, that “ the 
subject should be informed…” and that “the physician should then obtain the subject’s freely-given 
informed consent”. In the 2008 version, although all relevant principles still apply to research 
involving human data and tissue, projects which use only these have been accorded their own 
paragraph. The new paragraph 25 states that: 
“For medical research using identifiable human material or data, physicians must normally seek 
consent for the collection, analysis, storage and/or reuse. There may be situations where consent 
would be impossible or impractical to obtain for such research or would pose a threat to the validity 
of the research. In such situations the research may be done only after consideration and approval of 
a research ethics committee.” 
As noted above, research which makes use exclusively of human tissue and data is rapidly 
proliferating, and recognition that this research requires different regulation is necessary and 
timely.10 The paragraph is a reflection of, and reaction to, current debates in the literature on how to 
handle tissue samples.11-15 It covers the issues of informed vs. broad consent, the waiving of the need 
for any form of consent, and the identifiability of samples. These topics are new to the Declaration, 
but also fairly new in the field of biomedical ethics. Below, we address each issue in turn, explaining 
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the discussions which surround them, the Declaration’s approach, and the implications of its current 
wording. 
The role of “consent” 
 
Paragraph 25 represents a small revolution in the spirit of the Declaration. Previously, its key feature 
was the absolute need for informed consent from competent adults.16 Now this requirement can, in 
some cases, be waived. Waivers of consent are not unheard of in human sample research. The 
American Society of Human Genetics (ASHG) guidelines of 1996 state that the requirement for 
informed consent may be waived in certain (unspecified) circumstances,17 as do the US National 
Bioethics Advisory Commission guidelines on human subject research.18 Introducing waivers of 
consent in the Declaration of Helsinki, however, is a significant step motivated by the rapid 
expansion of biobanking, and the resulting increased focus on the use of human tissue. A large body 
of literature exists concerning the difficulties in obtaining informed consent for samples taken years 
ago, or for routine diagnostic purposes, and the limitations that traditional consent requirements 
place on researchers.19-22 In addition, the paradox of obtaining informed consent for as yet 
unplanned research has also motivated suggestions that a move towards less strict consent forms 
may be necessary for tissue samples.23 Including the potential for waivers in the Declaration is a 
response to the need for new ways of dealing with tissue samples. 
 
It is crucial to note that the wording of paragraph 25 calls for “consent”, as opposed to “informed 
consent”. This leaves open the possibility of obtaining broad consent at the time of tissue collection, 
whereby donors agree to any type of research being performed on their samples in the future. Broad 
consent has been praised for facilitating future sample research while still honoring patient 
autonomy, and criticized for paying only lip service to the consent process, as no real information is 
provided to donors.24 Interestingly, the ASHG guidelines explicitly reject “blanket consent” as a viable 
option, implying that a waiver is preferable to this type of consent. That the Declaration allows for 
the possibility of seeking broad consent, as well as for waivers, is a strong endorsement of these 
approaches. 
 
Justifying waivers 
 
The wording of the Declaration concerning the conditions under which waivers are justified is the key 
element in paragraph 25 and requires careful analysis. The question remains as to how much 
openness of interpretation is explicitly part of the wording and how narrow definitions should be in 
order to prohibit certain types of misinterpretation of the paragraph. Three terms are used to  
provide conditions for a waiver of consent. These are “impossible”, “impractical”, and “threat to 
validity”. Interpreting and applying these conditions involves a risk-benefit analysis on the part of 
ethics committees. 
In a foreseeable “worst-case scenario”, a committee may determine that seeking consent for the use 
of a sample is indeed impractical (perhaps due to high financial cost, or based on previous attempts 
at contacting donors), and approve the study, while fully competent donors continues with their life, 
unaware that their samples are being used in research that he may be fully opposed to. Errors by the 
committee in assessing risk, or widely differing national standards, are also potential undesirable 
outcomes. This is particularly true if “impracticality” is assessed as a balancing of inconvenience or 
costs to the researcher and perceived risks of the study. For example, potentially time-consuming or 
expensive attempts to re-contact previous donors for new consent will seem more impractical, given 
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presumed low risks of harm to these donors. By contrast, equally effort-intensive measures would be 
deemed obligatory in more traditional human subject research. In spite of this, we agree that the 
balancing of risks and benefits should lie in the hands of research ethics committees (RECs), as this 
permits adaptation to different cultural and domestic contexts. Discretion concerning the lengths 
which researchers must go to before the need for consent is waived is an appropriate part of these 
committees’ work,25   and is already standard practice in applying the United States’ Common Rule, 
and the HIPAA Privacy Rule. 26 
However, the scope of the Declaration itself is not a matter of context-specific application. It is 
intended to govern all human subject research, and therefore employs a number of terms which are 
not left for RECs to interpret, but which specify the aims of particular principles. In paragraph 25, this 
term is “identifiable”. Although it is used to describe the type of samples which require REC approval, 
the term’s use in different countries means that currently, the Declaration is not universally 
applicable, a problem we discuss in the following section. 
 
Identifiability 
 
Paragraphs 1 and 25 state that only “identifiable human material and data” are covered by the 
principles. This excludes anonymous and irreversibly anonymised samples, where any link to the 
donor has been lost or destroyed. Identifiability of samples is of key concern, as it is the principal risk 
factor in human material research, much as physical harms are the main risks in traditional human 
subject research.27 If a donor’s sample can be identified, this can have serious consequences: 
stigmatization of individuals or groups, problems obtaining health insurance, and the loss of the 
“right not to know” are all potential outcomes of a sample being linked to the donor.28 It is therefore 
important that in cases where the donor could be identified, every care is taken to ensure that this 
does not occur. This becomes increasingly important as large-scale, multi-center projects proliferate, 
samples are transferred away from the sites of the initial collection, and donors are more difficult to 
contact regarding the use of their tissue.23 
The most serious concern with the current wording of paragraph 25 is its reliance on the term 
“identifiable” to describe which samples must be accompanied by traditional consent, and/or ethics 
committee approval. Identifiability is ambiguous not because the term is inherently vague, but 
because it is used differently in different countries. Formerly in the United States and in Europe, 
samples were said to be “identifiable” if they were anonymized, coded, but could be potentially be 
traced back to the donor. However, in 2004 the United States’ Office for Human Research  
Protections (OHRP) amended their guidelines to include a new definition of the term. Samples which 
are coded and anonymized are no longer held to be “identifiable” providing there is some 
impediment, either legal or imposed by an ethics committee, to the researchers accessing the codes 
which would lead to identification of the donor. Samples are defined as unidentifiable because of a 
procedural barrier, not the absence of a link to identifying data.29 The use of these samples is 
therefore not considered human subject research, and so falls outside the remit of the US Common 
Rule, its federal policy governing such research (which as noted above, also permits waivers of 
consent in some cases). In practice, much of the sample research in the United States does not make 
use of tissue categorized as “identifiable” according to the 2004 OHRP statement, and consequently 
does not fall under the jurisdiction of the Declaration of Helsinki, despite the fact that identical 
studies, if carried out in Europe, would do so. This approach has been criticized for providing 
insufficient protection to donors, as, particularly in the case of whole genome research, DNA samples 
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can be identified despite the lack of accompanying clinical data30 (so long as the individual’s unique 
sequence subset or single nucleotide polymorphism data are known.)31,32 Communities, such as social 
or ethnic groups, are also at risk of stigmatization if identified; indeed, paragraph 17 of the 
Declaration specifically calls for the protection of community groups in research.33 
It is unclear in what sense “identifiable” is used in the Declaration of Helsinki. While it may have been 
in the minds of the drafters of paragraph 25 to allow some flexibility in the interpretation of 
“impractical” circumstances, the term “identifiable” must be precise and specific, in order that 
researchers and RECs are certain about what sort of material the Declaration refers to. 
The Declaration is, among other things, a force for harmonization: its principles are intended to be 
universally acceptable, and numerous previous revisions have been undertaken to minimize 
confusion about its applicability. Having asserted its own primacy, the Declaration must continue to 
live up to its role as core text on research ethics and set high standards for researchers and review 
boards where this is needed. While an organization may choose to ignore its guidance, as the USA’s 
Food and Drug Administration has recently done,7,34 it should not be easy for researchers to dodge 
requirements for ethical conduct by redefining the limits they are bound by. 
 
The importance of identifiability in this paragraph should not be underestimated: this term is crucial 
in providing protection for the donors of the tissue. For this reason, a precise definition of 
“identifiable” is an essential and valuable addition to paragraph 25. 
 
Conclusions 
 
The Declaration of Helsinki remains the most cited document on international guidance in research 
ethics. Its two main aims are the protection of research participants and harmonization of research 
ethics worldwide. These two goals can only be fulfilled if a balance is struck between allowing RECs to 
incorporate some variations based on local context and culture in applying the Declaration,35 yet not 
detracting from the universal nature of the underlying principles that are crucial to the protection of 
research participants, and are not open to negotiation.. The field of human sample research 
exemplifies both values: donors must be protected from possible misuse of their samples and data, 
while simultaneously international collaboration must be facilitated to enable efficient research. 
Sample research is both growing and evolving rapidly, and at present highly prescriptive regulations 
are not appropriate measures. Paragraph 25 is a well-judged approach to the issue, requiring ethical 
oversight in sample research, while allowing local committees some flexibility in their decisions. 
However, the variations in the meanings attributed to the term “identifiable” results in this 
paragraph lacking a clear meaning that can be universally applied. 
In our view, paragraph 25 should be enhanced, and the remit of the Declaration strengthened, by a 
more precise description of which samples and data count as identifiable. This change would have 
the dual effect of reinforcing more clearly the protection of research subjects and supporting the 
harmonization of international nomenclature and research ethics guidance. Human tissue and data 
research is becoming increasingly transnational, and the Declaration of Helsinki must respond to this 
fact. 
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2.3 CONSENT REQUIREMENTS FOR RESEARCH WITH HUMAN TISSUE: 
SWISS ETHICS COMMITTEE MEMBERS DISAGREE 
 
Flora Colledge, Sophie de Massougnes, Bernice Elger 
 
Abstract 
Questions: In Switzerland, research with identifiable human tissue samples, and/or its accompanying 
data, must be approved by a research ethics committee (REC) before it can be allowed to take place. 
However, as the demand for such tissue has rapidly increased in recent years, and biobanks have 
been created to meet these needs, committees have had to deal with a growing number of such 
demands. Detailed instructions for evaluating every kind of tissue request are scarce. Committees 
charged with evaluating research protocols therefore sometimes face uncertainty in their decision- 
making. 
Methods: We examine how a pool of Swiss REC members deal with a number of cases involving 
human tissue, in order to determine the standards they adhere to, and their understanding and 
implementation of existing laws and guidelines. 
Results: There is considerable divergence in the approaches and decisions of Swiss REC members 
regarding human tissue sample requests, particularly concerning the issue of informed consent. 
Despite recent trends towards less strict consent requirements for biosample research, many of our 
respondents continue to employ demanding standards for researchers. Furthermore, the 
disagreement between different committees, and in some cases, members of the same committee, 
may have a negative impact upon the assessment of research protocols. 
Conclusions: Our data suggests that there is uncertainty and disagreement on some matters, which 
should be addressed as far as possible in order to ensure efficient and harmonious review of research 
protocols. 
 
Introduction: 
 
Research involving human tissue, with or without accompanying clinical data, is currently regulated 
in Switzerland by a number of sources. The most specific is the new Law on Research on Human 
Subjects (Humanforschungsgesetz), which addresses tissue samples in Articles 32 to 35 1, but is not 
yet in force. The Swiss Academy of Medical Sciences (SAMS) has developed a full set of guidelines 
outlining best practices for biobanks, and these also offer some guidance on work with tissue 
samples 2. Elsewhere, the Federal Law on Pharmaceuticals and Medical Products3, and the various 
cantonal laws, also apply to some aspects of such research. 
While the SAMS and existing European guidelines 2,4,5 and domestic law provide some important 
information for researchers, and the ethics committee members who must regulate this research, 
the rapidly evolving nature of the field, coupled with the increase in demand for tissue samples, 
means that there are still unclear issues arising 6. How exactly should the degree of anonymisation of 
the samples affect the ethical review process 7? What sort of consent form must be obtained for 
human tissue samples 8-13? Should results be returned to donors, particularly if a potentially 
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dangerous diagnosis is uncovered14? These matters are still widely debated in the literature, yet they 
are crucial for research ethics committees (RECs) in their assessment of research protocols. 
Studies assessing the decision criteria of RECs are scarce 15 and do not specifically address research 
involving biological samples. Our study is an initial assessment of the approaches of Swiss REC 
members to research protocols involving informed consent to human tissue sample use. We aim to 
discover how the committees and their members respond to such requests, whether responses differ 
between committees and their members, and some of the reasons for their approval or rejection of 
various parts of the study protocol. By understanding the ways in which decisions are made, and what 
areas produce uncertainty, it is possible to uncover issues which may require more discussion         
and clarification for REC members and researchers. The aim of our study was not to obtain  
statistically representative results, but to explore broadly which issues are the most controversial and 
why. We therefore adopted a qualitative approach, asking participants to provide comments, in  
order to understand the reasoning behind the decisions of the committee members. The study is also 
a didactic means to encourage further discussion of the addressed issues, and the results were 
presented at the SAKK State of the Art Symposium in November 2011. 
 
Methods: 
 
After discussions with a number of Swiss ethical and legal experts and researchers involved in 
biobanking, a questionnaire was created based upon three case study examples, with several 
questions following. Responses were given using a Likert scale (certainly agree, probably agree etc. to 
certainly disagree) 16, and we asked participants to provide comments after each question explaining 
the reasons for their responses. The case studies were designed to prompt responses on the 
committees’ approach to proposed research using human data and tissue. 
 
Questionnaires were sent to the presidents of all working RECs in the French speaking parts of 
Switzerland. While the cantons of Valais and Vaud have one cantonal commission with or without 
subjections, Geneva was at the time of the study composed of 4 research ethics (sub)committees 
supervised by one central commission at the University Hospitals of Geneva, and we included all 4 
subcommittees. At the time of the study, the joint commission of the cantons Neuchatel, Fribourg 
and Jura was under reconstruction and not available and was therefore not included. Committee 
presidents were informed about the study in writing, and at a meeting of the Arbeitsgemeinschaft 
der Ethikkommissionen (AGEK), the Swiss umbrella organization of all RECs. One phone call and one 
follow up email were used as reminders. Ethical approval for this study was not required due to the 
nature of the research (non-invasive with a non-vulnerable population.) 
Three case study questions were used to introduce the issues to participants. The first concerns (1) a 
request for tissue sample without accompanying data. The second (2) concerns a request for tissue 
with accompanying data. The third (3) deals with the drafting of a biobank’s consent form. 
Completed questionnaires were analysed by all authors. Responses were grouped according to Likert 
scale levels, and comments were analysed and categorized by theme. 
Results: 
 
Overall, we received a total of 31 completed questionnaires: 22 members of committees from 
Geneva, 6 from Vaud, and 2 from Valais responded. One commission president opted to discuss the 
questionnaire during a committee meeting and to provide one single response for the entire REC, 
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while in the other committees, participants answered the questionnaire individually and 
anonymously. 
We include some totals representing the results of the Likert scale questions not to make 
representative quantitative conclusions, but in order to indicate which issues where particularly 
controversial among respondents. In what follows, we present these results in particular to discuss 
the corresponding commentaries that elucidate reasons explaining the controversies. 
 
Box 1: request for tissue sample without accompanying data. 
 
 
 
 
Case 1: Must a request for tissue for research purposes without accompanying data be approved by 
the entire REC? (see appendix: case 1) 
The great majority of respondents replied that, according to the recommendations followed by their 
committee, such a request would need to be approved by the committee as a whole, not fast- 
tracked (i.e. decided by the president only). Respondents mentioned that the president alone was 
not the appropriate judge of such requests, and that the study protocol still had to be carefully 
verified. 
 
Would you approve the project if the sample were irreversibly anonymised? 
 
A total of 21 out of 31 participants responded in favor of this proposition, with only four strongly 
opposing it. Respondents were also asked whether the patient’s consent would be required in such a 
case. Twelve respondents stated that consent would be necessary, 16 that it would not be necessary, 
while the rest were undecided. Of those who felt that consent was not necessary, the decisive factor 
was the lack of risk to the patient: “No risk of misuse”; “No benefit or risk to donor”; “Unnecessary 
and costly administrative procedure”. Those who said that consent ought to be obtained felt that 
“regardless of study type, the patient must be informed”, and that “a biopsy is the patient’s 
property”. 
Would you approve the project if the samples were reversibly anonymised (i.e. identifiable via a 
code)? 
Case 1 
A researcher working in the gynecological department of a university hospital is undertaking a 
study on the efficacy of chemotherapy on breast cancer. He/she has noticed that in some cases 
chemotherapy is very successful, while in other cases it seems to have no effect on the tumor, and 
maybe be nothing but dangerous for the patient due to its side effects. 
He/she wishes to carry out a comparative study between cases responding well to treatment and 
cases showing no response, in order to potentially identify markers for tumor response to 
chemotherapy. 
He/she contacts the head of the pathology institute explains the project, and asks for 50 samples 
of anonymised mammary carcinoma, 25 of which responded successfully to treatment, 25 of 
which did not. To ensure that the samples are comparable, he/she asks the pathologist to provide 
tissue At the same TNM stage. For this study, the researcher does not require the patients’ 
medical records or information. 
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Elaborating on the previous question, participants were asked whether the degree of anonymisation 
was the decisive factor in their approval of a project. In this case, 22 out of 31 respondents wrote 
they would still approve the project, although notably, more chose the “probably” option than in the 
previous question. 
Box 2: request for tissue with accompanying data. 
 
 
 
 
Case 2: Must a request for tissue for research purposes with accompanying data be approved by the 
entire REC? 
Once again, there was virtual unanimity on the fact that such samples, regardless of the degree of 
anonymisation, must be approved for use by the entire committee. 
Is the consent of the donor necessary for such a tissue request? 
 
A total of 18 respondents stated that consent was required if the tissue was irreversibly anonymised, 
and 11 felt that it was, at least probably, not necessary. For the use of identifiable samples, 27 said 
consent would be required, with only two stating that it might not be necessary. When asked to 
explain their views on both cases, most held that consent was an automatic requirement for sample 
use. One participant stated: “Quality and results depend on the cooperation of the donor, which is 
only possible if he has consented”, while another wrote “If the samples are not irreversibly 
anonymised, the patient must be asked if he wishes to receive results, and potentially, bad news.” 
However, another respondent felt that “There are situations in which it is preferable that the patient 
not be contacted.” 
 
Should the discovery of a potentially bad health outcome be shared with the donor? 
 
A total of 23 respondents thought that at least probably, such a discovery should be shared with the 
donor. Four disagreed, and four were unsure. Many of those who felt that the information should be 
shared commented on the fact that this must be made clear, and established, at the time of 
obtaining consent. Those who felt that perhaps the patient should not be contacted cited the 
possible unreliability of the study, and indeed the patient’s desire. The respondent had apparently 
Case 2 
A colleague of the previous researcher is also interested in factors related to breast cancer. 
He/she hypothesizes that certain tumours discovered during mammograms are stable, and, if left 
untreated, they would only rarely evolve into invasive carcinomas. In line with current treatment 
protocols, all suspected tumors are biopsied, and he/she would like to carry out a study on the 
possible difference between tumors in terms of malignancy. 
He/she contacts the pathologist, tells him about the project, and asks for 100 samples of breast 
tumor, diagnosed in the last 5 years. He/she also asks for access to the medical records in order to 
obtain information about the samples, such as the size of the tumor five years ago, the 
development of the case (recurrence, new tumor, death), the patient’s age, if signs for other 
cancers are present, and family history. 
The researcher also thinks that if he/she discovers predictors for malignancy, indicating, for 
example, risks of recurrence, it would be best to inform the patient. With this in mind, he/she 
asks the pathologist for reversible anonymised samples only, in order that the patient could be 
identified by the pathologist if necessary. 
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assumed that the patient was aware of this possibility, and therefore agreed, in principle, that results 
should generally be returned. 
Box 3: drafting of a biobank’s consent form 
 
 
 
 
Case 3: Do RECs find a multiple choice consent form acceptable? 
 
A total of 12 out of 31 respondents reported that they were probably or certainly opposed to a 
multiple choice consent form (see appendix: case 3, highlighted in the box), while 15 would at least 
probably accept it. An examination of the data reveals that in two separate cases, members of the 
same REC held diametrically opposing views. 
Should the choice permitting the samples to be used in any future medical research appear on the 
form (broad consent)? 
Respondents who opposed this formulation of a broad consent felt that the patient would not be 
sufficiently informed to make a proper decision. Interestingly, they indicated that a broad consent 
was practically impossible, not simply undesirable. Among the comments on this proposal were:  
“Too vague”, “Insufficient information for the patient”, “Prior consent would be required”, and “The 
protocol must describe the specific goals of the research”. One respondent cited the SAMS guidelines 
on biobanking stating that Article 4.3 of the guidelines does not permit broad consent(however the 
respondent apparently had a different understanding of the guidelines, as in fact, the article does 
allow for a “general” form of consent encompassing unspecified future uses). 
Of those in favor of broad consent, only one respondent gave a reason: “Patients in a hospital must 
expect their samples to be used in future research unless they sign a form refusing this.” On this 
point, in three separate cases members of the same committee gave diverging responses. 
Should the choice permitting the samples to be used for research on colorectal cancer appear on the 
form? 
Respondents in favor of this proposition approved of the fact that it limited the scope of the research 
to a specific domain, and that it was explicit enough to ensure that the donor would know what he 
Case 3 
A surgeon, who is also the head of a laboratory, intends to undertake a project on colorectal 
cancer, and its development, including initial stages, genetic risk factors, metastatisation, etc. 
For the project, he/she would like to develop a broad consent form for all patient hospitalized for 
surgery, in order to build a biobank in collaboration with the pathology institute. He seeks 
permission from the local ethics committee. 
Currently, the surgeon wants to use samples and clinical data for a project on the APC gene, linked 
to colorectal cancer, and in future, he7she would like to use these samples for  unspecified 
projects. In order to minimize the burden on patients, he/she would like to present them with the 
following consent form: 
 
“ I consent to my sample(s) and clinical and personal data being stored, so that they may be used 
for (please tick all that apply): 
Any  medical research. 
Medical research into colorectal cancer. 
Research on the APC gene.” 
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was agreeing to. One respondent explained “It seems sensible to me that if one goes to the trouble 
of creating a biobank, one ought to be able to use the samples for any aspect of colorectal cancer 
research, with the proper REC approval.” 
Those who opposed this choice stated, once more, that it was too broad. One respondent felt that it 
would be sufficient to indicate that the intended research was in the field of genetics. Others felt that 
this option was still too vague to enable the donor to be properly informed in his consent, though  
this option seemed to be generally more acceptable than the previous one.. 
Should the choice permitting the samples to be used for research on the APC gene appear on the 
form? 
Certain respondents again felt that this choice was “vague”, with one stating that “One must always 
specify the exact details of the research project,” and another stating that even research on a specific 
gene might have many aspects which the donor would not be aware of. 
Others felt that this provision was unduly limiting, as “it would require the researcher to re-contact 
his patients if he wished to perform further research” and “it’s restrictive: one could discover useful 
things on colon cancer.” One committee showed that two members held opposing views on this 
topic. 
 
Discussion 
 
Discussions about criteria for ethics approval of research involving tissue samples have been a 
feature of literature in a theoretical form for some time. The uniqueness of our study is that we have 
used real world detailed case examples and solicited the opinions of REC members about whether 
and under which conditions the projects should be approved. This debate can only be meaningfully 
advanced if the discussion takes into account real-world situations, and with the stakeholders 
directly involved in the decision making. 
For these reasons, a particularly important finding of our study is that there is considerable 
divergence in the approaches and decisions of Swiss REC members regarding human tissue sample 
requests. In some cases, only a few members of certain committees express different viewpoints, or 
raise questions concerning the examples used. However, on a number of issues, there are significant 
differences in approach. Some differences may be due to cantonal or institutional regulations, and 
are a normal part of the operations of the committees. More importantly, our results also 
demonstrate that members of the same cantonal committee hold opposite views. Divergence might 
be caused by a lack of knowledge, understanding, or clarity of laws and guidelines and would point to 
a need for more specific training and clarification from the inter-cantonal REC association (AGEK, 
Swiss ethics). These being the areas which can and must be improved on in order to allow optimal 
REC functioning, it is essential to understand their extent. Our findings are an initial indication of 
areas which require some harmonization efforts. 
The most notable finding of our study is that all three case examples, the greatest areas of 
disagreement concerned informed consent. Below, we discuss the points which produced significant 
differences, and suggest ways in which this could be minimized. 
Questions related to case 1 revealed that a high level of disagreement existed between committee 
members on whether research involving irreversibly anonymised samples, with no accompanying 
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clinical data, would require the informed consent of the donor. The SAMS guidelines 2 state, in 
section 4.3 that no express consent is required for such research. Irreversibly anonymised samples 
are widely held to pose virtually no risk to donors when used in research, and it is frequently argued 
that this lessens the need to obtain fully informed consent 17, 18. Hence, requests for consent by RECs 
risk slowing the progress of research12,19. 
While at the time of the survey and at present the law on human subject research is not in effect, it is 
important to note that the parliament approved the final text of the law in September 2011. It 
stipulates that the law is not applicable for research involving anonymised human biological material 
(Art 2, alinea 2). It is also worth noting that the World Medical Association (WMA) “has developed the 
Declaration of Helsinki as a statement of ethical principles for medical research involving human 
subjects, including research on identifiable human material and data” 20; only identifiable material is 
mentioned. The SAMS guidelines emphasise, however, that inappropriate irreversible anonymisation 
should be avoided: “Both in the interests of the patients and in the interests of research, samples  
and data should not be irreversibly anonymised, as far as this is possible. For the patient, irreversible 
anonymisation means that generally he can no longer be informed of relevant results; for research, it 
means that the samples and the data lose in informative value” 2(p.6). 
Regarding case 2, the most noteworthy result is that almost two-thirds of respondents are convinced 
that consent is necessary for samples accompanied by clinical data, regardless of whether or not they 
were irreversibly anonymised. As above, the SAMS guidelines and the Declaration of Helsinki do not 
make such a requirement. 
When comparing case 1 to case 2 it seems that the existence of accompanying clinical data is a 
motivating factor in the need for obtaining consent. Whether committee members feel that this 
increases the risk (which will depend on the richness of the data and the procedure of 
anonymisation), or that it increases the chance that useful results are found (a realistic possibility, 
given the views on return of results) is not clear, but responses suggest that members are adhering 
to guidelines rather than reacting to the sensitivity of the case. This suggests that a number of 
respondents overestimate the need for consent. 
Case 3 gives some of the most detailed explanation of respondents’ decision making, and provides 
insight into Swiss committees members’ approaches to the divisive field of consent in biobanking. 
Informed consent procedures typically receive a great deal of focus in ethics review 21. In Switzerland, 
informed consent is protected, though not explicitly, by Article 10 of the Swiss constitution 22 and 
Article 28 of the Civil Code 23. As well as being a crucial aspect of every international declaration on 
health care ethics since the Nuremberg Code, it is defended by Article 1 of the SAMS manual on 
research on human subjects 24. Switzerland therefore operates under a legal and ethical framework 
which recognizes the primacy of informed consent in medical research. 
 
Of the individual consent options (which could, but must not necessarily, form part of a multiple 
choice form), a majority of respondents opposed the notion of a broad consent. An even greater 
majority, however, were in favor of the two more specific options for consent. The more restrictive 
option (APC gene research) was no more favored than the slightly broader one (colorectal cancer 
research). Interestingly, respondents who would accept a multiple choice form would in most cases 
also accept a more broad consent. These options represent a somewhat enlarged approach to 
consent in comparison to the traditional human subject requirements, so the correlative acceptance 
of both ideas is perhaps to be expected. 
 
45 
 
 
Our results show that only about half of the respondents approve of these more open approaches to 
consent, demonstrating that this remains controversial among the participating REC members. 
According to the final version of the coming federal law on human subject research, biological 
material may be reused in coded or non-coded form if the sample source has consented after having 
received sufficient information (“nach hinreichender Aufklärung ”). The exact definition of how 
general or detailed the information may be in order to be considered sufficient will remain at the 
discretion of individual RECs. 
Our results indicate that at present REC members prefer to err on the side of restriction as many 
respondents have chosen to adhere to the traditional form of consent used in clinical trials. However, 
there seems to be growing agreement that the specifics of the study protocol can affect the level of 
consent and the details of information deemed necessary. Clearly, the interpretation of the SAMS 
guidelines should be clarified in further training for REC members. Indeed, the guidelines do not 
prohibit broad consent, as one respondent claimed, but might require more specific consent, if the 
primary investigator is aware of his planned research and reuse of the samples before he takes the 
samples. Here again, if the sample is part of a tissue extraction undertaken for treatment purposes, 
the need for specific consent may not arise (for a full discussion of the intricacies and different 
scenarios which can occur, see Junod and Elger, (2010)1). 
Finally, it should be noted that in case 3, on a number of occasions, members of a single ethics 
committee give different responses as to how their committee operates. This represents a 
noteworthy lack of agreement about the very policies and practices of the committee. If not all 
members of one committee agree about how protocol review should be handled, transparent 
criteria need to be used to resolve the inconsistencies. Our study highlights the need for committees 
to work closely, and together with committees from other cantons, in order to ensure a well-argued 
and transparent level of ethical review. 
 
Limitations: 
 
Our study has several limitations. We have included only RECs from one language region in 
Switzerland. Due to the higher number of REC members in the subcommittees in Geneva, the 
opinions of REC members in this canton are overrepresented. On the other hand, this represents to 
some extent the charge of protocols: RECs in cantons with university hospitals treat a much higher 
number of protocols than RECs in cantons without a university hospital. Furthermore, our aim has 
not been to present a quantitative overview about opinions in Switzerland but to explore agreement 
and disagreement as well as the reasons for it among REC members of the same committees and 
across some other cantons. The research design, including the qualitative analysis of the comments, 
has enabled us to show significant controversy. Another limitation is the hypothetical nature of the 
cases. We did not evaluate how RECs would react to real protocols and answers could be influenced 
by social desirability. However, we ensured strict anonymity of the answers, and given their 
sometimes controversial tone, we have no indication for a one-sided social desirability bias. 
 
Conclusion: 
 
Disagreement between REC members and different RECs 15 occurs for three main reasons. Different 
committees may assess risks and benefits using particular paradigms, or may assign different worth 
to certain values, for example patient autonomy versus public good 21. This is an integral part of the 
ethical review process itself, allowing for consideration of local norms and standards, and detailed 
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analysis of the need for research in that particular time and place. However, as addressed above, 
disagreement can also be caused by a lack of knowledge or a variable interpretation of relevant laws 
and guidelines (or indeed, the details of the protocol), or by an absence of such documents. In all of 
these cases, decisions are influenced by inappropriate external factors, hence differences of this kind 
should be minimized as far as possible. However, it is important to bear in mind that guidelines and 
laws as well as their interpretation may change over time, and are also sometimes left deliberately 
vague. Legislators may have purposely left certain parts of the law open to interpretation to allow for 
a degree of variation and adaptation to local culture or circumstances. The lack of specificity may, 
however, have the secondary effect of leaving committee members with insufficient guidance15. 
Our results indicate that there are some differences in the decisions made by Swiss ethics 
committees which cannot be explained simply by regional differences. Particularly important are the 
approaches to requiring informed consent for unidentifiable samples, and the various views on the 
level of consent necessary when tissue samples are obtained. We have suggested that this may be a 
result of the fact that traditional paradigms of informed consent are giving way to more relaxed 
recommendations in the case of tissue samples, and that certain ethics committees have yet to 
“catch up” with these changes. 
It is essential that ethics committees in Switzerland are fully aware of the laws which will affect their 
assessment of study protocols, and that all members of the committee are kept up to date with new 
developments. A Switzerland-wide training and information programme for committee members 
would be one way of working towards this25. Consultation with committees on the optimum way to 
transmit such information would also be a useful step. It has also been suggested that ethics 
committees could create sub-groups with specialisms in certain types of study15. 
As samples of human biological material become increasingly widely used in research, the 
traditionally strict requirements for informed consent are becoming more flexible, reflecting the 
potential benefits of such research, and the minimization of physical risk to human donors. 
Switzerland’s new law on human subject research and recent changes to the Helsinki Declaration 26 
reflects this trend. At present, there is a division in Swiss ethics committees on a number of issues 
concerning the use of human biosamples. While this division perhaps is to be expected at a time 
when regulations are changing, differing standards within RECs and between cantons are  
undesirable. They may be confusing to researchers, hamper prospective studies, and even contravene 
accepted guidelines. In addition, certain cantons may develop a reputation as being “easy to    
please”, while others will be avoided for their strict regulations, with potentially disruptive effects      
in scientific research in Switzerland. Our results show that discrepancies do exist across all 
participants, i.e. between cantons as well as within committees. Education and further training of 
researchers and committee members on ethical and legal issues surrounding research involving 
biobanks would be helpful to clarify uncertainties and to support timely and harmonized research 
review. 
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 PART 3: RESULTS OF THE EMPIRICAL RESEARCH 
   
3.1 OBSTACLES TO WIDENING BIOSAMPLE RESEARCH 
 
 
Flora Colledge, Jakob Passweg, Bernice Elger 
 
 
Potential barriers to biosample and data sharing risk slowing the development of this field.1-3 Many 
authors call for increased expansion and collaboration in biobanking and point towards difficulties in 
the sharing process.4,5 A systematic literature review identified numerous obstacles , including in 
particular the lack of homogeneity in standard operating procedures (SOPs), legal issues, and 
intellectual property and patent rights.6 The review is the first to address the explicitly documented 
obstacles in the exchange or availability of biosamples and data. However, a number of issues which 
might typically be seen as central themes in the biobanking process were found to be mentioned 
only rarely in the literature as explicit barriers. This is somewhat surprising, given the wealth of 
articles calling for increased sharing and methods to achieve this. 
 
It is therefore essential to gather empirical data on barriers in the biobanking world. This will provide 
confirmation regarding which of the obstacles identified in the literature exist in practice, their 
severity and extent, but will further enable the discovery of barriers mentioned sparsely, or not at all. 
It is possible that issues which receive great attention in the literature do not, or no longer, pose 
significant difficulties to those working in the field; equally, important issues may well be overlooked. 
This may be due to a disparity between those who work in biobanking, and those who write about it. 
It is also possible that some of the identified yet rarely mentioned barriers remain underreported in 
relation to their extent because they represent socially undesirable points of view, which could 
damage a researcher’s career, should they be attributed to a particular individual. Feelings of 
“territoriality”, a lack of desire to make samples available to others, may not be readily admitted to, 
and this applies also to reluctance in joining collaborative groups, networks, or working parties. 
Finally, it must be considered that biobank stakeholders may “not know what they don’t know”; in 
other words, they may feel that their efforts to share samples and collaborate are sufficient, but they 
lack awareness about relevant networks, collaborative partners and advanced sharing techniques. In 
order to fully assess these possibilities, targeted empirical research is necessary. 
A qualitative study was therefore carried out, in order to validate, contradict and/or supplement the 
findings from the review, and extend the literature dealing specifically with obstacles to biosamples 
and data sharing. Data was obtained through interviews with biobank stakeholders currently working 
in Switzerland. The reasons for employing this method were a) to obtain information on a wide range 
of themes, some of which might be unanticipated b) an interview setting would allow for a full 
exploration of the experiences of the interviewee, c) guaranteed anonymity would enable 
stakeholders to discuss issues which they might refrain from publicly airing, and d) personal meetings 
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would open to door to meeting other individuals involved in the industry through word-of-mouth 
recommendations. 
Methods 
Participants 
Participants in this study were biobank stakeholders currently working in Switzerland. In order to 
obtain a wide pool of experiences, a broad approach was taken to the term “stakeholder”. As many 
individuals as possible working in connection with a biobank, cohort study, in pathology, oncology or 
cardiology, or involved in the drafting of Swiss laws and guidelines concerning human biosamples 
were identified. Identification was made though internet searches and personal contacts. A 
“snowball effect” was anticipated, whereby interviewees would provide the names of other possible 
interviewees. The aim was to interview 40 stakeholders. Due to the hypothesized snowball effect, 
the interview process began before all stakeholders had been identified.  
 
Interview process 
Once potential interviewees had been identified, they were sent an email describing the project and 
inviting them to take part. Attached was a list of sample interview questions. Timing was described 
and anonymity was assured. If no response was obtained, a follow up email was sent two weeks  
later. If the second email received no response, candidates were telephoned to request participation. 
In case of a refusal of a stakeholder we searched for a person closely resembling the category of the 
previously approached person in terms of function, professional background and type of biobank 
network. 
If participants agreed to the interview, a date and time was set. Participants were offered the option 
of an interview face-to-face or over the telephone. Participants were also given some discretion over 
the timing of the interview. Interviews were carried out in English, except in two cases in which 
participants felt not sufficiently at ease to communicate in English. Hence, one interview was carried 
out in German and one in French. Participants were assured that the interview material would 
remain confidential. Interviews were recorded using the open source software Audacity. 
The interview process was semi-structured, based on an interview guide developed by the study 
team. The guide was developed based on information derived from the literature (both the above- 
mentioned review and general biobanking literature) and the resulting hypotheses concerning the 
barriers to biobanking. 
 
Results 
 
Among the approached 70 stakeholders 36 individuals working in connection with biobanks in 
Switzerland agreed to participate (17 in person interviews and 19 phone interviews). Among the non- 
participants, 25 individuals never answered e-mails or phone calls. The remaining 9 responded but 
declined, stating in all cases either that they had no time, or that based upon our description of the 
study, they could not be helpful in answering our questions. In practice, no significant snowball effect 
occurred, and only one contact with a subsequent interviewee was made based on the information 
provided during an interview. 
 
Analysis 
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Each interview was transcribed based on the recording, and anonymised by substituting code 
numbers for identifiers such as names and places of work. The transcribed interviews were read in 
full by each member of the research team involved in the development of the manuscripts. Flora 
Colledge, Heidi Howard and Bernice Elger then carried out a thematic analysis on the documents to 
identify and group key words, concepts, phrases and attitudes. The main themes were identified and 
selected for further analysis by Flora Colledge, and these findings were then compared to the themes 
identified by Heidi Howard and Bernice Elger, to ensure that no issues were overlooked. For each 
interview, a list of emerging themes was noted. The themes from every interview were then pooled, 
and the transcripts were read again to identify sub-themes. Subsequently, David Shaw and Kirsten 
Persson read every transcript to identify all mention of the themes we have addressed previously.7,8 
Jakob Passweg helped to develop the main themes addressed in the Discussion. 
 
While the foundations laid by the literature review served in developing the interview guide, the 
coding of the interview transcripts was not focused on the barriers identified in the review. Rather, 
every mention of any kind of obstacle to biosample sharing, explicit or not, was coded. It was borne  
in mind that some of the issues identified in the review might appear, but also that new themes 
would emerge, due to the specific conditions experienced by the interviewees, and due to the dearth 
of empirical research on barriers included in the review. 
Below are the main findings concerning barriers which arise from the qualitative empirical data. 
These results will be discussed in comparison to the literature review, highlighting new themes or a 
shift of focus and perceived severity of barriers identified in the interviews.) 
 
Logistics – fragmented views 
 
Standard operating procedures were cited as problematic by a great majority of our respondents. 
Shipping was variously described as costly, time-consuming, liable to be delayed at border customs 
controls (in particular, two participants stated that the Italian border control could takes several days 
to clear), and impossible or difficult due to legal restrictions in other nations (China, Russia and the 
United States were cited as examples). One respondent explained that incorrect boxes of samples 
occasionally were sent to the laboratory. Regarding the quality of samples themselves, there was no 
consensus among participants. While some felt that the biosamples they received were of poor 
quality, due to improper preservation methods or the sample itself being different to what was 
described (i.e. healthy tissue rather than tumour tissue), these comments were in almost all cases 
followed by a caveat that the issue is only a minor one. Two individuals also addressed the difficulty 
of finding, and maintaining, suitable storage facilities (sufficient space for freezers, backup  
generators in case of power cuts). However, more than half of respondents stated that sample 
quality was not a problem. 
The nomenclature used to describe samples and diagnoses was cited as a hindrance to efficient 
sample use post-sharing by two respondents, who mentioned that temporal or regional variances 
could make the subsequent identification of samples challenging. 
Six respondents addressed some aspect of the financial side of the biobanking process. A small 
number stated the obtaining funding to set up a biobank (as part of a larger, cohort study) was 
extremely difficult, with one respondent emphasizing the fact that biobanks themselves do not 
always have a foreseeable, concrete research output: 
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“I mean, the health insurances don’t pay you for biobanking. And then the hospitals don’t pay you for 
biobanking, so this is always done on, on third parties’ money. And that’s a limiting factor.” (I5) 
Obtaining and powering freezers, equipment for taking and preserving samples, and paying the 
salaries of lab technicians were given as examples of costs which are difficult to cover. However, the 
majority of respondents did not experience this particular financial issue, and those who did were 
not working in a hospital or laboratory, but rather for an independent study as part of an academic 
institution. Regarding compensation, eight respondents stated that they had a cost-recovery system 
in place for shipping samples, with eight stating that they did not. Three respondents were involved 
in the pharmaceutical industry, while the rest stated that there was no profit-generating aspect of 
their biobank. One participant stressed that the difficulty of valuing a biosample, and all the work 
that had gone into obtaining it, would itself be a barrier to commercializing the sample. Only one 
respondent stated that they would consider making their samples available, for a fee, to the 
pharmaceutical industry; numerous other respondents rejected this idea, although two had received 
grants from the industry. Financial issues were therefore only identified as being problematic or 
burdensome by a small number of respondents. 
 
Resources – lack of awareness leads to underuse 
 
Sample availability was identified by six respondents as being an obstacle to establishing a large 
sample collection, with one suggesting that the lack of large medical centers in Switzerland was a 
contributing factor (see below for more on the issues attributed to Switzerland.) By contrast, five 
respondents held that sample availability was never a problem, and that indeed there would always 
be more samples than research projects. As one put it: 
“[…] one realizes very quickly that the numbers of biosamples is rarely the limiting factor and it’s 
mostly the number of high impact proposals that are submitted that may be limited[…]” (I15) 
The awareness of the existence of a sample collection was a theme addressed by approximately half 
of participants, although it must be noted that these comments are indirect. On the one hand, eight 
individuals stated that their biobank or sample collection was a relatively new establishment, and 
hence they had rarely or never been contacted by others interested in obtaining samples. On the 
other hand, a number of participants said they were keen to engage in sample sharing and 
collaborative research, but were not aware of any establishments with the type of samples they 
required. Three also commented that a Swiss or international networking facility would be welcome, 
but that no such thing existed, despite the fact that such organizations are, in fact, operational (see 
sections on networks and Biobank Suisse, below.) This issue is also particularly striking in light of 
participants’ comments about personal contacts in the industry (see below). 
When asked about their experiences with biobank networks, several participants expressed either 
skepticism or ignorance. Five reported that they were a member of some form of network designed 
to put them in contact with other researchers in their field; only one individual reported membership 
in a “biobanking network” (in this case, the International Society for Biological and Environmental 
Repositories). Seven stated that they were not a member of any network, with four noting that they 
only sought collaboration with individuals with whom they had a specific interest in working. Two 
also expressed skepticism that biobank-specific networks would be successful in uniting researchers 
in the long term. One respondent specifically stated: 
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“[…] it might be wrong, but in the past I’ve seen many large scale things pass by… and then… for me 
it’s important that we do not plan over five years something and then it goes down in the sixth year, 
but that we are also active and can function. And then I do not see really their long term resources to 
do such a really large… large scale project.” (I5) 
However, three individuals reported that they were not aware of any networks, but would 
potentially be interested in such a system of meeting other potential research collaborators. One 
spoke of the need for a central banking facility connected to this network, and deplored the fact that 
“[…] there is nothing like this in Switzerland.” (I4) A lack of awareness of networks, not just biobanks, 
therefore also appears to be at play. 
 
Networking – signs of reluctance 
 
During the course of the interviews, ten respondents mentioned Biobank Suisse when asked about 
their networking activities. Biobank Suisse operates as a “broker” organization, aimed at linking 
researchers with samples via a members-only database, whilst also holding annual meetings to 
address key issues in the field. Three interviewees reported positive experiences with the 
organization, stating that they had found the meetings and IT support helpful. Seven, however, 
expressed concerns, stating variously that they had never been contacted despite their involvement 
in the network; that the database required data which they were unable to provide for 
confidentiality reasons; or that such a network was an unappealing medium of contact for those 
working with biosamples. This last issue was addressed particularly well by one respondent, who 
went on to elaborate on the role of personal contacts in the biobanking field (see next section): 
“I am pathologist, and I know how these....how function, how works the research. In pathology. So  
it's very difficult to give our sample to someone that we don't know. So many of our research activity 
with other centers, it function for personal, personal connection […] So if someone, if I receive a mail, 
please, there is this study, working on colon cancer or breast cancer, and they need such kind of 
cancer, we are very reluctant to give our samples so. Why? It's much easier if someone say, Hi, I am 
working on this topic, what do you think, do you have some cases like these, we would like, very 
happy, we are very happy to embark in such collaboration with you... it's completely different, you 
see what I mean?” (I29) 
 
Professional contacts play a central role 
 
The role of personal contacts, connections, and at times, friendships, emerged as an extremely 
significant yet unprecedented theme in the course of this study. When asked how they identified 
individuals to engage in sample transfer with, twelve stakeholders said that they collaborated with 
researchers they already knew. Reasons given for this were that researchers’ fields were small 
enough that everyone who could realistically be interested in collaboration was already known to 
them (through contact during training, and later at conferences and so on.) Seven respondents 
stated that they would only share samples within a collaboration where the other party was already 
known to them, and four reported that they would only collaborate in this way if they needed the 
samples for their own research goals. Personal contact was also cited as a basis for trust, essential in 
collaboration, and as a motivator for sharing samples. A number of the respondents who stated that 
personal contacts formed the majority of their collaborations echoed the words of I29, above, 
reporting that this is “how things are done” in the field, and is therefore the standard route for 
sharing biosamples. 
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The other side of the professional contacts coin is the potential difficulties which can arise through a 
two-party approach. The issue of territoriality was addressed by seven participants. They stated that 
certain individuals were indeed reluctant to share their samples due to concerns about being 
“scooped” by other researchers, fear of losing control over the samples, or a desire to garner 
prestige for oneself or one’s institution. One respondent noted that no research group or biobank 
would be willing to be the first to make all its samples and/or data available, out of fear that others 
would not follow suit. However, one respondent stated that territoriality is only an issue in more 
“common” areas of research: in the cases of specific, population-based studies, the likelihood that 
any other group would seek to carry out similar research is very low. 
Twelve respondents reported that they had a website concerning their biosample collection, while 
five stated that they did not. Among those who did, the frequency of updates, and general 
importance of the website, varied significantly. Three individuals mentioned that their website was 
intended to advertise the fact that their samples were available, and one reported that they had 
already received requests based on this information. However, the majority rarely updated the 
information, and did not advertise the extent or type of their sample collection. Two respondents 
also added that they rarely looked at the websites of other prospective collaboration partners. 
 
Regulatory issues – low concern levels 
 
Legal issues were cited by six stakeholders as posing difficulties to the sharing of samples. While only 
a small number of participants cited laws in other countries as limiting sharing (addressed in SOPS, 
above), several made comments concerning the laws in Switzerland; two in fact stated that it was 
illegal to ship biosamples outside of Switzerland. 
Ten individuals reported that they did not currently use a material transfer agreement in their 
biosample exchanges with others. Nine stated that they did. Those who did not use one reported 
that trust was sufficient guarantee for them, and that they saw no need to overly formalize the 
process; this was frequently attributed to the fact that the collaborators were already known to the 
respondents through prior personal contacts (as described above.) 
Intellectual property rights and patenting were addressed only once in our interviews. The 
respondent in question stated that these considerations would certainly limit the sharing between 
researchers of genomic data; biosamples themselves were therefore never linked to the question of 
IP or patents. 
 
Further widely discussed matters – consent and publication credit 
 
The issue of publication credit, or authorship, was addressed in detail by our respondents. The 
findings regarding the impact of this issue on biobanking are addressed in a separate paper.9 
Consent was addressed by approximately two-thirds of our respondents, with many addressing the 
topic thoroughly and identifying unexpected themes which impact upon biobanking in Switzerland. 
The findings on consent are also addressed elsewhere.8 
The Swiss perspective 
 
Finally, twelve individuals mentioned issues specifically pertaining to Switzerland as being barriers to 
wider sample sharing. Three stated that the federal nature of the country, with its 26 cantons, 
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complicated collaborations as there was a sense of separation between researchers. Three stated 
that the mentality, or culture, of biosample sharing is not yet well established. Two mentioned that 
biobanks in this country were being underused due to lack of recognition of their importance. Two 
individuals also emphasized that the small size of the country makes sharing difficult, as there are not 
a great variety of individuals working in specific fields. Finally, as already noted above, the lack of a 
central storage facility, and the lack of large-scale medical centres for recruiting, were also brought 
up. 
 
Discussion 
 
This data reveals a number of discrepancies with the findings of the literature review on the same 
topic. Barriers cited frequently in the literature were mentioned less often, or regarded as less severe, 
by our interviewees. By contrast, certain issues cited rarely in the literature addressing               
barriers explicitly (although in some cases apparent elsewhere in the literature as implicit barriers) 
were frequently addressed, or considered significant. Most notably, there was significant divergence 
amongst the interviewees themselves with respect to the perception and evaluation of various 
barriers. This is particularly important to note, as it may provide evidence of efficient troubleshooting 
methods employed in some biobanks which could be more widely adopted. Divergence may also be 
due to the differing interests of biobanks stakeholders, as discussed below. 
The most striking finding of our interviews is the juxtaposition of respondents’ views concerning the 
obtaining of samples. A third of our interviewees reported sharing samples with individuals they had 
previous professional relationships with as their primary method of sample exchange. Furthermore, a 
surprising third reported that this was the only way they would consider undertaking sample sharing, 
with four of these interviewees stating that they would only do so in cases where it was absolutely 
necessary to further their research. This was also a key reason cited by those who were skeptical of 
Biobank Suisse and other networks. Seven interviewees reported that territoriality on the part of 
other researchers had limited their access to samples, which supports the self-reported reluctance of 
some researchers to make samples freely available. It must also be remembered that two 
interviewees, as reported in our paper on definitions,7 were reluctant to have their samples 
collections caught up in the regulatory difficulties caused by owning an “official” biobank, a 
phenomenon recorded in other interviews with biosample researchers.10 Such reluctance is also likely 
to extend to time-consuming cooperation with efforts to document available Swiss biosamples, which 
may be resisted unless clear benefits for the researcher are apparent. 
 
However, highlighting the divergence in interviewees’ attitudes, many respondents regretted the 
lack of networking opportunities and contacts from other researchers, or felt willing to share but 
reported that there were no such opportunities in Switzerland. It appears that there is a division in 
biobanking between those eager to widen their collaborative pool (but who are unaware even of 
existing opportunities, a distinct problem in itself) and those who are satisfied with a more limited 
route involving personal contacts. Crucially, we do not appear to have two groups content with the 
status quo, but at least one group which feels that obstacles to sharing do exist, and potentially, 
some members in the second group whose reliance on personal contacts has meant that they may 
overlook broader possibilities for sample acquisition. 
An initial approach to this finding must take into account the local context. Twelve respondents 
mentioned that certain issues, which they identified as being specific to Switzerland, were barriers to 
biosample sharing. Their comments, above, are plausible explanations for some of the discrepancies 
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in stakeholders’ perceptions of the sharing situation. It presents a fragmented picture of the current 
situation in Switzerland, with some stakeholders keen to move towards a situation where central 
biobanks act as sample “dealers”, while others prefer to work with colleagues on prospectively 
collected samples for particular studies. Again, this is a situation which is to be expected, given the 
differing nature of researchers’ goals. The aim here is not to criticize those who are less eager to 
make human biosamples available to all-comers, but rather to examine how a strong research 
environment for both groups of stakeholder can be developed. These results give reason to believe 
that, for some stakeholders, there are both barriers and a lack of information in biosample sharing. 
However, caution must be taken in overemphasizing the Swiss situation, as many of the comments 
made by the interviewees apply in the international context. Europe is composed of small countries 
which are likely to experience the same difficulties in obtaining large numbers of samples at the 
national level. The great majority of the interviewees worked in other countries, or are not Swiss 
nationals, and drew on these experiences in responding to the questions. Switzerland is also 
undergoing the same development of new regulations and guidelines that are taking place in other 
countries. 
The above findings exemplify the kind of socially undesirable attitudes which anonymous 
interviewing brings to the fore. In addition, they demonstrate significant differences in approach on 
the part of various biobank stakeholders. 
Other differences with the results of the review are revealed. It is extremely important to note the 
controversy of sample availability. This issue was mentioned only three times in the literature 
reviewed, and by a sizable minority of respondents to the interview, as being a barrier to sharing. 
However, a similar sizable minority of respondents stated with confidence that availability is never an 
issue with human biosamples, and that methods of putting existing samples to good use are what is 
lacking, not samples themselves. This is a view echoed elsewhere in the literature,3 with several 
large-scale banks reporting low rates of sample use,4 and is a significant discrepancy to consider. 
First, it is reasonable to assume that two very different types of sample, or groups of sample type,  
are being discussed. Depending on the format of the research, the rarity of the disease in question, 
the biomarkers of concern, and so on, it is true that there are likely to be many very useful samples 
being overlooked for some research purposes, while other studies must gather new material for their 
specific goals. 
The heterogeneity of the biobanking world has emerged as a key theme of the literature in 
general,11-13 so such contrasting views are to be expected. What must be borne in mind, though, is 
that in light of the subsequent interviewees’ comments about lack of knowledge of other biobanks 
and networks, and the tendency to share samples with researchers already familiar to them, it may 
to some degree be true that useful samples are going to waste because lack of awareness, not 
availability, is the issue. If this is the case, it is a disappointing waste of material which has been 
collected, in many cases, from a public who wishes to see their material further research. It is in any 
case also a waste of resources to recollect a great number of samples which are lying in wait in a 
freezer elsewhere. The consequences of this potential problem (for the results unfortunately cannot 
shed light onto whether, or to what extent, useful samples go unused) will be addressed in greater 
detail below, in relation to further findings from the interviews. 
 
Given the size of Switzerland and other European countries, it is unreasonable to assume that 
individual research centres (whether in universities or otherwise) can amass the same number of 
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samples as comparable organizations in North America, despite the economic and logistical 
advantages.14 It must also be noted that creating a national registry of samples would involve huge 
investment, both of time and money, on the part of both the organizers and every research group 
involved.15 The Swiss National Science foundation has recently undertaken this task, reserving 204 
million CHF for the linking of biobanks and the furthering of translational medicine.16 Meanwhile, the 
Swiss Academy of Medical Science is seeking to incentivize collaborative projects.17 The efforts made 
by Biobank Suisse show that appropriate formats exist, but they may still be missing opportunities to 
link researchers across different disciplines, essential for translational research. At present Biobank 
Suisse lists only three partner institutions on its website, yet has a sophisticated database with 
detailed information about available samples (approximately 60 000 from some 23 000) patients. 
Biobank Suisse also provides multi-level support for researchers, including the promotion of the 
biobanking software CAISIS, and an informed consent template suitable for Switzerland. While some 
of our interviewees reported dissatisfaction with this system, and refrained from getting involved, the 
complaints of other participants about the lack of networking suggest that Biobank Suisse has not yet 
managed to fill the gap in Switzerland. Given what is available, and the report from our     
interviewees on what is still lacking to optimize biosample sharing, consideration can be given to the 
opportunities for moving forward. 
The suggestion that the needs of stakeholders, rather than the basics of biobanking, must now be the 
focus, is supported in an article by Simeon-Dubach and Watson, who suggest that the current 
generation of biobanks must enhance their value with regard to the requirements of stakeholders, 
and ensure their own sustainability.4 They suggest that greater focus on quality, stock management 
and accreditation are all important for the biobank, while researchers can play their part by reporting 
their research findings each time they use specimens from a particular bank. In this way, a system of 
mutual benefit, trust, and also professionalism is developed. 
 
Limitations 
 
Our study has certain limitations. First, in an interview setting, it is always possible that the 
interviewee will avoid certain responses that might be deemed professionally undesirable, in order to 
avoid creating an unfavorable impression among peers. However, the reporting of a number of 
contentious issues in our results leads us to believe that this was not a universal limitation. Second, 
our field of experts was recruited in Switzerland; thus, the results are necessarily reflective of current 
practices in this country, which limits their generalizability to some degree. We emphasize again that 
the great majority of participants had spent considerable time working overseas, were not Swiss 
national, and/or are engaged in work with colleagues in other countries. 
 
Conclusion 
 
While these are certainly important steps for biobanks and researchers to consider, the fact remains 
that when biobanks are spread between universities, hospitals, and individual laboratories, their 
visibility is necessarily limited, and entirely dependent on the efforts of the staff, whose time may 
already be overfilled. Increased participation in established biobanking networks such as the 
International Society for Biological and Environmental Repositories (ISBER), its European chapter the 
European, Middle-Eastern and African Society for Biopreservation and Biobanking (ESBB), and the 
research infrastructure, the Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) 
is a logical and necessary first step. 
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Abstract 
 
Aim: While there is widespread agreement on the broad aspects of what constitutes a biobank, there 
is much disagreement regarding the precise definition. This research aimed to describe and analyse 
the definitions of the term biobank offered by various stakeholders in biobanking. 
Methods: Interviews were conducted with 36 biobanking stakeholders with international experience 
currently working in Switzerland. 
Results: The results show that, in addition to the core concepts of biological samples and linked data, 
the planned use of samples (including sharing) is held to be a key criterion. It also emerges that some 
researchers avoid the term in order to circumvent certain regulatory guidelines, including informed 
consent requirements. 
Conclusion: Developments in the field of biobanking will be complicated if researchers are unaware, 
or deny that their collection is a biobank. A clear definition of the term is therefore an important step 
towards fostering collaboration amongst researchers, enabling them to more easily identify potential 
sources of samples. 
 
Introduction 
 
Human biobanks for medical research are an increasingly important scientific resource. These 
repositories of biosamples and data provide researchers with the opportunity to access large pools of 
material, and gain insight into disease development. They are therefore widely regarded as 
instrumental in enabling the development of new therapies, preventive strategies and diagnostic 
techniques. Biobanks are now highly regulated in most countries, and many official national and 
international guidelines offer definitions of biobanks. These definitions differ in their details, but the 
majority state that biobanks are repositiories of biological samples with accompanying linked data. 
For instance, the Organisation for Economic Co-operation and Development (OECD) defines biobanks 
as “structured resources that can be used for the purpose of genetic research and which include: (a) 
human biological materials and/or information generated from the analysis of the same; and (b) 
extensive associated information."1 The UK Biobank Ethics and Governance Council has stated that 
“the most robust contemporary definition of ‘biobanks’ is ‘rich collections of data plus biospecimens, 
specifically developed as resources for research’”.2 As in both these definitions, the term “biobank” is 
normally used for repositiories that are intended for use in research, rather than for diagnostic 
purposes. Using different terminology for different types of repository allows different regulatory 
regimes and consent procedures to be applied. 
 
However, the extent to which biobank stakeholders are aware of and agree or disagree with official 
definitions is unclear. Given the many differences in biobank type, size, and research focus, and the 
lack of an accepted formal definition, it is unsurprising that numerous definitions also appear in the 
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literature.3,4 While in some cases the differences are minor, in others they are fairly significant. For 
example, Vaught, Kelly, and Hewitt state that “Biobanking involves the collection... of biological 
samples and their associated clinical data and information”5 while Kaye claims that “it is unclear 
whether a biobank consists of just DNA samples or whether it includes personal information or data 
as well”.6 In contrast, Cambon-Thomsen states that “the collected samples do not need to be 
physical... [and can] contain only the data plus information on the sample origin and its geographical 
provenance.”7 The same author stated in an earlier publication that “The concept of biobank includes 
the biological samples themselves”, indicating how even individual definitions can themselves 
change over time.8 
 
Definitions are an important issue because the laws and regulations designed to govern biobanks are 
unlikely to be effective if biobankers themselves are unaware that their collections of samples are 
biobanks, or if they are reluctant to define them as such due to the regulatory requirements which 
can ensue. Furthermore, uniting researchers in collaborative networks will also be difficult if 
awareness about the existence, extent, and value of sample collections remains limited. In order to 
investigate this issue, and other potential barriers to biobanking, qualitative interviews were 
conducted with 36 stakeholders with international experience currently working in Switzerland. 
 
Methods 
Interviews 
In order to explore their definitions of a biobank, we conducted interviews with key stakeholders 
involved in biobanking. Based on a review of existing debate reported in the literature we developed 
a guide for conducting semi-structured interviews. We used purposive sampling, with the goal of 
identifying key stakeholders in biobanking in Switzerland through publications, biobank and 
academic networks, as well as personal contacts and a snowball approach. Among the stakeholders 
identified were biobank managers, pathologists, researchers, clinicians, lawyers and ethicists. 
Questions about definitions were included within a broader interview guide and were preceded by 
more general questions about biobanking activities. Our specific aim with regard to the issue of the 
definition of a biobank was to allow stakeholders to freely express their own definitions in response 
to the question “what is your definition of a biobank?”, and explore their criteria with follow-up 
questions. Interviews were carried out in person or over the phone based on the preference of 
interviewees and travel convenience, and were transcribed verbatim; they were conducted in English 
in order to ensure comparability. Two exceptions were made for interviewees who were not 
sufficiently fluent in English, with one interview carried out in French and one in German. 
Confidentiality was fully guaranteed and transcriptions were anonymized in order to prevent 
identification through names or recognizable situations. The study protocol was submitted to the 
local cantonal research ethics committee (EKBB) and we received a positive response after an 
expedited process (minimal risk study not involving patients). 
 
Response 
 
A total of 36 individuals working in connection with biobanks in Switzerland agreed to participate. 
Among the non-participants, 25 individuals never answered e-mails or phone calls. The remaining 9 
responded but declined, stating in all cases either that they had no time, or that based upon our 
description of the study, they would not be helpful in answering our questions. In cases where 
stakeholders refused to participate we identified a person closely resembling the category of the 
 
61 
 
 
previously approached person in terms of function, professional background and type of biobank 
network. 
Analysis 
 
The transcribed interviews were read in full by four members of the research team (including all the 
authors). Data were analyzed following classical qualitative methods.9 Transcripts were coded to 
identify key themes, concepts, phrases and attitudes. The authors compared codes and agreed upon 
the organization of sub-codes. 
 
Results 
 
Biological material / data 
 
The majority of participants share the opinion that a biobank must contain both biological samples 
and data; see Box 1 for some typical responses. Several participants said that biobanks must be 
“systematic” or “structured”, where structured means “a reproducible way and a transparent way of 
how the things got in there.”(I27). Some interviewees made a distinction between a “repository” or 
“collection”, which do not (need to) have data, and a biobank, which does: 
“A repository is… the difference between a repository and a biobank is, a repository is a collection of 
biopsecimens. Maybe also some data. A biobank… by definition have to have both: biospecimens and 
data. Otherwise it’s not a biobank.” (I11) 
In contrast, a minority of participants stated that a biobank need not contain data: “It’s an 
organization to store… biological samples for later usage.” (I19) In terms of the biological material 
itself, a minority of participants mentioned that the biological material need not be human: “…it’s… I 
would say it’s extremely broad… it’s any biological material being animal, plant…that is…. You know 
located somewhere.”(I16) A few participants claimed that the samples must be of several different 
types of (human) tissue: 
“I would maybe restrict it to… to biological material… tissue and, and fluid…. And I don’t know if I 
would go so far to say that every DNA or RNA or protein piece is a biobank.” (I25) 
 
 
 
 
Size 
Box 1: Biobank stakeholder’s views on the general definition of “biobank” 
I4: “A biobank, well it’s a systematic collection of biological samples…” 
I27: “Any structured sample collection of biological material.” 
I28: “That is biological material... that is annotated...so a certain amount of clinical data 
that is linked to biological material.” 
I36: “…it’s a physical… physical collection of… biological samples, so samples of… of 
organismic origin…together with… meta, or information about these samples.” 
I9: “I think a biobank is any part of the body, either liquid or consistent, I think, and it’s 
frozen down and kept together with clinical data, obviously you need data about the person 
and, and so on, yeah.” 
I13: “A biobank, this is, this is for me a place where you collect and store biospecimens from 
patients, together with clinical information that you can use at some point for starting 
some, some new projects. Yeah, that would be the definition of a biobank.” 
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Most participants did not mention size as being part of the definition of a biobank, but a minority did 
think that size was relevant. Several participants stated explicitly that size could determine whether a 
group of samples constituted a collection or a biobank: “…it’s not a biobank to have ten samples in a 
freezer and Excel sheet. That’s a collection.” (I31). 
Another participant said that whether a collection of samples was a biobank depended on how rare 
the disease in question was: 
“It very much depends on… I mean if you have a rare disease, even a few samples are quite valuable. 
If it’s a more common disease you may need several samples because, depending on… I mean, 
depending on the scientific question, you may not answer a question with ten patients. In Hepatitis C 
for examples, it would be very difficult, unless you are looking at a very rare phenotype.” (I17) 
Use of samples 
 
A substantial minority of participants mentioned the intended use of samples as being a component 
of the definition of a biobank. Among those who did mention the purpose for which samples would 
be used, all mentioned research (see Box 2 for examples). One participant expressed an objection to 
biobanks with no specific purpose: 
“I resent the idea of biobank without questions… I think that biobanks should be focused on 
questions. On scientific and clinical questions.” (I32) 
The same participant stated that s/he had to “…fight with my hospital which is creating a biobank 
which I think is useless…”(I32). Finally, the importance of diagnostic biobanks and of potential 
rediagnosis was also mentioned by several subjects. 
 
 
 
 
Sharing 
 
Some interviewees mentioned sharing as a key component of a biobank: “I think a biobank should be 
something that is used by different researchers, and collaborators also, it’s not something you are 
only doing for yourself.” (I30). Another participant thought that sharing was relevant to determining 
whether his/her collection actually was a biobank: 
 
“So, if you, that's the question, if your definition of a biobank is any storage of samples, then yes, we 
have a biobank, if biobank means it’s so to say like external... we have samples for anybody... Then 
no, we have no biobank.” (I26) 
Box 2: Biobank stakeholders’ views on the use of biobank samples 
I28: “And, let's hope it's used for research, or for... clinical work.” 
I24: “…a biobank … is used to do research that has nothing to with the direct treatment of 
the patient anymore.” 
I12: “…to provide researchers or clinicians with, with tissue, and data.” 
I13: “…A biobank, this is, this is for me a place where you collect and store 
biospecimens...that you can use at some point for starting some, some new projects.” 
I36: “I just want to make this possible, research on biological samples, and this is how I 
would do it. That’s more the… like the banker, not… the banker he doesn’t have, he doesn’t 
own the money, he basically offers services, if people have money, he can handle that… 
and… make more out of it.” 
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Avoidance of the term “biobank” 
 
Several participants said that some biobank stakeholders (on some occasions including themselves) 
choose not to call their sample collections “biobanks” in order to avoid regulation “because of the 
legal aspects” (I22): 
“if I would call it biobank, I would get into a lot of troubles….because all these crazy regulations 
concerning with biobanking…The problem with biobanking is…these people who have brought up 
this, this topic, had thought, thought of, had invented… a whole, very long list of regulations, how 
you have to deal with biobank specimens, how the patient has to get involved yeah, and this for us, 
only meant increase of bureaucracy, complicated, complicated the whole thing… for example 
exchange of archival material, even anonymous, between departments, which was… which was a 
custom, which was a regular habit, yeah, is now very difficult because what is missing for our archive 
material is the… a written consent of the patient.” (I22) 
The same participant went on to explain why these regulations meant that very valuable samples 
might go unused: 
“…but we have all these, we have all these wonderful specimens with very rare tumours, and so, and 
these data, these, these… data security issues… now almost prohibits that we reuse these, these 
specimens, yeah? We always have to say that we use them for quality control. That’s allowed, 
yeah?...but that’s… that becomes legally difficult.” (I22) 
Another participant also mentioned avoiding the biobank ‘tag’ because of the issue of consent: 
“people will start thinking about whether they want to be biobank or not…because biobanking then 
is... you know, it's, to be a biobank, considerable effort…. I mean if you call it a biobank you would 
have to have informed consent forms.” (I27) 
Discussion 
 
Biological material and data 
 
The views of most participants were in line with the official definition of the Swiss Academy of 
Medical Sciences (SAMS, see below), although only one participant mentioned this particular 
definition specifically. As such, biological material and data were seen as the baseline criteria for a 
biobank. Interestingly, however, several interviewees suggested that some collections that contained 
both material and data might nonetheless not be a biobank, with one suggesting that a collection 
could have some linked data without being a biobank, and two suggesting that even large DNA/RNA 
collections might not be a biobank. This is a departure from the majority of the commonly-used 
definitions of the term; it is possible that such comments arose due to the regulation issues 
associated with biobanks (see below). In contrast, some interviewees stated that even collections 
without data were technically biobanks; this view seemed to be more common among pathologists, 
even if they admitted they would hesitate to call them biobanks in practice. This may be because 
some pathologists’ collections are composed only of samples, with the data being stored elsewhere; 
it could be argued that such a collection only becomes a biobank when hospital data are linked to the 
samples. 
 
Size 
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Most participants agreed that size was not an important part of the definition of a biobank, but a few 
claimed that a relatively small number of samples and linked data is simply a collection. This is in 
accordance with the UK Biobank Ethics and Governance Council criterion of a “rich collection”, but it 
is unclear why a “poor” collection with linked data should not also be regarded as a biobank and 
subject to regulation. Furthermore, as another interviewee pointed out, the value of a sample is 
linked to the rarity of a disease, meaning that size alone does not determine the richness of a 
sample. 
 
Use of samples 
 
Almost all participants who mentioned the intended use of samples stated that research is the main 
purpose of biobanks, which is in line with the UK and OECD definitions. Interestingly, one participant 
claimed that biobanks focused on a central question are more valuable than those used for general 
purposes, but unfortunately did not provide any clear reasons for this belief. 
 
Sharing 
 
Although sharing is not mentioned in most official definitions of biobanks, it is encouraging that 
several participants saw sharing samples with external institutions as a key aspect of a biobank, as 
this practice is widely promoted as a means of facilitating research.10-12 
 
Avoidance of the term “biobank” 
 
Perhaps the most interesting finding is that several participants admitted that they would not 
describe their collections as “biobanks” despite the fact that they did meet a number of the 
commonly held criteria. One noted that calling his collection a biobank would lead to him getting into 
trouble. To this interviewee, the perceived overregulation of biobanks means that adopting the term 
to describe sample collections brings with it a number of undesirable consequences. While choosing 
to avoid the term “biobank” is not in itself problematic, carrying out research upon samples without 
ethics committee approval could be regarded as research misconduct. This participant and another 
admitted describing research as quality control in order to circumvent biobanking regulation This is a 
common problem in research review generally: researchers wish to avoid the perceived 
complications of obtaining approval from an ethics committee, so instead attempt to label their 
study as audit or evaluation.13,14 While this might be understandable from a pragmatic perspective, 
conducting research without the necessary approval contravenes the basic principles of the 
Declaration of Helsinki, and is against the law in many jurisdictions (as one participant seemed to 
realize).15 The attitude of the interviewees in question appeared to be that this is just how things get 
done in their line of work; the lack of a standard definition allows such practices to continue, as the 
choice of what to call one’s sample collection is, to some degree, decided on a case-by-case basis. 
(This attitude of “this is how things are done” parallels the attitudes of some biobankers to 
authorship and fairness in sharing).  While a globally accepted definition  of the term  “biobank” 
cannot in itself encourage individuals to call their collections biobanks, it may facilitate holding 
medical practitioners accountable for the use they make of certain samples. We discuss this point 
further below. 
 
Several participants also mentioned the burden of obtaining informed consent from patients. Of 
course, some sample collections are genuinely not biobanks and it would not be helpful or necessary 
to require informed consent for use of such samples. One participant expressed his frustration that 
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regulations make it difficult to use valuable samples that were obtained without consent. A new law 
governing human subjects research in Switzerland comes into force on the 1st of January 2014 and 
will allow the use of historic samples without patients’ consent, which could address researchers’ 
concerns to some extent.16 However, this option does require approval from an ethics committee, 
which means that there might still be some motivation to claim that research is “quality control”. 
 
The importance of a clear definition 
 
Our results make it clear that there is widespread disagreement about the definition of a biobank. 
This may have important implications for sharing and cooperation between biobanks and regulation 
of the use of biological samples. First, if a researcher thinks that his collection is not a biobank, he is 
unlikely to respond to any local, national or international communications concerning biobanks or 
biobank networks. Such researchers are therefore less likely to share samples with other biobanks or 
ask for samples to be shared with them. Second, if a researcher does not think he has a biobank, he 
will not think that any relevant biobank standards or regulation apply to him (see previous section). 
This means that the use of samples might not be regulated properly. While poor sample quality and 
inadequate regulation are also important barriers to sharing, ignorance or denial that a collection is a 
biobank can act as a barrier to sharing even if quality and governance are of a high standard. 
 
What, then, is the best definition of a biobank? Remarkably, no previous paper has focused on the 
issue of exactly what a biobank is. As mentioned above, a wide range of definitions are provided by 
official bodies and in the literature. The results from our study confirm that samples and data are 
seen as the basic requirements for a biobank, with use of samples also identifies as an important 
aspect. Our interviewees generally felt that the size of the collection was unimportant, which reflects 
the majority of national laws and guidelines.19 If we are to arrive at an ideal definition, it will be 
necessary to decide whether size and/or use are essential components of a biobank. 
 
The SAMS provides the following definition: 
 
Biobanks are systematic collections of samples of human body substances (e.g. organs, tissue, blood, 
cells etc.) and DNA as carrier of genetic information. Data that contain information on the donor 
(demographic data, type of disease etc., but also genetic data) are stored, either together with the 
samples or separately.20 
 
In fact, we would argue that this definition is actually superior in one respect that offered by the 
OECD, because it does not dictate that the information associated with biobanks must be 
“extensive”. A biobank can be a very valuable resource without having particularly detailed 
associated data or (as one participant mentioned) thousands of samples, and imposing such 
conditions would allow very many collections to remain outwith biobank regulation despite their 
importance for medicine. However, while it avoids this problem, the SAMS definition has the 
contrasting disadvantage of casting the net too widely: it would include any collection of routinely 
collected biological specimens with linked data, even if such a collection was never intended to be 
used for research. 
 
As such, we would suggest that the best definition of a biobank would be one that does not refer to 
the size of sample collections or the richness of data, but does state that the purpose of the biobank 
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is research. Adding the research criterion to the definition has the dual benefits of reflecting current 
biobank practices, and regulating what needs to be regulated without accidentally catching 
collections that would not require for their intended purpose. This ensures that any samples that are 
to be used for research will be regulated, but those used for quality control, diagnostics or forensics 
(none of which require consent) will not. This would also avoid the problem of researchers having to 
deal with regulation when they have no intention of using historical samples. Therefore, we 
tentatively suggest a definition such as the following: “A biobank is any collection of human biological 
samples and linked data that is to be used for research.” 
 
A clear and widely accepted definition of biobanks would remove the ambiguity currently 
surrounding some collections, making it easier for researchers to  determine whether any given 
collection is in fact a biobank. However, in addition to publicizing the SAMS or an alternative 
consensus definition, it may be necessary for individual institutions to conduct internal audits of 
collections to check that no biobanks are being  overlooked; some institutions have established 
committees for this latter purpose. Such audits could also help increase the number of biobank 
samples available for sharing. 
 
Conclusion 
 
The results of this study reveal that there is substantial disagreement among biobankers about 
exactly what a biobank is. There is a general consensus regarding the key criteria of biological 
samples, data, and their use for research, but quite divergent views on the importance of size, 
sharing, and diversity of samples. Defining biobanks is an important part of regulating biomedical 
research, but the possibility that such definitions might be unwelcome for a variety of reasons has 
not previously been explored. Clear definitions of biobanks and education of biobank stakeholders 
may be necessary to facilitate future biobank development and sharing. Tighter regulation of non- 
biobank collections and sanctions for those who attempt to ignore guidelines may be necessary to 
prevent researchers exploiting this loophole. 
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Abstract 
 
Background: Multi-collaborator research is increasingly becoming the norm in the field of 
biomedicine. With this trend comes the imperative to award recognition to all those who contribute 
to a study; however, there is a gap in the current “gold standard” in authorship guidelines with 
regards to the efforts of those who provide high quality biosamples and data, yet do not play a role 
in the intellectual development of the final publication. 
Methods and findings: We carried out interviews with 36 individuals working in, or with links to, 
biobanks in Switzerland, in order to understand how they interpret, apply and value authorship 
criteria in studies involving biosamples. The majority of respondents feel that authorship is an 
important motivating factor in working and publishing collaboratively. However, our findings suggest 
that in some cases, authorship guidelines are being ignored in favor of departmental standards which 
recognize “scientific work” as meriting authorship. 
Conclusions: Our results support the current calls in the literature for an alternative method of 
crediting biomaterial contributions, in order to ensure appropriate authorship inclusion and promote 
collaborative research involving biobanks. 
 
Introduction 
 
In recent years, there has been a steady increase in clinical research involving large numbers of 
collaborators, often spanning multiple departments and research centers, sometimes between 
several countries. This is partly due to the growing importance of translational research, whole 
genome studies, and biobanks.1 It is now possible, and even necessary, for researchers to pool 
resources from around the globe, either by sharing clinical or genetic data, or by sending physical 
samples to one another.2 Consequently, many individuals are involved in some phase of these 
studies, and their contribution must be acknowledged in the final stage of the research process: 
publication.3 
Being credited as an author on scientific articles is an essential part of a researcher’s career.4 In some 
countries it is also a yardstick by which academic departments are assessed and awarded funding.5 
Coupled with the above-mentioned “team sport” nature of current research, it is not surprising that 
the increase in multi-collaborator studies has been matched by an increase in authors on published 
articles.6 Author lists of several dozen names are now commonplace; some papers have hundreds.7,8 
In light of this, even those accustomed to the norms of scientific research have raised eyebrows 
about how so many contributors can be said to have had a hand in authoring a single work.9 
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The criteria for authorship developed by the International Committee of Medical Journal Editors 
(ICMJE) have stood for almost thirty years, with periodic revisions, and are adhered to by the  
majority of biomedical journals (some of which also have their own detailed standards.)10 They state 
that authors must make a “substantial contribution” to the conception, analysis or obtainment of the 
material, the drafting or revision of the manuscript, and approval of the final version. The goal is to 
ensure that any individual listed as an author can defend the work.11 However, bending and breaking 
of these rules is widely reported;12,13 it is frequently taken as given that certain authors on a paper 
may have made only a few comments, or scanned a draft. Jostling for a place (and particularly a 
prestigious place) on the author list can lead to bickering and, in some cases, significant career 
setbacks, especially for those in dependent positions who lack negotiation authority. 
 
Projects involving biosamples from multiple sources add another complication: how to credit people 
who have provided essential materials, but have not necessarily contributed significantly to the 
analysis or reporting that followed.14 In such cases, the research could not have taken place without 
the contribution of these individuals, who nonetheless do not meet the full ICMJE criteria. To credit 
such contributors as authors would therefore violate the current guidelines if they are interpreted in 
the stricter sense. This potentially creates a problem for the development of biobanking, in that 
those who manage and provide samples might feel they are not receiving sufficient recognition for 
their work if the authorship criteria are respected.15 This issue has been neglected in the biobanking 
literature, and our results reveal some important findings on this topic. 
 
Methods 
 
Ethics statement 
 
The study protocol was submitted to the local cantonal research ethics committee (Ethik Kommission 
Beider Basel) and we received a positive answer after an expedited process (minimal risk study not 
involving patients). The ethics committee did not require written consent to be obtained for the 
competent, non-vulnerable individuals who took part in this non-clinical study. Verbal consent was 
therefore obtained and recorded at the beginning of each interview. 
 
Study protocol 
 
Semi-structured interviews were carried out with individuals working in, or with close links to, 
biobanks based in Switzerland. Using purposive sampling, we aimed to identify appropriate 
individuals through author lists on publications, biobank and academic networks, professional 
contacts, and a snowball approach. Biobank managers, pathologists, researchers, clinicians, lawyers 
and ethicists were all identified and approached, first by initial and follow-up email, and in the case  
of non-response, by telephone. Depending on the convenience of the interviewee, interviews were 
then arranged either in person or by telephone. The interviewer followed a semi-structured  
interview guide (see details on development below), and interviewees were informed that they 
should feel free to introduce issues not addressed by the interviewer. Confidentiality was granted; 
subsequent transcriptions were fully anonymised in order to prevent identification through names or 
recognizable situations. 
The interview guide was developed in tandem with a literature review on current roadblocks to wide 
biosample sharing. Issues identified in the literature informed the key question areas, following a 
brief section to obtain demographic data. Questions regarding authorship were posed in the context 
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of a broader interview guide which addressed other biobanking activities. Questions covered the 
motivating effect of authorship, interviewees’ perceptions and experiences with current authorship 
arrangements, and possible problems with the status quo. 
Following each interview, verbatim transcriptions were made. Upon completion of the interview 
process, these were analyzed by four members of the research team, including all authors. Content 
analysis and coding, following classical qualitative methodology,16 was carried out independently in 
order to develop themes and sub-themes. These were then compared amongst four team members, 
including all authors. The authors then agreed upon the themes for this article. The qualitative 
methodology we employ is based on the model outlined by Mayring in “Qualitative Content 
Analysis”, employing first inductive development, then deductive development, of themes. Due to 
the relatively small sample size and nature of our interview guide, we did not develop a model to 
categorize our findings beyond the general subject groupings we present in the text. Instead, we 
opted to present broad themes using quotations extensively, in order to give a descriptive overview 
of our findings, rather than seeking to quantify particular response categories. 
 
Results 
 
70 stakeholders were approached; 36 of these agreed to be interviewed for our study (17 face-to- 
face, and 19 by telephone). Amongst those who did not participate, 25 could not be contacted by 
either phone or email; the remaining nine replied with a refusal, stating either that they did not have 
time to participate, or that they felt that they could not be helpful in answering our questions, based 
upon an introductory description of the study. In each instance of non-participation, we sought to 
identify stakeholder with similar professional qualities and biobank affiliation. Participants include 
seven biobank managers, three lawyers or ethicists working in the field of biobanking, two 
administrators, and numerous clinicians from various disciplines. A small number work for private 
organizations, with the majority employed by an academic institution. Our group contains Swiss, 
British, Swedish, Italian and German nationals. The majority of interviewees have also worked and/or 
trained abroad for several years. 
In all but two cases, interviews were carried out in English in order to ensure comparability. 
Exceptions were made for individuals who felt more comfortable expressing themselves in their 
mother tongue. Consequently, one interview was carried out in German and one in French. 
Interviews lasted between 30 minutes and one hour. 
 
Authorship as motivating factor 
 
The great majority of those interviewed agreed that authorship on a publication was indeed a 
motivating factor in collaborative research and sample sharing, although none stated that it was the 
chief factor. A number of different reasons as to why authorship credit is such a strong motivator 
were cited. Prestige in publishing in a well-known journal was often mentioned, with some 
respondents noting that this was important for institutions as well as individual careers: “…there’s 
another opportunity to put your laboratory in a bigger paper that will make Nature again, then you 
share the samples.”(I35). Another noted that the influence of funding bodies was a factor: “…it’s very 
important for you to have, let’s say, a first authorship in a very good journal, because that will help 
you to get money for research in the next round of grant applications…” 
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While “publish or perish” is the oft-cited mantra of university departments, our respondents also 
emphasized that non-academic institutions have an interest in publication credit: “…for example, we 
are not a university institute, but it’s nice for us to be part of a publication which is visible…” (I22); 
“…for some, let’s, say gastroenterologists in private practice, that’s quite an achievement, they see 
publication with their name on it even indirectly, and they can, show it in their private practice…” 
(I15). 
Two respondents also stated that authorship acts as an alternative motivator to financial 
compensation for sample use: as one put it, “Authorship is a kind of payment.” (I6) 
However, a sizeable group stated that authorship was not a motivating factor, or at least not the 
most important one, in encouraging sample exchange. The small number who suggested that 
authorship did not motivate collaboration at all stressed that this would be an inappropriate focus  
for biobank stakeholders and researchers. This sentiment was echoed among the slightly larger  
group who felt authorship was simply not the main motivation: “ I think it’s not always possible, it’s 
not always applicable, but I think the motivation should… it’s like with money. And I think one should 
not work for the payment, just having that as prior aim, but this is something you need to go 
further.” (I6) Respondents felt that answering research questions was the key motivating factor: “It’s 
not that we just do it for publications, I mean we do it because we want to answer the scientific 
questions.” (I7) 
Although respondents did not discuss it in terms of a motivational aspect, the visibility which 
authorship brings to the researcher’s biobank was noted several times. When asked about how they 
identified potential collaborators, respondents pointed towards publications: “…it wasn’t looking for 
biobanks, and then, but it was more that they publish in an area so you got aware of them.” (I14) 
 
Criteria for authorship 
 
When questioned about the criteria which must be met to become an author on a paper, our 
interviewees identified a variety of considerations. A large number felt that authorship was a form of 
recognizing contribution: “…people … wanted to be recognized for the work they are doing...And 
recognition in university, is authorship.”(I18) 
Interviewees who held this view of authorship generally stated that involvement in the research 
process was the necessary element: “If they do some scientific [work] then it’s no question to be a 
co-author.”(I11) 
Several participants described criteria for authorship using numbers and percentages of samples (or 
patients) contributed relative to the study size: “… if you share ten samples in a biobank that has 500, 
then they do some research, and they publish something, is it fair that you ask co authorship, or then 
you… the only thing was you took ten samples?” (I33) In most cases, they stated that while this 
method was often employed in some way, it was not clearly established in all cases prior to 
collaboration, and sometimes led to confusion : “Now this is not always easy, because some senders 
they give me fifteen patients, others they give me one patient, and then each one of them wants to 
be recognized, because, someone gave me one patient, four clinicians were involved in that or 
whatever, and the sender that gave me fifteen patients gives me only two clinicians, so how do I 
keep… a sense of justice?” (I32) A small number do, however, have a standard policy based on 
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numbers contributed; for example: “And the few, you know, there's a limited amount of authors that 
can be listed, so we will also pick those who have the highest amount of samples contributing.”(I28) 
While discussion of the criteria for authorship was somewhat vague, some interviewees had strong 
sentiments about what were not sufficient criteria. In direct contrast to the comments above, several 
stated that guidelines on authorship do not recognize mere sample contribution as grounds for 
inclusion: “The criteria to be on a paper, are pretty clearly defined, I think you have to, just to send 
samples or to be, or recruit patients, that’s not enough.” (I24) There was a marked distinction 
between respondents who agreed with this standard: “…what is the scientific work to go to the cellar 
and open a freezer and take out some samples?” (I11); “…publication for me means also exchange of 
effort between the researcher.” (I6) and those who appeared to recognize the standard, but 
knowingly ignore it: ”…but that's just the way it works, the way it works is that if you want their 
samples you have... or their patients, you have to.. do yourself the work, and be accommodating. 
You can, maybe you can call this very unfair, but that's the way the world is.”(I27); “… I cannot 
contribute, because I need the data to…say something. And then I said it’s nice… if you want to keep 
me as a co-author it’s ok, but.. and then we come back to the criteria for the co-author, you should 
be involved and you should know what they [other authors] say [in the paper].”(I33) 
 
Difficulties 
 
Biobank stakeholders we spoke to reported experiencing certain problems directly related to 
authorship arrangements. In view of the comments above, it is interesting to note that a few 
interviewees disagreed strongly with the suggestion that providing samples should not lead to 
authorship. Broadly, the notion that contributing samples is “mere” administrative work was 
contradicted: “Absolutely no. Absolutely no. This is… so… underestimated, our effort. So you need a 
lot, a lot of time, manpower also.” (I29); “… and we always fight to being credited when biological 
samples are used, so that… some of the researchers who join later, the project, who are just not 
aware what it had cost to, to get all these samples organized, they think it’s just available to be 
used…”(I14) 
Beyond the issue of whether or not collaborators deserve authorship for a given contribution, several 
respondents stated that arguments over inclusion and position do occur, sometimes with serious 
consequences: “I’ve seen so many friendships destroyed because of authorships, and I don’t want to 
be part of that.” (I32) 
The most frequently mentioned grievance in such disagreements was the use of rank, or hierarchy, 
to determine authorship, rather than man hours: “… big boss in one lab that I know well signed the 
paper, the guy who had the initiative and the idea, and the postdoc who did the work was in the 
acknowledgments. Big boss wants his name on it… if he’s a schmuck he’s a schmuck.” (I32) 
Even amongst respondents who had not experienced any difficulties, personal relationships, in 
particular the influence of the lead investigator, were noted as being instrumental in establishing 
authorship: “I think it’s fair in this department, I think it’s a culture that the boss creates, whether it 
is fair or not.” (I9) 
Interestingly, one respondent brought up the possibility of refusing an offer of authorship due to 
disagreement with the use of their samples: “… even if this person would pay me a lot, I, I would not 
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agree. If this center would say, “You are going to be on the publication” and I cannot trust what 
they’re doing… it did even happen during the years that I refused to have my name.” (I6) 
Numerous authors on science papers 
 
Finally, several of our interviews brought up the topic of the ever-increasing number of authors on 
scientific papers. Those who had been working in the field for a long time noted that this 
phenomenon is relatively new: “I was struck by the fact that [a few decades ago] maybe on 5% of 
scientific papers has co-authors…” (I34). Another described the discussions about assigning credit in 
such cases as “…like a souk… I’m not going to fight with 179 other co-authors… ” (I32) Despite the 
potential for conflict in such a situation: “…you put together your samples, and you do a genetic 
study, then you identify something, a publication comes out, and it is clear that not everybody can be 
a first author or last author.”(I30) All those who discussed the issue were ambivalent about the 
development: “…if you have a publication, and, and you’re the author number thirty-two, of fifty- 
five, what is the value of that? You can publish in Nature, it’s still nothing. ” (I11) It was also suggested 
that this ambivalence might be a reflection of individual career status, rather than the lack                  
of value in being one amongst many authors:“… these researchers, they are very advanced… they 
don’t care that much if they are 1 in 300 authors because they have the name already.” (I35) 
 
Discussion 
 
To our knowledge, this is the first qualitative study which has sought to describe and analyze the 
experiences and perceptions of biobank stakeholders regarding the attribution of authorship in 
research using human tissue and/or data. As tools for biomedical research, biobanks are also by 
default tools for publishing findings, and authorship is a crucial aspect of professional life for the 
majority of individuals working in connection with biobanks. In multi-center, population-wide or 
transnational studies, the number of individuals with a stake in having their name on a paper may be 
very high. In view of the difficulties associated with publication credit, our results provide valuable 
insight into how affected individuals perceive, and deal with, current practices. 
Our interviewees were nearly unanimous in agreeing with the proposition that authorship is a 
motivation to make samples available to other researchers, or collaborate with individuals external  
to their own department in some way. However, a significant number stated that it was not their 
main motivation, and several respondents made comments to the effect that chasing authorship 
could in some cases be a distraction from research itself.  Given that this latter attitude may be a 
more socially desirable one, it is interesting to note how many respondents were ready to admit that 
authorship was in fact a strong motivator. 
Several interviewees also expressed ambivalence about being included on a long list of authors, and 
stated that this provided few of the above-mentioned career benefits. Indeed, senior authorship 
seemed to be the most important motivating factor for researchers working at universities, although 
others found authorship credit as such motivating. Our interviewees also addressed other issues 
which are prevalent in the literature, such as disputes regarding position and the influence of 
hierarchy, which are generally accepted as unfortunate but predictable in the course of academic 
research publication.17,18 
Our most interesting finding is the respondents’ views regarding criteria which do, or do not, qualify 
an individual to appear on the list of authors. As noted above, the ICMJE has three conditions which 
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must be fulfilled by all authors. It is therefore striking that not only were these conditions, and the 
document itself, never explicitly referred to; in a number of cases, interviewees adhere to systems 
which differ significantly. In particular, several interviewees stated that contributing samples (usually 
above a certain number), or providing some kind of “scientific” input, would be grounds for inclusion 
as an author (indeed, this is a requirement in some material transfer agreements, such as that of the 
Chernobyl biobank19). In some instances, the policy of basing authorship on sample contribution was 
described, and then questioned or objected to, by the same individual. This indicates a certain 
acceptance of such conditions as being just “the way it works”, an attitude which supports the 
literature suggesting that disregard for, and unawareness of, the ICMJE criteria is widespread.3,5,20,21 
Our findings indicate that there seems to be a more or less variable culture of attributing authorship 
that goes beyond the present ICMJE criteria. It is important to stress that what respondents in our 
study describe is not classical “guest” or “gift” authorship, as the biosample contributions were time- 
consuming and included significant scientific and organizational work. Clarification of rules and 
transparency of the types of contributions is of utmost importance, as significant diversion from the 
guidelines has potentially serious consequences22;  furthermore, systematic disregard for guidelines 
will devalue them.23 Several interviewees in our study described policies which seem to contravene a 
strict interpretation of established guidelines in the sense of both over-inclusion and under-inclusion 
of authors. Misattribution of authorship is at best “research misbehavior”,24 at worst research 
misconduct, and can lead to negative consequences for those involved.25 Not being credited as an 
author may hinder an individual’s chances of promotion or obtaining future research grants (this may 
also be the case if a researcher’s named is pushed further down the list solely due to lack of 
seniority).26 Furthermore, inclusion as an author on a paper which is later revealed to have flawed or 
questionable findings may be just as detrimental as being omitted from the list of an important 
publication.27 Our interviewees indicate that both excessive and insufficient crediting currently 
occurs, in accordance with the findings of Glänzel and Schubert, who note that certain studies show a 
tendency to under-acknowledge in-house collaborators, while collaborations with other departments 
are more thoroughly credited.28,29 Nevertheless, the tacit acceptance of disregard for these criteria 
remains a troubling aspect of work with human biological samples. 
 
Implications 
 
Although not all participants felt that material contribution merits authorship, and some directly 
contradicted this notion, the decisive element in the disagreement appears to be the amount of effort 
required to make samples available, rather than correspondence with the ICMJE’s three criteria.    
This suggests that authorship is currently viewed as the only valuable method of rewarding              
and recognizing significant professional effort, despite the fact that not all collaborators may be 
involved in “authoring” the final work. Respondents also emphasized that publication credit is not 
only important for its traditional influence on individual careers, but is also a form of promotion for 
the biobank itself. In the absence of standardized methods of biobank accreditation and indexing, the 
presence of a member of staff on the author list increases the chances of the biobank being contacted 
by external parties. 
There is no provision in the ICJME guidelines which reflects the reality of the evolution of research 
that necessarily implicates multiple centers and collaborators. Some universities, journals and 
organizations provide their own guidelines which are more adapted to crediting material 
contributions: the Swiss Academy of Medical Science, whose directives apply to all our respondents 
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currently, directs authors to their various university guidelines, and provides a list of authorship 
criteria similar to that of the ICMJE, but requiring that only one condition, rather than all, be 
satisfied.30 The University of Basel states that authors should “have made a substantial personal 
contribution to the planning, execution, evaluation, or supervision of a given research publication 
[…]”, a standard which encompasses the work involved in providing biosamples, with or without 
accompanying data.31 However, the very fact that institutional guidelines differ from the 
international standard is troubling, as it is likely to confuse researchers, particularly those involved in 
inter-departmental research. This issue is not confined to Switzerland; the multiplicity of subtly 
different guidelines from organizations around the globe does little to improve an already 
complicated matter. 
Although some biobanks have a policy of only requiring a mention in the acknowledgement section,32 
it is possible that researchers involved in work with tissue samples feel obliged to designate  
important collaborators as authors in the absence of a universally recognized system for rewarding 
scientific and material contributions. To achieve this, they may take a broad view of the ICJME 
guidelines, accepting that small changes to the draft, and a final reading of the article, satisfy a 
relaxed interpretation of the requirements. It seems that an addendum to the guidelines which takes 
into account the possibility of “scientific work” as fulfilling the criteria of study design and creative 
contribution is now imperative. While some flexibility in guidelines to allow for individual discretion   
is advisable, a clearer definition of what constitutes “scientific work” is required to avoid continued 
misappropriation of author credit, and to enable biobank stakeholders and researchers be 
acknowledged in a meaningful way. 
Several alternatives currently exist, or have been proposed, which recognize contributions outside of 
the traditional authorship framework : these include acknowledgement sections, contributorship 
statements such as those pioneered by the British Medical Journal,33 the Biological Resource Impact 
Factor15 and the ORCID (http://www.orcid.org/) initiative to permit recognition of both bioresources 
and stakeholders. The latter two are particularly promising prospects for biobank stakeholders, as 
they are specifically tailored to the challenge of acknowledging sample contribution (important for 
individuals), yet also to providing visibility and endorsement for sample collections (important for the 
biobank as a research entity). Suggested methods include assigning biobank unique identifying 
numbers which can then be used to credit banks that provide resources which lead to publication, 
and standardized, universally employed recognition of biobank employees in the methods section of 
articles. Universal adoption of such a system will be a key step in both resolving authorship issues  
and promoting biobanks as indispensable research resources. It may also be illuminating to look to 
other disciplines for inspiration. Dozens of particle physics papers, for example have over three 
thousand authors.34 One collaborative team, in 1998, pioneered a novel set of standards for 
authorship on all publications issuing from the group, requiring all authors to have worked at the lab 
for a year, although independent of the direct input of that individual on any particular project. The 
existence of a "highly bureaucratic internal structure, small size, people doing tasks and thinking 
together in the same site"35 means that such authorship criteria, while not traditional, are an adaptive 
means of coping with evolving research norms. 
 
Limitations 
 
Our study has some limitations. First, authorship is a very sensitive issue and in spite of anonymity 
interviewees might not have felt secure enough to speak openly. In addition we expect a bias 
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towards social desirability. It is therefore a strong finding that some interviewees admitted openly to 
be motivated very much by publications. We believe that it is not a significant limitation that 
interviewees were recruited in Switzerland because there is no reason that their opinions would vary 
significantly from researchers of other Western countries. Most of the interviewees have 
international experience and work in international collaborations. None of them reported a different 
“Swiss way”, but referred to an international authorship culture they encountered as part of their 
multiple collaborations. 
 
Conclusion 
 
Authorship continues to be a benchmark by which researcher’s careers are measured, yet the 
guidelines for its attribution are frequently disregarded, in some cases due to ignorance of their very 
existence. As multiple-author papers proliferate, so too do the problems associated with them. 
Biobanks are a chief source of the collaborations which produce such papers. Our interviews with 
biobank stakeholders in Switzerland reveal that authorship is considered a motivating factor for 
collaborative research, but that there are numerous instances of inappropriate credit and dispute. A 
main factor in this may be the lack of a suitable alternative method of recognizing the essential 
contributions of those who provide well-annotated, high-quality bio-specimens, but may not 
contribute to the intellectual development of resulting articles. In order to maintain the integrity of 
the authorship system, and encourage the evolution of biobanking, a suitable system of crediting 
authors must be agreed upon by researchers and journals. 
 
References: 
 
 
 
1. Riegman, P.H., Morente, M.M., Betsou, F., de Blasio, P. & Geary, P. Biobanking for better 
healthcare. Mol Oncol 2, 213-22 (2008). 
2. Shickle, D., Griffin, M. & El-Arifi, K. Inter- and intra-biobank networks: classification of 
biobanks. Pathobiology 77, 181-90 (2010). 
3. Wager, E. Bye bye by-line, hello contributors. Journal of the Royal Society of Medicine 99, 
542-543 (2006). 
4. Wilcox, L.J. Authorship: The coin of the realm, the source of complaints. JAMA 280, 216-217 
(1998). 
5. Bhopal, R. et al. The vexed question of authorship: views of researchers in a British medical 
faculty. BMJ 314, 1009 (1997). 
6. Leopold, S.S. Editorial: Research is a team sport: updated authorship guidelines for CORR. 
Clin Orthop Relat Res 471, 701-2 (2013). 
7. Lander, E. Initial sequencing and analysis of the human genome. Nature 409, 860-921 (2001). 
8. Okazaki, Y. Analysis of the mouse transcriptome based on functional annotation of 60,770 
full-length cDNAs. Nature 420, 563-573 (2002). 
9. King, J.T.J. How Many Neurosurgeons Does It Take to Write a Research Article? Authorship 
Proliferation in Neurosurgical Research. Neurosurgery 47, 435-440 (2000). 
10. Editors, I.C.o.M.J. Uniform requirements for manuscripts submitted to biomedical journals: 
ethical considerations in the conduct and reporting of research: authorship and 
contributorship. (2009). 
11. Jones, A. Can authorship policies help prevent scientific misconduct? What role for scientific 
societies? Science and Engineering Ethics 9, 243-256 (2003). 
12. Bennett, D.M. & Taylor, D.M. Unethical practices in authorship of scientific papers. 
Emergency Medicine 15, 263-270 (2003). 
 
77 
 
 
13. Wislar, J.S., Flanagin, A., Fontanarosa, P.B. & DeAngelis, C.D. Honorary and ghost authorship 
in high impact biomedical journals: a cross sectional survey. BMJ 343, d6128 (2011). 
14. Mabile, L. et al. Quantifying the use of bioresources for promoting their sharing in scientific 
research. Gigascience 2, 7 (2013). 
15. Cambon-Thomsen, A., Thorisson, G.A. & Mabile, L. The role of a bioresource research impact 
factor as an incentive to share human bioresources. Nat Genet 43, 503-504 (2011). 
16. Mayring, P. Qualitative Content Analysis. Forum Qualitative Sozialforschung / Forum: 
Qualitative Social Research [On-line Journal], 1(2). Available at: http://qualitative- 
research.net/fqs/fqs-e/2-00inhalt-e.htm [Date of access: 07.01.2013], (2000). 
17. Erlen, J.A., Siminoff, L.A., Sereika, S.M. & Sutton, L.B. Multiple authorship: Issues and 
recommendations. Journal of Professional Nursing 13, 262-270 (1997). 
18. Riesenberg, D. & Lundberg, G.D. The order of authorship: Who's on first? JAMA 264, 1857- 
1857 (1990). 
19. Thomas, G.A. et al. Integrating Research on Thyroid Cancer after Chernobyl — The Chernobyl 
Tissue Bank. Clinical Oncology 23, 276-281 (2011). 
20. Barrett, K.A., Funk, C.L. & Macrina, F.L. Awareness of Publication Guidelines and the 
Responsible Conduct of Research. Accountability in Research 12, 193-206 (2005). 
21. Pignatelli, B., Maisonneuve, H. & Chapuis, F. Authorship ignorance: views of researchers in 
French clinical settings. J Med Ethics 31, 578-81 (2005). 
22. Smith, J. & Godlee, F. Investigating allegations of scientific misconduct. BMJ 331, 245-246 
(2005). 
23. Bhandari, M., Einhorn, T.A., Swiontkowski, M.F. & Heckman, J.D. Who Did What? 
(Mis)Perceptions About Authors' Contributions to Scientific Articles Based on Order of 
Authorship. The Journal of Bone & Joint Surgery 85, 1605-1609 (2003). 
24. Marris, E. & Check, E. Disgraced cloner's ally is cleared of misconduct. Nature 439, 768-769 
(2006). 
25. Geggie, D. A survey of newly appointed consultants' attitudes towards research fraud. 
Journal of Medical Ethics 27, 344-346 (2001). 
26. Strange, K. Authorship: why not just toss a coin? American Journal of Physiology - Cell 
Physiology 295, C567-C575 (2008). 
27. Smith, R. Authorship: time for a paradigm shift? BMJ 314, 992 (1997). 
28. Glänzel, W. & Schubert, A. Analysing Scientific Networks Through Co-Authorship. in 
Handbook of Quantitative Science and Technology Research (eds. Moed, H., Glänzel, W. & 
Schmoch, U.) 257-276 (Springer Netherlands, 2005). 
29. Laudel, G. Collaboration, creativity and rewards: why and how scientists collaborate. 
International Journal of Technology Management 22, 762-781 (2001). 
30. Scientific Integrity Committee of the Swiss Academies of Arts and Sciences. Authorship in 
scientific publications: Analysis and recommendations. (Bern, 2013). 
31. University of Basel Vice-Rectorate for Research. Code of Academic Integrity and Good 
Practice in the Conduct of Research. (2011). 
32. Vaught, J., Kelly, A. & Hewitt, R. A Review of International Biobanks and Networks: Success 
Factors and Key Benchmarks. Biopreservation and Biobanking 7, 143-150 (2009). 
33. Smith, R. Authorship is dying: long live contributorship. BMJ 315, 696 (1997). 
34. Adams, J. Collaborations: The rise of research networks. Nature 490, 335-336 (2012). 
35. Jacob, M.-A. But What Does Authorship Mean, Indeed? The American Journal of Bioethics 11, 
28-30 (2011). 
 
78 
 
3.4 4 GETTING A FAIR SHARE: ATTITUDES AND PERCEPTIONS OF 
BIOBANK STAKEHOLDERS CONCERNING THE FAIRNESS OF SAMPLE 
SHARING 
 
Flora Colledge, Bernice Elger 
 
Bioethics 2015 Jul;29(6):424-30. doi: 10.1111/bioe.12134. 
 
(Impact Factor 1.333) 
 
Introduction 
 
Biobanks are a key tool to advance research about the genetic and environmental factors that affect 
various diseases. In order to enable meaningful results, biobanks need to obtain large amounts of 
samples. Researchers and clinicians are requested to collaborate and to pool efforts to share available 
samples.1 This practice of ‘sharing’ takes many forms. Biological samples and data may                
change hands between researchers, pathologists, public or private biobanks, or clinicians, in 
transactions which can resemble exchange, sale, gifts, or pooling of resources. 2 This variety is a 
reflection of the many different branches of biological research in which biobanks play a role, and of 
the different professionals who find themselves connected in some way to a collection of samples 
and data. Therefore, all forms of biobanks create new challenges as they involve the collaboration 
and communication of individuals from a number of backgrounds. 3  These collaborations typically 
involve some ‘give and take’ from all individuals involved, and are generally undertaken with the goal 
of achieving some professional recognition for the work that takes place: hence, an important aspect 
of these collaborations is their fairness. The UNESCO International Declaration on Human Genetic 
Data 2003 states that countries should ‘ensure fair access’ in the cross-border transfer of samples  
and data. 4 Indeed, a number of biobanks note on their websites that fairness is an integral value of 
their operations. 5-7 
In a pluralistic world in which there are different ideas about what is fair, it is nonetheless evident 
that a lack of perceived fairness can interfere significantly with efficient biobank research. 
Unwillingness to share certain samples, competing interests of various groups, and lack of 
recognition for sample provision are just some current examples of this. 8-11 In the absence of any 
hierarchical or financial dependency, perceived fairness and the feeling of ‘getting a fair share out of 
it’ will be a crucial factor in motivating stakeholders to participate in joint biobanking efforts. 12 The 
importance of fair access has been emphasized in the literature. 13,14 However, no research has 
addressed the elements which researchers themselves feel are important for fairness in sample 
distribution. Even general investigations into how fairness considerations affect collaboration in 
scientific practice are lacking. 
 
Fairness as a property of human interactions has been characterized in several slightly divergent 
ways. It has been described as the impartial application of rules, the appropriate doing of what ought 
to be done, or ‘self-centred inequity aversion’. 15-17 It can be attributed (at least) to both processes 
and outcomes. 18,19 However, what all theories agree upon is that fairness is an attribute of personal 
relationships in which things stand to be lost and gained, and that, when fairness is perceived as 
prevailing, it is a positive, motivating feature of a situation. In other words, promoting fairness is 
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likely to increase an individual’s desire to be involved in collaboration. This is particularly true in the 
field of biobanking, which not only involves personal interaction with the chance of benefit, but is 
also a continuously evolving practice. Furthermore, few laws or guidelines address the details of the 
sharing process, focusing instead on acceptable sample use and consent practices. Exchange is 
therefore controlled at the biobank/researcher level, so individually perceived values such as fairness 
are even more important in ensuring motivation to collaborate. 
 
Methods 
 
In order to explore stakeholders’ perceptions about fairness and their understanding of whether and 
how it contributes to biobanking, we conducted interviews with key stakeholders involved in 
biobanking. Based on a review of existing debate reported in the literature we developed a guide to 
carry out semi-structured interviews. Our aim was to explore a) what fairness means for those 
involved in biobanking (and by extension, collaborative scientific research) and b) how biobank-based 
transactions could be made as fair as possible from the perspective and experience of the 
interviewees. We used purposive sampling, the goal being to identify key stakeholders in biobanking 
in Switzerland through publications, biobank and academic networks, as well as personal contacts, 
and a snowball approach. Among these stakeholders we included biobank managers, pathologists, 
researchers, clinicians, lawyers and ethicists. Questions about fairness were included within a  
broader interview guide and were preceded by more general questions about biobanking activities. 
Interviews were carried out in person or over the phone based on the preference of interviewees   
and travel convenience and were transcribed verbatim. Interviews were carried out in English in  
order to ensure comparability. Two exceptions were made for interviewees unable to speak English, 
with one interview carried out in French and one in German. Confidentiality was fully respected and 
transcripts were anonymised in order to prevent identification through names or recognizable 
situations. The study protocol was submitted to the Ethikkommission Beider Basel (local cantonal 
research ethics committee) and we received a positive response after an expedited process (minimal 
risk study not involving patients). Data were analysed using classical qualitative methods; categories 
were identified independently following analysis by the two authors, then compared, and the 
resulting themes developed. 20 In this paper we report results relating to codes and sub-codes 
concerning fairness within biobanking activities. 
 
Results 
 
Among the 70 stakeholders who were approached, 36 individuals working in connection with 
biobanks in Switzerland agreed to participate (17 in person interviews and 19 phone interviews). 
Seven are biobank managers, three work on the legal and ethical aspects of biobanking, two work in 
administrative roles, and the rest are clinicians in various disciplines. While the majority of 
interviewees work in universities, a few work for private organisations. Five nationalities are 
represented, and the majority of interviewees had worked and trained abroad for several years. 
Among the non-participants, 25 never answered e-mails or phone calls. The remaining nine 
responded but declined, stating in all cases either that they had no time, or that based upon our 
description of the study, they could not be helpful in answering our questions. In case of a refusal of 
a stakeholder we searched for a person closely resembling the description of the previously 
approached person in terms of function, professional background and type of biobank network. 
 
Defining fairness 
 
80 
 
 
The term fairness was never mentioned spontaneously by any of the respondents in the sections of 
the interview concerning the practice of biobanking, including informed consent and sharing of 
 
Notions of what 
fairness involves 
Interviewee comments 
A matter of personal 
relationships 
I1: ‘Well what is fair? I told you, in my view it’s based on personal 
connections mainly, and is personal connections fair, no, but… if there’s 
nothing else, it’s fair.’ 
I17: ‘Well, as long as we deal with fair people, yes, I think so, I hope so.’ 
A baseline assumption I27: ‘Well I mean, usually when people exchange things, you don't have to 
look and ask whether it’s fair, you have to look, whether it's unfair. Find 
the unfairness.’ 
Varies case-by-case I33: ‘I think fairness is a very important point […] It’s relative on the 
project… Depending on, on what your contribution was to the whole 
project.’ 
Implies some 
restrictions 
I25: ‘So yes I think it’s fair if you… do not have to share the tissue with 
everybody, because it also grants for some restriction of use.’ 
Depends on mutual 
agreement 
I4: ‘Well…we… we try to make it fair. By putting it written and sending the 
document back and forth, so that people’s parties can make their points 
and a solution can be found.’ 
samples. The term was introduced for the first time by the interviewer as part of the final section of 
the interview guide. First, it is interesting to note that a sizable minority of participants (about one 
third) responded to this first question about fairness with their own question: some variation on 
‘What do you mean, fair?’ The majority then went on to answer the question by providing some 
description of fair situations or conditions, without giving a clear definition of fairness itself (see 
Table 1). 
 
Table 1: Interviewees’ initial reactions to the issue of fairness 
 
A slight majority of respondents stated that they would class the current system of sharing - either in 
their biobank, or, if they were not directly linked to a bank, of biobanks they knew about in 
Switzerland - as fair. However, a number interviewees said outright that they did not feel the system 
was fair (see Table 2). 
 
Table 2: Reasons for which interviewees felt fairness was lacking/sub-optimal 
 
Reason for perception 
of unfairness 
Interviewee comments 
Unverified publication 
data 
I31: ‘… it actually is not fair to have publications in Nature where we have 
no idea whether the sample really had the illness they say… this is not 
fair, this is… quality of science, or actually input is not controlled at all.’ 
Lack of rules governing 
sample use 
I24: ‘[…] there is no set of rules what to do with the sample, I think, that’s 
often very unclear, and that leads to a lot of misunderstandings and 
aggression and frustration on each end.’ 
I16: ‘More fair… maybe it should be clearer to everyone, you know, what 
are… the rules, what are the guidelines… [we have] struggles and 
problems, because no one is really sure about what are the guidelines.’ 
Financial cost 
associated with sample 
access 
I1: ‘…in the commercial bank it’s not fair because if you don’t have 
enough money, you can’t have samples... I believe once the money’s 
involved, it will not be fair... However, from the industry point of view, 
they would say ‘We have the money, and you don’t want to give us 
 
81 
 
 
 [samples], this is not fair.” But… I consider I would rather keep this 
for…for the people who need it for themselves.’ 
I26: ‘And that's a big problem because even if... there's money for this 
type of research... the clinicians try to get this money for themselves […] 
So... in this way... if a lab is involved that's usually doing routine work, in 
most cases this is not informed that this sample is for research tasks.’ 
Lack of recognition for 
input 
I3: ‘The collaboration is, you give and we take.’ 
I14: ‘Yeah, I think the work and the effort, and the type of infrastructure, 
is underestimated, I really think that this is underestimated….on an 
academic type of question, the science is probably under represented, 
but it’s a supportive function… From the practical, as well as all… the 
organizational things, or logistic part, I think that is a little bit 
underestimated.’ 
 
 
Several respondents stated that while they felt that some aspects of the sharing process were less 
than fair, this compromise had to be made for the sake of continuing with work. Interestingly, these 
respondents all summed up their position with a similar phrase: ‘I don’t know what… I don’t know 
what fair is, I think nothing is fair in this world… well it’s not fair, but I think we have to find a way that 
somehow both of us, both of the parties, can live with it.’ (I17); ‘…since I retired my name is on…  
from day one, my name practically disappeared from the papers… Which, personally, I don’t think it’s 
fair. But it’s the way it is. So you have to live with that.’ (I3); ‘How shall I put it… I think the answer I 
can give is, I can live with it.’ (I15) 
 
Fair conditions 
 
In general, interviewees had far more to say about the fairness of the conditions of their work, and 
ways in which it could be promoted or increased, than about the definition of fairness itself. 
Discussion of fair conditions led to two main thematically different responses. While a number of 
interviewees discussed fairness to external parties (see Table 4), an even larger proportion of 
respondents (see Table 3) referred primarily to fairness for themselves or fair exchange between 
biobankers, researchers and other collaborators. 
 
Table 3: Existing or desirable elements contributing to fair sample sharing 
 
Actual/desirable 
conditions 
Interviewee comments 
Transparency I9: ‘[…] in general we, we have a protocol, we wrote the grant, what we 
want to do, and then there is a PI of this sub-project, and he’s gonna do 
the study, and the others are part of it. I think that’s fair enough.’ 
I8: ‘[…] the problem, the main problem, from my view, is there should be 
transparency from the very beginning. At the start of a project it must be 
clear.’ 
I34: ‘What makes exchange fair… it’s the goal you decide on for the 
exchange, that is… what the person who makes the request wants to do 
with the samples, and, let’s say, exactly, a goal, clear and simple, well 
thought-out.’ 
I24 : ‘Transparent... it doesn’t have to be rules it just should be more 
transparent , what’s happening.’ 
Credit for contribution I9: ‘[… ]it also depends on the institution, in general I had the golden rule 
that the fellow who does most of the work is the first author, and if I run 
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 the project I’m the last author[…] Fairness is that those who contributed 
the most are the most visible, you know.’ 
I35: ‘I think it is that each party gets appropriate credit. That it’s related 
to the amount of work, the amount of intellectual contribution, and the 
financial contribution to the project.’ 
I17: ‘I mean I think it’s very important… to recognize everybody’s input.’ 
I3: ‘[… ] when you have done a lot of work in putting a lot of work and 
effort into something, then you should have a certain right to it. And 
within [our study] there is a huge team and everyone has contributed, so 
they all have a certain right, to me, and that’s fairness for me.’ 
Rules, laws and 
guidelines 
I12: ‘Yes I think it’s fair. Provided you follow all the rules, which have to 
be, which have to be followed or done… we have one paragraph saying, 
ok, if another biobank is following the same rules we have here, then we 
are allowed to share samples, or give samples to them.’ 
I35: ‘[…] specific guidelines or specific texts that deal with sharing… that 
has been debated and scrutinized, worked out by different individuals 
and different organizations, perhaps that might help.’ 
I17: ‘[…] it is fair because it’s made between peers who must set the rules 
before any kind of collaborations, and as long these rules are respected…’ 
I13: ‘… more fair in the future… I don’t know… maybe these people from 
Biobank Suisse they, they should also propose some typical contract for 
sharing in a fair way information or material from the biobank structure 
to different users.’ 
I14: ‘[…] do the best to have it standardized… be part of a network that 
has certain standards, and not try to have your own solution somewhere, 
what works for you but cannot be linked… even try to be part of 
developing a larger system, that makes it fair, and then I think that there 
are understandable… rules who and how the samples are distributed, and 
how you could access them… Yeah, I think fair would be really that, that’s 
part of something bigger.’ 
Mutual benefit I16: ‘I would say, I mean no one is losing anything. […]I mean if something 
happens and one of them is profiting… maybe both are profiting.’ 
I13: ‘Fair for, for the patient who give the material, for the partners with 
whom we are working… I think it should be anyway a win-win situation.’ 
I36: ‘In general… when it [sharing] happens then it is exactly because 
everybody sees their mutual interest.’ 
I4: ‘[…] go from the point of view that the other person is also trying to 
act in the best of his interests. In the sense of… they don’t want to harm 
you, they want to… have benefit for themselves, so it’s just that both 
parties will try to have the most of the benefit for themselves, and they 
have to agree on that.’ 
External control I14: ‘[…]but this is done in a, in an understandable, rational, whatever 
type of way, like with the ethics committee, and the type of questions 
that there are worked out. Also independently.’ 
I28: ‘Well, it's very [fair], because of the committee that reviews them, 
they are not [cohort] members.’ 
 
 
The quotations shown in Table 3 represent the best examples of respondents’ views on key issues; 
generally, these themes emerged repeatedly throughout the interviews, and stakeholders held 
similar positions. However, in a few cases, there was divergence. In contrast to the general calls for 
clear rules and guidelines, one respondent stated: 
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‘[…] I don’t like leveling, leveling from the bottom…So I don’t want to do that, if I clarify things too 
much, then I think it may backfire and do more damage than not clarifying it.’(I32) 
Similarly, another was cautious about uniform documents: 
 
‘I think an important one is that… individual projects are discussed, and also participation, be 
decided on an individual project basis. So you’re not really generally forced to, to participate in 
anything, that’s already important.’(I5) 
 
Table 4: Fairness considerations regarding the public 
 
Considerations Interviewee comments 
Scientific responsibility I21: ‘Well, it [fairness] would be the respect of what was, you know, the 
ethical considerations, and, that it’s good science being done.’ 
I14: ‘I hope. I mean, it [fair sharing] certainly would be one of the 
priorities, actually, because I really believe in the, in the thing, the 
research has a responsibility to society, and that would be one way.’ 
Use of public funds I31: ‘I think many studies are designed not on the question, what is an 
important answer, and then, OK, what tissues do I need to answer this 
question, but many studies are… because this is a nightmare to get all the 
tissues, it’s done the other way, what tissues do I have, what questions 
can I ask to my tissues, so this is the way it goes… and this not fair 
actually, this is not fair for the community who pays, for any, every, 
everything.’ 
I2: ‘I mean I sincerely hope that a proposal that was not fair would not be 
approved. I mean… we can take the fairness issue with this question to 
another level, the funding for this project is coming from taxpayer’s 
money… money that’s come from taxpayers has a huge castle, and 
empire, of incredible responsibilities, that scientists had better  
appreciate, somebody’s worked their butt off to make this money…and 
this is tremendous privilege to be a scientist, that society’s giving you this, 
so you know, the fairness… of sticking to what you said you’d do.’ 
 
 
Discussion 
 
We know of no other study to date which has closely examined stakeholder attitudes to the fairness 
of scientific collaboration and material sharing between biobanks. As research becomes increasingly 
transnational and transdisciplinary, and the number of researchers involved in each project grows, 
this issue becomes ever more pressing. The topic of fairness is a delicate one, and is also difficult to 
quantify and regulate; nevertheless, as we note above, it is a crucial aspect of ensuring participation 
in collaborative research, and avoiding obstacles in material exchange. The field of biobanking, which 
depends upon such exchange, is therefore an ideal focus to understand what fairness entails for 
researchers themselves. 
The most striking result of our study is the strong variance between interviewees’ perceptions of 
whether the current system is fair. There is clear divergence in respondents’ experiences, which is 
consistent with the fact that there is currently a lack of uniform guidelines governing sharing. It is   
also interesting that three interviewees used the same phrase, ‘I can live with it’, to characterize their 
attitude. Given the abstract and potentially sensitive nature of our questions, this response may 
suggest a fairly negative perception of current conditions, while simultaneously implying that it is not 
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worth considering further. It is possible that other respondents also discussed conditions that they 
have learned to ‘live with’, but which might not be optimally fair when taken out of the daily 
professional context. The fact that most participants believe that they can live with the current 
system suggests that any unfairness is at least not intolerably unfair. 
Our findings show that biobank stakeholders do not mention the term fairness spontaneously, but do 
say that fairness is an important aspect of the sample sharing process when questioned directly. 
Respondents were initially uncertain about the term ‘fairness”, and were vague about its definition.  
It is interesting to note that the UNESCO Declaration, and the biobanks which prominently advertise 
‘fair’ sample access on their websites, also do not offer a definition of the term. Nearly all of our 
interviewees did however have strong notions about what fairness requires in practice. They also 
answered questions about fair conditions without hesitation, despite the term fairness itself leading 
to counter-questions. This supports the notion that ‘getting a fair share’ is important to stakeholders, 
and they have considered these matters before, even if they have not been called upon to discuss 
them as such. However, it is also possible that, when confronted with an unexpected line of 
questioning, respondents adopted the newly-introduced term ‘fair’ to describe processes that they 
might previously has described as ‘good’, ‘bad’, ‘inefficient’, etc. 
In general, there was a good deal of agreement between respondents on key aspects of fairness. 
Issues such as transparency, rules, and responsibility to the public were brought up frequently, 
without prompting, and opposition to these attitudes arose in only a few cases. The need for more, 
or more visible, guidelines and rules was particularly prevalent. Participants made little comment as 
to the content of such rules, however; it is unclear whether the mere existence of rules was thought 
to be sufficient. While visible regulations may help with the transparency of sample exchange, it is 
arguable that rules in themselves may also be perceived as unfair by some parties. Indeed, their 
rigidity may produce instances of unfairness in processes which were previously adaptable on a case- 
specific basis; accordingly, we recommend that written agreements may be a good solution (see 
below). The desirable criteria for fairness also match a number of points on the ‘fair access’ scheme 
employed by the UK DNA bank network. However, our respondents did not bring up the issues of 
limiting access for non-collaborators, or long-term support and tracking of sample use. 13 
Interviewees also addressed the topics of publication credit, or authorship, and fairness vis-à-vis 
patients in their responses. These topics were described with unprecedented detail and revealed 
several interesting and unique perspectives from biobank stakeholders. A detailed analysis of 
respondents’ responses related to authorship, and concerns for patients/donors, is presented 
elsewhere. 
Our results reveal two contrasting aspects of why fairness is a motivating factor, which reflect the 
theoretical accounts. One the one hand, participants mentioned the systems that can or do promote 
fairness (Table 3), while on the other, the motivation came from external sources (Table 4). The latter 
set of reasons suggests an outcome-based approach; the former approach is more process-oriented. 
Simmons (2003) notes that a distinction can also be drawn between procedures (which establish 
collaborations) and processes ( the progress of said collaboration). 19 This is reflected in stakeholders’ 
concern with establishing collaborative agreements that are universally acceptable upfront, but can 
also be referred to as insurance that all parties fulfill their obligations. 
 
Interestingly, the process-oriented responses tend to result in fairness for researchers and 
biobankers, while the outcome-oriented responses resulted in fairness for those not involved in the 
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sharing process itself. This may be due to the fact that, as mentioned above, sample exchange is still a 
relatively unregulated field: stakeholders themselves are therefore instrumental in establishing the 
sharing process, and hence have well-developed notions of fairness which encompass their own 
needs and interests. Fairness therefore becomes a matter of reciprocity. There is then a second, 
outward-looking meaning of fairness, which is more a matter of public trust and keeping one’s word 
as a professional. However, this second type of fairness also has a significant influence on motivation. 
A number of respondents stated that duties to others were an incentive to actively share samples. 
This is consistent with the partly outward-looking nature of biobank-based research, given its 
patient-oriented aspects. 21 
Implications 
 
Two respondents mentioned that biobanking is a field in which exchange amongst individuals is 
indispensable: ‘[… ]sharing is the only reason that you need a biobank, otherwise we don’t need 
biobanks, collections are fine, without sharing, so… for the biobank sharing should be, is their 
motivation to exist.’(I31); ‘Because this is the reason of the biobank. It’s not a bank. It’s not a money 
bank, you put your money, you are the only one to take, you know from your account, no, it’s for […] 
improving translational research.’ (I1) Promoting widespread and effective sharing is the priority of a 
number of governments, research networks, and biobanks themselves. While these bodies may 
develop infrastructures and guidelines on sample storage and use, researchers’ motivation to 
participate in wide sample sharing is essential to moving the field forward. Given that some 
participants mentioned that sharing only with known contacts was unfair, better communication 
between biobanks may also be important to make the system fairer. 
The answers given by our respondents show a number of clear fairness criteria that motivate their 
actions involving biosamples. Developing and promoting these criteria is therefore likely to have a 
positive impact on the extent of sample sharing. For the most part, the conditions that were 
important to our interviewees could be enhanced by elaborating written agreements at key stages of 
the exchange process. This is in line with the findings of Vaught, Kelly and Hewitt, who note that 
successful biobanks tend to have well-established access policies and published governance 
standards. 22 This may also serve to motivate large-scale exchanges, by acting as a safeguard for 
researchers who may have had little previous personal contact, and thus not built up the trust which 
facilitates smaller collaborations. Access policies can satisfy the outward-looking fairness 
requirements of meeting public expectations for research carried out with their money or tissue 
samples. 23 ‘Fair access’, in contrast to less-regulated ‘open access’ schemes, can provide the 
restrictions necessary to protect donor privacy and intellectual property.24 These concerns for donors 
and the public are also essential to recruiting participants and maintaining trust in the biobanking 
process. 25 
In addition to access agreements, according recognition for a biobank’s compliance with existing 
guidelines could allow prospective collaborators to see the standards followed by that bank; this 
could perhaps be incorporated into a system such as that proposed by Anne Cambon-Thomsen, the 
Bioresource Research Impact Factor. 26 
Limitations 
 
We have chosen to focus on biobank activities in one country, which could limit the generalizability 
of our results. However, most of our respondents have an international medical background and 
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have spent some time working abroad, mostly in adjacent European countries, the UK and the US. 
Many of them referred not only to practice that they encounter in Switzerland but explicitly 
mentioned experiences from their work abroad. In addition, a significant number of interviewees 
referred to international collaborations, i.e. multi-country projects that received international 
funding. Therefore, we conclude that most parts of our results are generalizable and refer to practice 
that is found nationally and internationally. 
The fact that almost half of the approached interviewees did not answer our request or declined 
participation could mean that our sample is biased. As we made sure to replace each non-participant 
with a person from a similar ‘category’ of participants, we do not think that a bias exists towards 
particular groups or towards particular views held by the interviewees that agreed to participate. 
However, it is possible that those who agreed to participate were generally more motivated to 
conduct further biobank research. 
 
Conclusion 
 
Our findings show that considerations of fairness are important to biobank stakeholders, as sample 
and data sharing is a major aspect of their work. While most of our interviewees felt that current 
sharing practices were quite fair, some areas that require improvement were identified, and some 
instances of outright unfairness were also noted. Perceptions of what constitutes fairness were well- 
rounded and broad-ranging, taking into account both the inner circles of scientific research, and the 
general considerations of public and professional responsibility. These clear accounts of fairness 
mean that improving the status quo should be straightforward. Fairness is a significant factor in 
motivating researchers to widen the scope of their sample exchange. Since fairness is not something 
that is regulated per se, encouraging conditions which foster transparency, mutual benefit and 
professional accountability is a necessary step for biobank stakeholders. 
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Abstract 
The ability to exchange samples and data is crucial for the rapid growth of biobanking. However, 
sharing is based on the assumption that the donor has given consent to a given use of her or his 
sample. Biobanking stakeholders therefore must choose one of three options: obtain general consent 
enabling multiple future uses before taking a sample from the donor; try to obtain consent again 
before sharing a previously obtained sample; or look for a legally endorsed way to share a sample 
without the donor’s consent. In this study, we present the results of 36 semi-structured qualitative 
interviews with Swiss biobanking stakeholders regarding these options and the role of ethics 
committees in the process of authorizing sharing. 
Our results show that despite a lack of legal or guideline-based barriers to general consent, some 
stakeholders and ethics committees have reservations about this method of consent. In most cases, 
however, a general consent form is already in use. Many interviewees describe processes involving 
the ethics committees as time-consuming and cumbersome and their requirements as too 
demanding for donors/patients. Greater awareness of donors’ opinions and preferences and the 
content of guidelines and recommendations could therefore be helpful for a better justified 
perspective of biobanking stakeholders and ethical committee members, equally. Finally, it may be 
necessary to differentiate between procedures governing future samples, where general consent is 
clearly desirable, and the use of old yet still relevant samples, where the option of using them 
without consent can be highly beneficial for research. 
 
Introduction 
The rapid evolution of the field of biobanking has presented clinicians and researchers with a number 
of challenges which require different approaches to those faced in research involving human subjects. 
The potentially huge benefits of accessing samples from large pools, spanning decades, are 
accompanied by certain difficulties. Stored biosamples must be cleared for use in research projects   
in line with departmental, national and international laws and guidelines. The focus of the most 
stringent of these requirements is the form of consent which must be obtained before the samples 
can be made use of. 
 
Due to the relatively recent developments, and wide-ranging applications, of biosample research, 
regulatory documents have emerged at staggered intervals, as international organisations, 
governments and institutions seeks acceptable solutions to regulating such research.1 Not 
surprisingly, the documents produced by these various bodies sometimes contain significantly 
divergent recommendations on informed consent (IC).2   While some organisations may require a 
specific consent to be obtained from the sample donor which covers only one research project, 
others allow for a general consent to any future use of the sample for research purposes.3 Within the 
last few years, attention has been turned to harmonising the laws regarding the consent 
 
89 
 
 
requirements for biosamples, in part a reflection of the wide debate in the literature on this topic. 
Although a number of authors stress the potential risks to donors of giving general consent, and 
suggest that consent to an unknown project is not consent at all,4,5 the majority of papers now call 
for the widespread implementation of a general consent, in order that valuable biosamples can be 
fully exploited.6-8 Since a core aspect of the worth of biosample collections is their longevity, it is 
argued, it makes little sense to effectively impose an expiry date on their use by ruling out the 
unforeseen research of future years. By the same token, existing sample archives which may lack 
general consent from all donors have also become a focus for medical organisations and 
governments. 
 
Two options exist for rendering archived material eligible for research: consent can be sought 
retrospectively (in cases where a limited consent has already been obtained, this is known as 
“reconsenting”),9 or the requirement to obtain consent can be waived.10 Seeking consent or 
reconsent is the responsibility of the researchers, and can, particularly in cases where old or poorly 
catalogued samples are involved, be a time-consuming and complex process. Waivers of consent 
have therefore become increasingly common; in the absence of laws governing the issue, 
international and national medical organisations have included this option in their guidelines. 
 
The Declaration of Helsinki (2008) states: 
 
“[f]or medical research using identifiable human material or data, physicians must normally 
seek consent for the collection, analysis, storage and/or reuse. There may be situations where 
consent would be impossible or impractical to obtain for such research or would pose a threat 
to the validity of the research. In such situations the research may be done only after 
consideration and approval of a research ethics committee” (§ 25.). 
 
Similarly, the recommendation given by the Council of Europe (Steering Committee on Bioethics 
(CDBI)) states: 
 
1.i. If the proposed use of identifiable biological materials in a research project is not within 
the scope of prior consent, if any, given by the person concerned, reasonable efforts should be 
made to contact the person in order to obtain consent to the proposed use. 
 
ii. If contacting the person concerned is not possible with reasonable efforts, these biological 
materials should only be used in the research project subject to independent evaluation…” 
 
Finally, though it does not address waivers, the Swiss Academy for Medical Sciences (Schweizerische 
Akademie der Medizinischen Wissenschaften, SAMW) recommends general consent in their 
guidelines on biobanking: “Consent can generally also cover the further use of the samples and data 
for future research projects (general consent). Restriction of their use to one specific field of research 
is possible.”2 
The confirmation that all these conditions are fulfilled is the responsibility of the local ethics 
committee. Thus, researchers must ensure that they have satisfied the committee on all points 
regarding consent (or the lack of it) before their research can proceed. However, as noted above, the 
guidelines upon which these committees must base their assessments are evolving and occasionally 
contradictory; they are also a significant departure from the traditional specific consent   
requirements for research on human subjects. The extent to which ethics committees influence 
informed consent requirements has so far been only sparsely addressed in the literature, yet it is 
during committee meetings that the debate concerning consent has a tangible impact upon research. 
We asked a group of biobank stakeholders working in Switzerland to discuss their experiences with 
consent for biosamples, and the ethics approval process. In doing so, we aimed to identify any 
difficulties in the process which might negatively affect research. 
 
 
2         http://www.samw.ch/dms/de/Ethik/RL/AG/Biobanken_D_06.pdf 
 
90 
 
 
Methods 
We conducted 36 semi-structured interviews with key stakeholders in Swiss biobanks (researchers, 
clinicians, pathologists, lawyers, ethicists and biobank managers). For a more detailed description of 
the methods see Shaw, Elger and Colledge (forthcoming).11 
Results 
Most of the interviewees identified informed consent as an important part of their work: a great 
majority of persons mentioned the topic, although they were not explicitly asked about it in many 
cases. This awareness reflects the enormous number of publications and the broad academic debate 
about informed consent in the medical field. 
One focus of the presented findings here will be on difficulties regarding samples that had been 
stored without explicit consent and interaction with ethics committees, which have amongst other 
things the power to approve the use of samples without (re-)consent. 
Types of consent 
Biobanking stakeholders provided several justifications for the type of consent used in their 
institutes. A majority prefer a general consent as it means flexibility for future projects: 
“I13: […] our informed consent,[…]they are very general,[…]and based on this we can use these 
samples for whatever projects […]” 
“I24: […] they gave consent to use it for other projects, except for any germ line analysis. And I could 
use it for other, I could give it on, and it had to be anonymised[…]” 
“I31: […]the broad consent is actually a good way Switzerland is going, I would say. […]” 
 
Another participant emphasises the advantage of having an optional general consent on top of the 
project-specific IC for a clinical study. That way, it is up to the patient to whether to agree to a 
specific or a general consent: 
“I28: […] we ask that they provide the material for just the basic pathology department assessment 
review that's part of the clinical trial, but that we then have, like an additional question that they can 
mark yes to, or no, whether they would agree for this to be held back, banked for yet unknown 
translational research or so.” 
 
The specific IC, in contrast to general consent, is described as an important limitation to data sharing 
by two interviewees: 
“I21: […] it’s more tricky thing, because we are bound by ICHGCP, and […] be quite clear what the 
samples could be used for and where they would go etc., so unless you thought about it in advance, 
it’s difficult to share samples” 
“I31: I think this is important basis for having decent sharing where we work now, is informed 
consent. […] project specific informed consent, then we don’t need to talk about biobanks if we have 
this, because then we do […] our little own projects, and that’s it[…]” 
However, if the patients cannot precisely be informed about the future use of the sample they 
donate, there might be reasons for them not to sign a consent form. More explicitly, interviewee 21 
earlier explained: 
“[…]if you want to have high collection rates in a clinical trial, you have to have narrow consents.[…]if 
you want to go broad, […]you reduce the number of patients who would sign up for that” 
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The ethics committee 
Ethics committees appear to play a crucial role in imposing limitations on biobanking and sample 
sharing. A particular reluctance is described by some persons when it comes to the approval of 
general consent: 
“I3: Yes, it was a broad consent, and […] it was long discussions about this, also how[…] valid is it 
for[…] the genetic analysis, but the ethical committees decided we don’t have to go back to it […]” 
The IC requirements imposed by ethics committees present a challenge as described by this 
interviewee: 
“I12: […] we have to… send out forms, four five six pages long, just to get a consent of the patient. So 
why not say, dear patient, we have here a biobank, and […]we also collect a piece of a diseased tissue 
from you, and need this for research purposes. Period. So this would be the easiest way, but this is not 
allowed, so we have to[…] ask them for which kind of research projects we want to perform. We can’t 
answer this, because no one knows in five years which methods are around” 
 
In the next sentence, the same individual emphasizes related difficulties for patients: 
 
“[…] there are many many different thing which have to be read by the patient and answered[…] and 
many patients […] don’t read it so clearly, because they do not understand it, or they won’t 
understand it, or maybe they are faced with […] More problematic things. And this is I think the[…] 
most problematic thing we have here. “ 
 
These two statements clearly demonstrate the key problems this interviewee sees in the current IC 
procedures: over-demanding requirements imposed by ethical committees, the impossibility of 
explaining the future use of a sample when designing general consent forms, and the potential 
inability of the patient to be thorough and thoughtful in their decision, which is partially due to the 
overwhelming bureaucracy of the forms. 
The powers granted to the ethics committees by the Declaration of Helsinki can enable a study or 
biobank to use huge numbers of samples without consent. Their expectations are described as 
unrealistic and demanding in a way that hinders research, especially when particularly regarding the 
obligation to re-consent: 
“I27: the task was then to get the informed consent from that patients, so they sent letters to all the 
patients, the problem is that a patient who […] has been hospitalized […] a year ago[…], you send 
them a letter […], he will either not understand the letter, not respond to the letter, or he might be 
already dead, and, his spouse is angry at the hospital […] in the end you get a response by […] ten 
percent […]Of the probands. […] and then it gets reviewed by the ethics committee, and they say it’s 
very poor quality because only ten percent responded.” 
A suggested reason for ethics committees’ hesitant reaction is that “[…]they think they need to 
protect the donors from this and that […]”[I21]. 
A contrasting view is presented by one interviewee, who believes that ethics committee approval 
wrongly makes people believe that everything is in accordance with patients’ wishes: 
“I2: if people really gave consent[…] then I think that is a huge barrier.[…] . It’s breaking trust, 
[…]there’s no utilitarian arguments that can justify breaking trust with someone who’s entered into a 
consent believing that. […] I’m not happy that people think you can justify this if an ethics committee 
says “OK”, for me this is a very dangerous direction[…]” 
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Samples without consent 
The handling of samples without consent is one of the most crucial issues described by the 
biobanking stakeholders within these interviews. One group of participants gave examples of 
successful (but challenging) reconsenting procedures that were used before the new law was passed: 
“I28: Yes, we have material in our older trials, […] fifteen years ago […], it wasn't yet so standardised 
[…] we've actually had to go back and reconsent for a trial where we had eight thousand patients, 
and it crossed really all the continents, so it was highly intense work that took a lot longer than 
anticipated. […]it's not so easy to go back to patients who've been on the trial for eight years or 
so[…]But in fact we generally received a very good positive response.” 
 
I24: “[…]usually if you go back and you have anonymised data, you can do it, but it’s work. It’s work.“ 
As the guidelines allow the use of samples without consent only when it is impossible to obtain a re- 
consent, these individuals present cases in which the corresponding paragraphs are not applicable. 
Many persons mentioning the samples without consent, however, characterise the process of 
obtaining re-consents as almost impossible: 
 
“I12: […]many of the cases of course from the old[…] samples, we don’t have any consent. […]And 
most of the people[…]already died. And it’s very hard to ask for a consent to go to the relatives […]. So 
it’s, it’s problematic. And that’s why we explain the ethic committee this  this ethic problems. And it 
depends on the ethic committee, they say ok, no or yes.“ 
 
“I21: it’s a theoretical possibility, […]I don’t think we’ve done that here, re-consented patients, we 
might have gone back to ethics committee. […]But not all the way.” 
 
“I8: […]If you connect every donor twenty years ago … “Hello, we have… do you remember you had 
this operation in 1999 and we have still a little bit material of your stomach, and now we want to do 
research with it, do you agree or not?”[…] they won’t do it.” 
 
Discussion 
In general, two aspects of our findings are particularly notable: 
1) Although general consent is not only tolerated but explicitly recommended by the Swiss 
Academy of Medical Sciences, researchers perceive difficulties in using general consent 
mechanisms for their research. An important factor seems to be ethics committees’ 
reluctance concerning the approval of general consent forms. 
2) Instead of obtaining general consent, many researchers reported experiences with using 
large numbers of samples without explicit consent and the procedure of reconsenting - 
despite the associated difficulties. 
Different types 
Overall, the issue of informed consent has been widely discussed in the literature, which could be 
one of the reasons that many interviewees mentioned it without being asked.12-16 At the same time, 
it may also be one of the major issues in their everyday work, so that it came to their minds 
immediately when talking about dealing with their samples. 
 
The stakeholders’ predominant opinion – a preference for general consent due to several difficulties 
with more restricted versions – is supported by theoretical claims in the literature: 
According to Widdows and Cordell13 there are several reasons why a narrow informed consent as 
defined by the Nuremberg Code3 is inappropriate for biobanking. This is in line with the responses of 
those interviewees, who explained that they preferred general consent to specific consent: They 
explicitly mentioned the difficulty in providing information about – unknown – prospective research 
 
 
3        http://history.nih.gov/research/downloads/nuremberg.pdf 
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and to address the donors several times, especially when they work with large sample sizes or over a 
longer time span. 
 
Considering these reasons, the question is what obstacles obstruct the use of general consent within 
research institutions. One suggestion mentioned by a minority of stakeholders was the unwillingness 
of patients to give general consent. Caulfield et al17 have argued that one-time consent violates the 
individual’s autonomy, and even a carefully developed and long discussed general consent is useless 
if people are not willing to sign it. However, Elger and Caplan2 mention broad acceptance of general 
consent among donors, and a review by Wendler18 comes to the same conclusions. These findings 
support some interviewees’ assumptions about patients’ potential willingness to cooperate, even 
when they cannot be informed about details of future projects. 
 
If general consent forms were adopted as a standard, the necessity for reconsenting procedures 
would become redundant in most cases, and the potential conflicts between researchers and ethics 
committees regarding the applicability of national and international guidelines could be avoided. 
The ethics committee 
Although empirical studies suggest many ethics committees have not yet done so,19 some recent 
findings suggest that there are several reasons for them to agree to general consent. It is not self- 
evident that specific consent protects patients’ rights while general consent does not. If people are 
motivated to think altruistically when a general consent form is presented to them,14 there are even 
ethical reasons to prefer general consent. In many cases, such as genetic research, a person can have 
a good reason not to sign a general consent form. However, a partially restricted consent that 
excludes certain research areas can still be an alternative to the burdensome reconsenting that has to 
be obtained for every new project.2 The inability to provide detailed information about future 
projects, especially when it comes to data and sample sharing, is characteristic of biobanking13 and 
must be considered when approving the type of consent for a biobank. Furthermore, as interviewee 2 
points out, ethics committees cannot make moral decisions for patients and researchers. It is 
important not to give the impression that having an approved (general) consent form means that it is 
a moral imperative to sign it. To make an autonomous decision and give informed consent, patients 
must have a real choice.20 The expectation that researchers will reconsent patients is highly 
demanding, and international guidelines as well as similar provisions in Art. 34 of the Swiss Human 
Research Act4 that will come into force in 2014 or 2015 facilitate research by defining circumstances 
in which it is allowed to proceed without consent. 
 
Samples without consent 
Reconsenting is commonly considered “logistically impracticable, prohibitively expensive and, in the 
case of long term projects where the donors have died, impossible”.17 This position is supported by 
several of our interviewees’ statements. In particular, in those cases when patients have died and 
relatives are asked to agree on behalf of them, the question is whether this process is in some cases 
more “harmful” to the relatives than the use of the sample without reconsent would have been to 
the person that passed away – although proceeding without the relatives’ consent could be against 
their will in certain cases, too. 
 
Although some stakeholders state that the reconsenting process is possible, the majority of them 
describe it as cumbersome and time-consuming. According to the Declaration of Helsinki the ethics 
committee has to decide whether the conditions for a use without consent are met. Thus, there is a 
shift for the researchers from simply obeying the law to negotiating with an ethics committee. On the 
one hand, if the committee is permissive this can result in a successful use of huge numbers of 
samples from pathologies that were taken long times ago. On the other hand, It can be argued that a 
better (international) communication structure between biobanks could improve sample access in 
certain cases even without using samples without consent.  However, there is a possibility that, given 
 
 
4         http://www.bag.admin.ch/themen/medizin/00701/00702/07558/ 
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the option of using samples without consent, researchers might make less effort to obtain general 
consent in the first place, and consider the procedure of a retrospective permission via an ethics 
committee as simpler. What was meant to be an exception could therefore become the standard, 
excluding donors from the process in a an unethical misuse of the consent procedures. 
Conclusion 
The findings of this study give an overview of biobanking stakeholders’ opinions about challenges 
they face concerning informed consent and the ethics committees. First, it can be stated that despite 
a lack of legal or guideline-based barriers to general consent, both stakeholders (although only a 
minority) and ethics committees have reservations about this method of consent. The aspects 
involving ethics committees suggest that further research is needed regarding their role in  
biobanking research in general and in dealing with consent for previously obtained samples in 
particular. Second, it can be concluded that greater awareness of donors’ opinions and preferences 
and the content of guidelines and recommendations could be helpful for a better justified 
perspective of biobanking stakeholders and ethical committee members, equally. And third, it may  
be necessary to differentiate between future procedures – where general consent is clearly desirable 
– and the use of old yet still relevant samples – where the option of using them without consent can 
be highly beneficial for research. 
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 PART 4: DISCUSSION 
   
4.1 1 MAJOR FINDINGS 
 
The results of this study provide unique insight into a field which has huge implications for  
biomedical research in Switzerland, yet until now has never been explored. Biobanks are 
indispensable tools for research, and permit projects on a scale far beyond what many research 
groups are able to achieve through solo sample collection. Although Switzerland has a strong 
biomedical research tradition, and multiple research centres, no examination has been made into the 
best methods to optimize these resources. Our study is the first to approach biobank stakeholders 
themselves in order to address the issues brought up by sample sharing. Without the views of 
individuals involved in the field, any attempt to change the biosample practices of a country risks 
missing the needs, desires and interests of those who will use any developing infrastructure. This is 
particularly important at a time of change in the biobanking field, which was the case as we carried 
out our study; national guidelines, the law, and existing biobanking infrastructure all made significant 
changes around this time. This study provides a comprehensive chronicle of the spectrum of issues 
which currently affect biobanks and their stakeholders in Switzerland. 
Given the exploratory nature of our research, and the desire for a narrative structure for our results, 
semi-structured interviews producing qualitative was the optimal approach. This technique ensured 
that as many relevant issues as possible would be identified and addressed, and absolute necessity 
given the lack of existing research in this area, and the consequent potential for missing important 
issues if quantitative measures were employed. It must also be borne in mind that this is, in some 
aspects, a delicate matter; questions were asked which had the potential to produce “socially 
unacceptable” answers, or at least answers which might make the interviewee appear as an 
unsympathetic colleague or research partner. Our results bore this out, with contentious comments 
concerning networking, definitions and authorship in particular. For this reason, it was also important 
that we were able to offer and preserve strict anonymity for our interviewees. 
Furthermore, the foundation for the empirical investigation was laid by extensive literature. This was 
a further essential step in developing the project, as it served to validate the research question, and 
fill in “background” details concerning international developments the responses of ethical 
committees to the shifting landscape in biobanking. 
That both the theoretical and empirical parts of this study were unique and of value to the research 
community has been confirmed as the project moved forward. In 2012, a redrafting of the 
Declaration of Helsinki was undertaken. I presented our views to the World Medical Association 
Satellite Meeting in Rotterdam in June. In 2013, a revised version of the Declaration was published, 
which incorporates one of the amendments we discussed; the word “impractical” is now replaced by 
the stricter term “impracticable” in what is now Paragraph 32.1 
Drawing on empirical data from a previous study, we presented an analysis of the approach that a 
number of Swiss ethics committees took to requests for research with human tissue samples in 2010. 
Our findings indicated that sample requests are handled differently in different cantons, and that 
even within committees, confusion can exist about the committee policy on such requests. Since this 
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data was gathered, the Humanforschungsgesetz has come into force in Switzerland, which provides 
concrete guidance on correct protocol with human tissue samples. 
That the issues identified in our empirical research are of importance in the biobanking field has also 
been validated by literature published in the past 12 months. 
Wei and Simpson (2013) discuss the importance of biosample quality, emphasizing that consistent, 
standardized sample processing is essential for later use,2 as do McQueen et al (2013).3 Solutions for 
global harmonization practices have also been put forward; there has been a move from suggested 
innovations to locally piloted practices which may be adapted to a larger scale.4-6 
Other technological innovations include new Electronic Laboratory Notebooks to facilitate data 
sharing between labs, a preferable alternative to the older paper versions.7 The value of linking, for 
example between cohort studies and disease registries, is reiterated in articles such as that by 
Brescianini et al (2013), who report on the development of the Italian Twin Register, permitting 
statistically strong research on heritable disease.8 Finally, Brochhausen and colleagues (2013) detail 
their development of an “ontology”, a tool which enables numerous variables (in this case, the focus 
is on administrative aspects) to be sought from biobank databases.9 
From the legal perspective, Soini (2013) details Finland’s new Biobank Act, in force from the 1st of 
September 2013, which, among other things, aims to facilitate the use of older samples and data, for 
which current consent standards may be lacking.10 There are also limits imposed on a biobanks ability 
to restrict access to its database after it has been queried by researchers. Black et al (2013) also 
summarise 23 laws and guidelines which address the requirements for the disclosure of incidental 
findings, and examine the financial implications of this from the biobank perspective.11 This is a 
potentially large added burden that many researchers may not have fully considered, and  
preparation for the need to disclose such findings is essential; careful checking of local ethical and 
organisational requirements is key. 
 
Hofman et al (2014) specifically address the issue of making biosamples accessible, again with an 
emphasis on quality, although their article pertains to public-private partnerships, rather than  
general biobanking.12 They explain that biobanks have different goals, and therefore, values, 
depending on the particular sphere in which they find themselves: public interest is for health care 
and research purposes, while private interests are in commercial drug and test development. This 
disparity is one cause of incompatibility of samples and data (which may be gathered, stored and 
recorded according to the foreseen use); another problem is the development of material transfer 
agreements which enable publicly collected samples to be put towards private ends. Accreditation of 
biobanks is also recommended to guarantee a level of “professionalism”, which allegedly brings with 
it assurances of quality and reliability. 
 
Hirschberg, Knuppel and Strech (2013), in an innovative article, compare the consent forms of 30 
German biobanks, and find significant variation in the content and wording of the documents.13 They 
note that this threatens biobank networking opportunities, due to the potential incompatibility of 
samples with institutional ethics requirements. That such problems persist, even at the national  
level, is an indication that the harmonization of biobanking practice continues to lag behind its 
technological development. 
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Finally, the argument that the needs of stakeholders, rather than the basics of biobanking, must be 
the focus of biobankers, is supported in an article by Simeon-Dubach and Watson, who suggest that 
the current generation of biobanks must enhance their value with regard to the requirements of 
stakeholders, and ensure their own sustainability.14 They suggest that greater focus on quality, stock 
management and accreditation are all important for the biobank, while researchers can play their 
part by reporting their research findings each time they use specimens from a particular bank. In this 
way, a system of mutual benefit, trust, and also professionalism is developed. 
 
A number of other articles reiterate the issues identified in this thesis without making a new 
contribution to the discussion of solutions. The harmonisation of guidelines, and detailed attention 
to the ethical requirements of governing tissue sample transfer continue to pose a challenge;15 the 
underuse of samples is still a significant concern, as reported in a survey of 456 biobanks in the 
United States;16 and the trend towards broader consent with ethical committee oversight 
continues.17 
This thesis is the first work targeting the obstacles specific to the evolution of biobanking, and 
collecting the experiences of those affected. The literature to date has supported the importance of 
troubleshooting in this area, yet concrete goals and solutions are still lacking. The results presented 
here are all points which must be considered in further efforts to harmonise biosample sharing at all 
levels. In the following sections, the practical importance of these findings is supported by a 
normative examination of the extent to which sharing can be required. Finally, the implications for 
future research are addressed. 
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4.2 2 IS THERE A DUTY TO SHARE? ETHICAL APPROACHES 
AND NORMATIVE IMPLICATIONS 
Calls in the literature for increased biosample and data sharing emphasise the research possibilities 
which will follow such action.1,2 These appeals are made on pragmatic grounds, but must navigate 
obstacles which are not only logistical, but also ethical. This was validated by our findings with regard 
to territoriality and fair sharing practices. Consequently, there arises the possibility that action to 
increase sample sharing must consider another set of questions: is there an ethical duty to share 
samples and data? What is the basis of such a duty, and how far does it extend? What are the 
normative implications? And how does the duty to share conflict with other ethical requirements in 
biobank research? 
 
To date, there has been to our knowledge no discussion of the questions posed above in relation to 
biobanks. Simple data sharing receives attention in the context of particular circumstances: in the 
case of the return of genetic results,3 or conceived as a responsibility to make one’s genetic test data 
available for research purposes.4 There is also discussion of the placement of genomic data in a 
forum accessible to researchers on a global scale.5 It must be borne in mind that in the first two of 
these examples, the “sharing” in question is a form of “publication” of data, rather than an act of 
permission to use raw materials. In sharing biosamples and data for research purposes, a biobank or 
research is giving another party access to a resource that the party is likely to benefit from in a 
professional sense. By contrast, making data on incidental findings available to research participants 
will not have this effect. Moreover, ethical arguments are rarely used in these discussions. 
A moral duty to share can be grounded in the values of solidarity6, justice and beneficence.7 The duty 
may be limited by other duties; in the case of biomedical research, duties of patient confidentiality 
and one’s professional contract could have competing claims.8 In order to assign a duty of sample 
sharing to biobank stakeholders, the basis for that duty, beyond pragmatic grounds, must first be 
concretely identified, and then competing duties balanced. 
 
There is some precedent for the sharing of data-as-resource which is useful to consider in this 
context. Kaye et al (2009) describe the advances made in data sharing in genomic research, where 
resources such as the database of Genotypes and Phenotypes (dbGaP) supply researchers around the 
world.9 In this field, funders have come to require that study data be made accessible: “The rationale 
for these policies is that science and creativity are furthered by access to openly available data, and 
that data created by publicly funded bodies should be freely available in the research community.” A 
moral duty is not directly appealed to; nevertheless, a requirement based on reciprocity is advanced, 
and it is one which overrides research-group interests to some degree. 
 
Moral arguments come into play in an article by Langat et al (2011), which describes the difficulties   
of elaborating a data sharing policy in the context of public health emergencies.10 Crucially, they refer 
to the non-emergency context norm of scientists enjoying a “proprietary right” to the material 
derived from their own research efforts. The lack of internationally applicable documents on sharing 
have perpetuated a situation in which there is a tendency to shy away from data sharing, even in 
emergency cases of public health importance (the authors identify the example of the lack of 
international cooperation in the wake of the SARS pandemic in 2003). 
 
Langat and colleagues advance three broadly consequentialist arguments against data sharing which 
they feel confident do not apply in the context of public health emergencies. First, that scientists 
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have some ownership over the data and samples that they have collected; second, that it would be 
unfair to force those who have exerted effort in collecting resources to simply give it to others who 
have not; and third, that the scientific landscape values commodities (essentially, publications) which 
sometimes require that data and samples be held by one research group only. Their counterclaims 
apply equally well to non-emergency situations: the authors point out that the “ownership” of 
research data is not a foregone conclusion, due to the public funding which supports it. Biobank 
material is therefore public in nature the way genetic material is “familial in nature”;11 “Render unto 
Caeser,” etc. This public aspect demands a reshuffling of the concept of burden and fairness, 
entailing, in some cases, a duty to share samples in order to benefit the public. It is concluded that 
the nature of current scientific research, though it may depend upon publication figures, is also 
inextricably linked with collaboration, and cannot continue with it. Sharing by researchers is therefore 
not only not morally neutral; there exists a duty to share which, on this line of                
argumentation, clearly extends to biobanks and biosample collections. 
 
Melton (1988), in an article which applies well to the particular case of biobanks, makes appeal to a 
moral argument based on openness being the gold standard of scientific research.12 On this 
understanding, those engaged in this research are bound by a duty to openly share their data. 
Melton provides interesting challenges to this argument, and to the one above, citing authors who 
have suggested that privately funded research and the possible divergence of the interests of 
research participants and the general public make generalised claims for openness and sharing of 
data problematic. These counterclaims are compelling because they are made on moral, not 
pragmatic grounds. However, they do not inherently threaten the notion of a duty to share; rather, 
they refer to other duties which bind those engaged in research. In what follows, the question of 
competing duties will be examined. 
It may seem a moot point to discuss a duty to share strictly in terms of biobanks (less official 
biosample collections are different, and the above arguments apply excellently). Biobanks are set up 
to share biosamples, after all. But two considerations must be remembered; first, the implications of 
a duty to share on the practice of biobanks, particularly those less well established, must be 
addressed; second, the conflict of a duty to share with other ethical duties will give rise to certain 
normative conclusions. 
While a strictly deonotological approach would be difficult to employ here, consequentialist and 
principalist theories of morality will have no difficulty embracing a duty of sharing. An ethical duty, 
grounded on public benefit, to share biosamples, requires that biobanks make their resources 
available to researchers who are able to demonstrate that they can carry out a potentially valuable 
research investigation using those samples. For biobanks set up to provide samples, this amounts to 
a negative duty to not prohibit access to suitable applicants. It is interesting to consider whether 
there might be a further, positive duty for biobank managers to ensure that their valuable resources 
reach as many interested parties as possible. A positive duty might entail some requirement to 
publicize the bank, a certain level of network involvement, and other strategies involving the bank as 
agitator. 
It would be difficult to conceive of a positive duty of self-promotion for biobanks, and indeed on the 
practical level it would require effort and infrastructure beyond most existing banks. A negative duty, 
by contract, would seem to be an essential part of a biobank’s work, given biobanks’ status as 
publically supported, in part publically funded, research resources for public health. It is interesting 
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to consider, in light of Lagat et al’s arguments, to consider to what extent such a negative duty can  
be extended to unofficial biobanks, sample collections of the type discussed in this thesis. If a duty to 
share on the basis of public good exists, can it be said to apply to all those who have potentially 
useful samples and data? 
At several points in this thesis, the heterogeneity of sample collections has been commented upon, 
together with the consequence that this makes distinguishing biobanks from mere sample collections 
difficult, if not impossible. It has been suggested that intended use of the material (and again, this is 
tricky, given the unforeseeable nature of much biosample research) plays a role in determining the 
type of collection. Material for research purposes is fundamentally different from material for 
diagnostic, quality control, or as yet unspecified purposes. This is because the tissue donor has  
agreed to uses of the sample on the understanding that it may, if only to a small degree, contribute to 
useful findings on a particular research question. While this argument rests on the assumption that 
appropriate consent was obtained for the sample, it is plausible to suggest that in the great     
majority of research with human tissue and data, informed consent ought to be obtained, and its 
absence justified by suitably difficult circumstances, as discussed in Chapter 2.2 on the Declaration of 
Helsinki. Samples and data with research uses therefore fall into the category of material which can 
further the public good, and can therefore conceivably entail a duty of sharing. 
As noted above, other duties, long-established in medical research, are also a factor in research with 
human biosamples and resulting data. Doctor-patient confidentiality, respect for the limits of 
informed consent, and ethical requirements for proper study procedures all entail duties, indeed 
positive duties, to handle material in a certain way, and often that will place some prima facie  
limiting factor on sharing. In the case of biosample sharing, it has been argued that these duties 
might be less respected by secondary researchers, removed from the data collection and consent 
process, than by the initial investigators.9 This, however, is not an exceptional circumstance in 
medical research ethics; frequently, duties will conflict, such as in cases where beneficence appears 
to conflict with autonomy,13 or in case of incidental research findings not foreseen when the study 
was designed.14 A review of health care practices by the National Information Governance Board in 
England concludes that “The duty to share information can be as important as the duty to protect 
patient confidentiality.”15 Bioethics consists of analysing and balancing such duties, and the result is 
typically a guideline document presenting a consensus, and subsequent proper practice. The duty to 
share biomedical research material is, to date, missing from most guideline documents. 
 
The reason for enshrining a duty in a document is not simply a recognition of its importance, but a 
sign that it is not to be violated, despite the fact that it may well be an individual’s or a research 
group’s interest to do so. Guidelines for biomedical research balance duties, yet also enforce them (in 
so far as possible) by placing duties before pure scientific interest in the hierarchy of research   
values. It might be of benefit to the public, in pure health terms, to allow unrestricted access to any 
biosample and data, without the requirement for informed consent, but this would violate numerous 
patient and practitioner rights, and consequently, it is forbidden. By the same token, it might be 
desirable for certain research groups to monopolise sample and data pools, and this might even lead 
to a significant discovery by that group; in the view of Cambon-Thomsen (2004), “…many restricted 
uses and opposition to sharing bioresources are a result of intellectual property rights or the control 
that scientists want to exert on the biobanks they have established with great effort, rather than 
ethical issues related to respect for the individual rights of donors.”16 It is, however, worth noting the 
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possibility that in many cases, the work of individual research groups may in fact be far less 
disadvantaged that might be assumed.17 
In the presence of continued conflict, it is up to national and international bodies to weigh interests 
and safeguard patients; but for this to be carried out properly, the possibility that there is a duty to 
share biosamples and data must at the very least be considered. 
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4.3 IMPLICATIONS FUR FUTURE RESEARCH 
 
Our data is exploratory, and we have presented our results in a descriptive form, as is appropriate to 
the aims and methods of our study. We set out to identify obstacles to biosample sharing in 
Switzerland, and met this goal. However, we have only briefly touched on the potential solutions to 
these problems; and, as with any research project, the answers that we found lead themselves to 
further questions. 
First, our empirical data was drawn from a relatively small pool of individuals working in a single 
country. While, as we have explained, our interviewees in fact represent a large percentage of those 
working in the field in Switzerland, and the majority have had international work experience, we 
cannot generalize our findings to the global level. Hence, a fully comprehensive approach to the 
barriers to sample sharing must involve international data gathering. It would be extremely 
illuminating to compare the results of such a study to the results of our literature review. 
Second, the issue of networking, both formal and informal, professional visibility (largely web-based), 
and the role of personal contacts, is perhaps the key theme of this dissertation. It is addressed in 
detail, and held in high importance, by our interviewees, and also plays a role in questions of fairness 
and authorship. Therefore, a detailed examination of biobanking networks, their aims, successes, 
failures, and future development, is crucial in the further development of the field as a whole. A large 
variety of networks already exists, and implement numerous harmonisation measures; however, the 
fact that even networks are numerous and diverse contributes to the fractured nature of biobanking. 
In a field that is driven by researchers, rather than oversight bodies, incentives for universal 
collaboration are essential, and networking systems promise this. The limitations of these 
organizations are likely to have a negative impact on biosample sharing. Further research into the 
optimal way to broaden participation in biobanking networks is therefore an important future 
avenue. 
Our conclusions about future directions regarding authorship agreements for biosample use, and 
transparency of documents to ensure fair sharing, can be found in the Discussion sections of each of 
these articles. We have also recommended a definition that we feel is appropriate to ensure the 
regulation, not “strangulation”, of researchers who work with human biosamples. 
Finally, in order to understand what researchers would benefit from in the biosample research, it 
would be beneficial to address not simply the obstacles to current practices, but the views of 
stakeholders about their desires for the development of their fields of research. Adopting this 
“positive” questioning tactic will allow for the development of new, perhaps unforeseen measures 
which might unite researchers with valuable biosamples, rather than simply seeking to make 
alterations to existing patterns of sample identification and requests. Examples of this approach 
include questioning stakeholders on the ideal sample size, type, and population for their research, 
and on the multidisciplinary expertise required to design new projects. Biobanking is in itself a new 
technique, enabling research on a scale which previously was virtually impossible. Thus, it is an ideal 
field in which to pilot new research methodologies; future research must take this into account, and 
foster its full potential. 
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4.4 CONCLUSION 
A number of conclusions regarding the barriers currently affecting biobanking in Switzerland are 
made in this thesis. It is possible to classify them in two catch-all themes; transparency and 
information. We have suggested that clarity and transparency is required in the written material 
which governs human biosample transactions: this includes the wording of governing documents, 
inter-biobank transfer agreements, authorship agreements and the nomenclature used to describe 
samples; it extends to the definition of the term “biobank” itself. This must be promoted by 
consensus documents created by stakeholder groups and can by facilitated by the international 
networks such as ISBER and BBMRI. We have suggested that biobank stakeholders must be informed 
about the potential for collaboration, existing infrastructures, and potential research partners, and 
that ethical committees which deal with human tissue research must be informed about the 
appropriate regulations and content of this research. This is more difficult to accomplish, as it is not 
the responsibility of any party, other than the biobanker him or herself, to promote participation in 
networks and seek out researchers with common goals; hence, the risk is that those who are in the 
dark will stay in the dark as they remain unaware of the possibilities for broader networking. 
However, cautious optimism about the work of Biobank Suisse and ESBB is warranted, as these 
organizations actively seek to identify biobank stakeholders and encourage membership. A decision 
not to participate is at the discretion of the stakeholder. While other barriers to biosample sharing 
were identified, limitations to transparency and information encompass those which are truly 
significant for the stakeholders we interviewed. These are directions which require attention to 
minimize obstacles to biosample exchange, which should, in turn, allow for promising research to 
progress. 
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4.5 APPENDICES 
 
4.5.1 INTERVIEW GUIDE 
 
 
 
Intro for interviewee 
 
To get started we will ask you questions about 
 
1. yourself and the biobank(s) you are associated with, then 
2. we will ask you questions about your experiences with and views on sharing samples and 
data, and finally 
3. we will ask you about your views on fair and just sharing practices. 
 
 
 
Our interview method is semi-structured meaning that we will ask you questions regarding a topic 
but you have a lot of leeway on how to answer. Of course, you don’t have to answer all the 
questions if you don’t have an opinion or don’t have the information. Overall, we want you to tell 
us what you think is important about each topic so we want to hear your ideas even if our question 
may not have anticipated your answer. That being said, because we know your time is precious, and 
we don’t want to over stay our welcome, we may sometimes guide you away from a theme or have 
to stop discussion about one topic in order to make sure that we get information on all the basic 
themes of our study. 
 
 
 
Regarding confidentiality of the information you provide, we want to remind you that the link 
between your identity and your answers will be coded and the only persons with access to the code 
will be the researchers Heidi Howard, Flora Colledge and Bernice Elger. 
 
 
 
Now, before we being, may I ask you how much time you have scheduled for this interview today 
so that I can judge, as we progress through the questionnaire, how much time we have left. 
 
 
QUESTIONNAIRE 
 
Information about the Interviewee (part of this information will be pre-filled, so this may be more 
of a verification) 
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 1- What is your Primary affiliation 2- How would you identify your primary work functions/activities as being: a. Do you mainly do research? Clinical activities? Managerial or administrative 
tasks? 3- Number of years in post: 4- What field is your formal training/education in? Medicine, health science, humanities? 
 
 
 
 
Information regarding the biobank and the interviewees role with the biobank(s) 
 1. What biobank(s) are you associated with/ work with? a. If more than one, choose one or two to discuss, but make sure it is clear 
what scenario is being discussed 
 
 2. Can you tell us about the biobank and your role/involvement in it? (any documents, 
links, etc. are welcome) a. See below for the specific information wanted re: bbk. If they don’t 
answer all these questions on their own, ask directly. 
 
 3. Just to clarify, are you involved with an official bbk as well as being involved with the 
gathering of samples for a research or clinical lab? a. Do you see these as being one in the same? b. If not, when you answer the questions, please specify which scenario you 
are referring to. 
 
 
Information about Biobank 
 2. What is the Name of bbk(s)? 3. What is the primary Location? 4. Is the BBK part of a larger network? 5. What is the main goal of the bbk? 6. Is it recognized as an official bbk? 7. How would you classify the bbk? i. Are both samples and data banked? ii. What type of data: clinical, molecular & lifestyle/environmental? iii. What type of Samples: tissue, genetic iv. Is the bbk a private or public entity? v. Is the bbk for profit? vi. Is the main goal of the bbk for clinical or research purposes? 
8.    What type of biobank is it? In their own words 
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 9. Who collects/donates the samples? 10. Who makes the decisions about sharing samples/data? 
 
 
 
How would you define a biobank? Basic 
Questions re: Sharing/providing 
 
Before we begin, please note that throughout we will be talking about the sharing of samples 
and/or data. If you feel like you want to distinguish between the two please let us know. 
 
 
1. Are you sharing (define sharing as providing) biological samples and/or data from: i. your 
lab to other labs ii. your lab to a biobank iii. from the biobank to other labs or biobanks 
 
 
VIP!! with scientists, if not explained earlier, please specify the possible contexts of sharing: are 
you talking about sharing samples/data from your lab to other labs or a bbk? Or are you talking 
about how the bbk shares? 
 
 
For the rest of the questions, it could be important to specify the context (i.e.: the researchers’ 
view/practices vs. the bbk’s view/practices 
 
 
a. YES: Who do you share the samples with? i. A bbk? If so are you aware how the (the bbk) shares? ii. With researchers Regionally, Nationally or Internationally? iii. As part of a network(s)? which ones? iv. Ad hoc? Organized? 
 
2. YES: If you do share, Why have chosen these partners/researchers? a. Are they part of the bbk? b. Are they part of an organization? c. Do you have an understanding with them? If so, what is it? 
 
3. NO: If you don’t share, why not? a. What are reasons for you to decide not to share i. via the formal channels (formal biobank) ii. informal channels (colleagues and collaborators) 
 
 
 
 
 
 
4. Are  you  also  borrowing  (define  as  receiving)  data/samples  from  a  biobank  or 
colleagues/collaborators? 
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 a. Specify samples or data or both? b. If yes with whom? i. Regionally, Nationally or Internationally? ii. As part of a network(s)? which ones? iii. Ad  hoc?  Organized?  Informal  channels  (with  colleagues  and 
collaborators) 
 
 
5. Do  you  feel  like  you  have  a  responsibility  to  share  your  samples  with  other 
labs/bbks? What is the basis for this responsibility? 
 
 
 
6. Could  you  give  us  a  list  of  reasons/incentives/motivations  why  you  share  your 
samples/data? a. via the formal channels (formal biobank) 
b.   informal channels (colleagues and collaborators from other labs) 
 
 
 
7. Are you aware of other motivations even if they don’t apply to you personally? 
 
 
 
8. In practice, what, according to you, is the most persuasive incentive to share samples and 
data? 
i.   Now, more theoretically, can you think of any incentives, even if they don’t exist at the 
moment, that could encourage sharing? 
 
 
 
 9. Would payment for access to your samples be an incentive for you to lend/share them? i. What about for other researchers/bbks ii. Do you have (or plan for) a system of selling samples? 
 
 
 
 10. Would authorship on research publications be an incentive for you to share/lend your 
samples/data? i. What about for other researchers/bbks 
 
In practice, what do you expect to “get” or “obtain” when you share? ii. Do you usually/always “get” this? 
 
 
 
 
11. Do you have reservations about sharing your samples/data? 
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12. What, for you, are the disadvantages of sharing sample/data? i. Do you feel that sharing samples would/does involve a large drain on your time? 
 
 
 
 
13. Why, in general, do you think researchers/bbks do not share samples/data? 
 
 14. What are the minimum conditions/criteria that need to be fulfilled in order for you 
to share data and samples? i. Are there certain studies for which you would refuse to allow your samples/data to be 
used? ii. Have you ever denied anyone access to your samples? If so, what was the reason? 
 
 
15. Do you (or the bbk you work with) have a “sharing” policy? If so, i. what is the policy? ii. What is it based on? Who designed it? iii. Is it official/formal/strict? iv. What “jurisdiction” does this policy have? v. In this policy, what do the researchers who donate samples get in return for sharing? vi. Do you have a policy on awarding publication credit for those who share/collect 
samples? vii. Do you think your policy (on publication credit?) gives fair recognition for the effort put 
in? viii. What do you think about your policy? What do you consider to be the good/bad 
things about your policy. 
 
 
16. Have you, personally, encountered problems with sharing/borrowing (from your lab or from 
the biobank)? i. Can you give concrete examples of problems? 
 
 
 
17. Are you aware of other problems even if you did not experience them personally? 
 
18. What do you think are the biggest barriers to sharing samples/data? i. Do you think these are the same for different contexts? ii. Why don’t researchers share with bbks? iii. Why don’t biobanks share with researchers? iv. Why can’t researchers obtain samples/data? 
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19. Who  do  you  think  is  responsible  for  the  process  of  sharing  and  borrowing  in 
biobanks? 
a. Who do you think has the responsibility of resolving problems? 
 
 
 
 
20. In general, how do you see the present way of sharing data and samples? a. What is positive about it? b. What is negative about it? 
 
 
Although some questions above have already addressed some of the issues concerning fair and 
just sharing, now we want to ask about your views specifically about justice and fairness of 
sharing 
 
 
 
21. Do you find the present way of sharing data and samples “fair” within your bbk/lab? 
 
 
 
22. In general (among other bbks and labs) do you think sharing is happening in a just way, or 
is it always the biggest labs who get the good samples? Is that fair? i. Is access to samples and data fair and equitable for all labs/researchers/bbks? 
 
 ii. Are people getting the right amount of credit for the work they are doing? 
 
 
 iii. Have you ever shared your samples/data and felt you were not properly recognized for 
this? 
 
 
 
23. What do you consider “fair” sharing? 
 
 
 
24. If it is not already the case, How could “fair” sharing be realised? 
 
 
 
 
 
 
 
 
Now, we have almost completed the questionnaire, but before we end I have two last 
questions: 
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Are there any themes you feel we have not addressed about barriers to sharing that you think we 
should address? 
 
 
 
 
 
 
Are you aware of any other Swiss Biobanks and/or of other persons that could provide us some 
information about sharing? 
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